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5Foreword
This is the 11th annual report of the European Monitoring 
Centre for Drugs and Drug Addiction, available this year in 
23 European languages. Looking back across the reports 
issued by the agency over the years, it is hard not to be struck 
by the growth in the level of detail in the information now 
available — reflecting a more complex situation both in the 
use of illicit drugs in Europe and in the way Europe responds 
to the drug problem.
The information available to support our analysis has grown 
considerably. This year’s report is based on data from the 
25 EU Member States and Norway and, where available, 
from Bulgaria, Romania and Turkey. Not only has the 
number of countries providing information increased, but 
the amount of comparable information available from each 
has continued to grow. This information provides us with 
a far more detailed picture of the European drug situation 
and its dynamics than ever before. It is the EMCDDA’s 
task to explore this complexity, drawing together common 
experiences where they exist as well as commenting on 
differences. In investing in data collection and collaborating 
in the work of the centre, our Member States have come 
to understand that their neighbours’ problems today may 
become their own problems tomorrow. This awareness is 
evidenced in the new European Union drug strategy and 
its accompanying action plans, which are underpinned 
by consensus on the importance of collecting and sharing 
information; the need to identify and disseminate good 
practice; and the value of cooperation and coordinated 
action in response to the common threat to the health, 
well-being and security of our citizens posed by drugs.
A reflection on the information available also reminds us 
of the need for continued vigilance and of the dangers of 
complacency. Warning notes are sounded in this report 
in respect of drug-related HIV infections and drug-related 
deaths. Nonetheless, in Europe as a whole, a tremendous 
effort has been made to address these sorts of problems, 
and tangible progress has been made. This has meant that 
European policymakers have had to make difficult choices, 
and they have largely done so after carefully studying the 
available evidence. Such a policy perspective should be 
applauded. The global debate on the drug problem is not 
short on rhetoric regarding the need for a balanced and 
evidence-based approach. In Europe, perhaps more than 
anywhere else, this rhetoric has become reality. Despite 
differences between our Member States in the details of 
the drug problems they each face and in their priorities for 
action, there is common agreement on the importance of 
sharing information and cooperating in order to reduce the 
supply of drugs as well as on the need to balance supply 
reduction activities with demand reduction measures, and 
there is a growing consensus regarding the need to be 
guided by the evidence in making hard choices about what 
programmes and actions are in the best interests of our 
citizens. This European approach is manifested not only in 
the new European drug strategy, but also in the national 
drug strategies that our Member States have adopted, in the 
stronger and more unified voice that emerges from Europe 
on this issue, and in the work of the EMCDDA as we strive 
to play our part in facilitating informed policymaking by 
providing an unbiased and scientifically rigorous analysis 
of the information available on the drug phenomenon in 
Europe.
Drug use is a complex issue, and it is not one that lends itself 
to simple conclusions. However, one conclusion does clearly 
emerge from the European experience — we have learned 
that working together not only works but is also indispensable 
if we are to develop effective responses to the challenges 
presented to us by the use of illicit drugs.
Marcel Reimen
Chairman, EMCDDA Management Board
Wolfgang Götz
Director, EMCDDA
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9Introductory note
This annual report is based on information provided to the EMCDDA by the EU Member States and candidate countries and 
Norway (participating in the work of the EMCDDA since 2001) in the form of a national report. The statistical data reported 
here relate to the year 2004 (or the last year available). Graphics and tables in this report may reflect a subset of EU countries: 
the selection is made on the basis of those countries from which data are available for the period of interest.
An online version of the annual report is available in 23 languages and may be found 
at http://annualreport.emcdda.europa.eu
The 2006 statistical bulletin (http://stats06.emcdda.europa.eu) presents the full set of source tables on which the statistical 
analysis in the annual report is based. It also provides further details on the methodology used and over 100 additional 
statistical graphs.
Country data profiles (http://dataprofiles06.emcdda.europa.eu) provide a top-level, graphical summary of key aspects 
of the drug situation for each country.
Three in-depth reviews accompany this report and explore the following issues:
• European drug policies: extended beyond illicit drugs?
• A gender perspective on drug use and responding to drug problems
• Developments in drug use within recreational settings
The selected issues are available in print and online (http://issues06.emcdda.europa.eu) in English only.
The national reports of the Reitox focal points give a detailed description and analysis of the drug problem in each country 
and are available on the EMCDDA website (http://www.emcdda.europa.eu/?nnodeid=435).
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Commentary — the drug problem in Europe
A new European framework for coordination 
and cooperation
Although defining national drug policies remains the 
prerogative of individual European Member States, there 
is now strong agreement on the benefits that can accrue 
from working together at the European level. This can 
be seen in a number of recent developments that support 
coordination and cooperation activities. Among these 
developments are the coming into force in 2005 of two new 
EC regulations on precursors and a Council decision on 
new drugs. In addition, measures against drug trafficking 
are strengthened by new legal instruments to address 
money laundering and confiscation of assets. However, 
the development that is most central to shaping European 
collaboration and future actions on the drug issue is the new 
EU drug strategy for 2005–12 and its two accompanying 
action plans. In the first of these, around 100 planned 
specific actions are detailed by EU Member States to 
be implemented by 2008. A continuous programme of 
evaluation is envisaged for the strategy, with annual 
progress reviews and impact assessments at the end of each 
of the two action plan periods.
The strategy can be seen as representing a European 
consensus on how the drug problem should be addressed. 
There is an explicit commitment to a balanced approach 
combining both supply- and demand-side measures, 
matched by an acceptance of the need to base actions 
on the evidence of effectiveness and, furthermore, 
to systematically evaluate progress. Important policy 
differences between European Member States still exist, 
often reflecting differences in the national drug situations 
and in the configuration of responses. Nonetheless, the 
new drug strategy suggests that the European policy debate 
on drugs is increasingly characterised by agreement on a 
common framework for activities. For example, virtually all 
demand reduction strategies include prevention, treatment 
and harm reduction elements, although the emphasis on 
each varies between Member States. Some policy options 
continue to generate considerable debate — but in general 
this is against a background of broad agreement on the 
fundamentals that underpin the European response to the 
drug problem.
Drug use and drug supply: a distinction increasingly made
A continuing trend, again evident in the new information 
reported this year, is for changes to national drug laws to 
emphasise more strongly a distinction between offences 
of drug possession for personal use and those involving 
trafficking and supply. Generally, there is a shift towards 
increased penalties for the latter and a reduced emphasis on 
custodial sentences for the former. This development is in line 
with a greater emphasis overall across Europe on widening 
the opportunities for drug treatment and on giving more 
attention to interventions that divert those with drug problems 
away from the criminal justice system towards treatment and 
rehabilitation options. For those countries that have made 
a legal distinction with respect to the possession of drugs 
for use rather than supply, the question arises whether there 
is an explicit need to legislate on what quantities of drugs 
constitute a threshold for personal use. Here no consensus 
currently prevails and different approaches have been 
adopted across Europe, ranging from the issuing of general 
operational guidelines through to specification of legal limits.
Heroin use: an important part of a bigger picture
Data presented in this report show that across Europe as a 
whole the historical focus on heroin use and injecting as the 
central elements of the drug problem needs to be widened 
because of the increasing importance of polydrug use and 
stimulant use and the growing public health implications of 
widespread cannabis use. Nevertheless, in many countries 
opioids (largely heroin) remain the principal drugs for which 
clients seek treatment, accounting for about 60 % of all 
recorded treatment requests in 2004 — and among these 
clients just over half (53 %) reported injecting the drug.
Nearly 25 % of opioid treatment demands are made by 
individuals aged 35 years or more, with only 7 % of clients 
seeking treatment for the first time being aged under 20. 
It should be noted that treatment demand data reflect the 
number of clients requesting treatment during the reported 
year and do not include people continuing in treatment; 
consequently the total number of clients in treatment is 
considerably higher. Across Europe as a whole, the 
substantial growth in drug substitution treatment that has 
occurred in recent years means that the treatment system 
kg609922insideEN.indd   11 27/10/06   10:13:30
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includes an increasing, and ageing, population of people 
with heroin problems, who are likely to require care and 
remain major consumers of resources for many years to 
come.
Heroin consumed in Europe is manufactured predominantly 
in Afghanistan. Europe continues to account for the greatest 
quantities of heroin seized worldwide, and, as a result of 
an increase in seizures in south-eastern European countries 
(particularly Turkey), this region has surpassed western and 
central Europe in terms of volume intercepted. This rising 
trend in heroin seizures not only underlines the value of 
coordinated action against trafficking at the wider European 
level but also raises important questions about the impact 
of increased heroin production on the European market. 
No clear trends are visible with respect to average purity; 
however, the five-year price trend (1999–2004) corrected 
for inflation is downwards in most countries. Nevertheless, 
although heroin is more readily available and cheaper 
in Europe, there is no evidence yet that this is influencing 
overall levels of consumption. Overall indicators would 
suggest that the incidence of new heroin use is still declining 
in Europe within what is probably a stable situation — with 
a significant proportion of those with opioid problems now 
receiving substitution treatment, at least in some countries. 
Among those new to treatment, the numbers with a primary 
opioid problem have been decreasing in most countries. 
Nonetheless, this is an area where waves of epidemic use 
have been seen in the past, and therefore complacency must 
be avoided.
In this year’s report, there are worrying indicators that the 
number of drug-related deaths, which has generally declined 
since 2000, increased slightly in a majority of countries in 
2004. It is too early to judge whether these small changes 
herald a long-term shift, but it must be remembered that 
drug-related deaths represent one of the major public health 
consequences of illicit drug use. Even though the proportion 
of drug-related deaths occurring in young people has been 
falling, supporting suggestions that new heroin injecting 
is declining, available city-based estimates of drug-related 
mortality (overdose and other causes) suggest that currently 
10–23 % of overall mortality among adults aged 15–49 can 
be attributed to opioid use.
Injecting and injecting-related health problems: 
a constant companion
In many countries, drug injecting is almost synonymous 
with heroin use, but there are exceptions, with a few EU 
countries reporting significant levels of stimulant injecting, 
mostly among heavy users of amphetamines. Mirroring to 
some extent the picture for heroin, overall the information 
available suggests a general decrease in drug injection 
over the longer term. However, in many of the new Member 
States injecting rates remain high. An important caveat here 
is that the availability of national or subnational estimates 
of drug injecting is poor. Moreover, studies of injecting in 
some regions have even reported slight increases recently. 
The most comprehensive picture of this behaviour comes 
from monitoring heroin users in treatment, among whom the 
proportion of injectors has declined dramatically in some 
countries, but not in others. Notably, among the old Member 
States, Denmark, Greece, Spain, France, Italy and the United 
Kingdom all report declining rates of injecting among heroin 
users in treatment.
The relationship between drug injecting and health 
problems is well known, and drug injectors have a high 
risk of overdose and serious infection as well as other 
health problems such as septicaemia and thrombosis. HIV 
infection is the health risk that has galvanised the European 
public health response to this form of drug use, and almost 
all countries now have interventions aimed at preventing 
new infections. For example, needle and syringe provision, 
once regarded as a controversial intervention, is available 
to some degree in virtually all Member States, although 
the coverage varies considerably between countries. Most 
countries report low rates of newly diagnosed HIV infection 
attributable to drug injecting, and HIV infection rates among 
injectors are estimated to be below 5 %. However, again 
important caveats should be borne in mind: first, two of 
the largest countries most affected by AIDS among drug 
injectors, Spain and Italy, currently do not provide national 
HIV case reporting data; and, second, it is reported that HIV 
transmission is continuing to occur in specific injecting groups 
across Europe, and there are even signs of increases in some 
of the population groups studied.
A far more negative picture presents itself for rates of 
infection with the hepatitis C virus (HCV), which remain 
almost universally high among drug injectors. Treating the 
HCV-related health problems among drug injectors and 
ex-injectors is likely to remain a major health cost for many 
years to come. In drawing the conclusion that drug injecting 
may be slowly declining and that Europe has responded 
well to the challenge posed by the epidemic spread of HIV 
in the 1990s, there is a real danger that this may lead to 
complacency about the health threats still posed by this 
behaviour. High levels of endemic HCV infection, continued 
transmission among drug injectors, with increased incidence 
observed in some groups, and a large high-risk group of 
injectors in some of the new Member States all speak of the 
need to continue to regard drug injection, and its associated 
health problems, as a major public health issue in Europe 
and a critical area for drug policy and research vigilance. 
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Cocaine: signs of stability for Europe’s second most 
common illicit drug
Estimates of cocaine use (last year prevalence) now place 
the drug slightly ahead of amphetamine and ecstasy 
as Europe’s second most used illicit drug. However, the 
general picture is one of stabilisation in levels of use after 
a period in which users of the drug increased considerably 
in number. The large increases in cocaine prevalence 
experienced by Spain and the United Kingdom from the mid 
to late 1990s seem to have stabilised since 2000 or 2001. 
Elsewhere, while some moderate increases in levels of 
cocaine use have been noted in a few countries, dramatic 
increases are not being reported. Overall, the cocaine 
situation remains very heterogeneous in Europe and 
significant cocaine use is restricted to a few, mainly western 
European, countries.
It would be wrong to conclude that the signs of stabilisation in 
use of cocaine will necessarily result in a stabilisation in the 
extent of problems attributed to use of this drug. In Europe, 
cocaine use is at historically high levels, and studies suggest 
that it is a common pattern for increases in problems relating 
to a drug to lag some years behind increases in prevalence. 
This is because it takes time for intensive and regular 
patterns of drug use to develop and for problems to become 
visible. This may be beginning to happen in those European 
countries where cocaine use is now well established. In both 
the Netherlands and Spain, at least one in four treatment 
demands is now reported to be cocaine related, and overall 
in Europe new treatment demands for cocaine roughly 
doubled between 1999 and 2004. Although the use of 
crack cocaine remains very limited in Europe, reports of 
problems from some cities suggest that the situation may be 
deteriorating.
Cocaine is often found in the toxicological analysis of 
deaths attributed to opioid drugs, and in a number of 
countries concurrent cocaine use has become a recognised 
problem for those treating heroin problems. Although data 
are limited, in the 2005 national reports over 400 deaths 
were identified as being causally related to cocaine use, 
and cocaine-related deaths appeared to be increasing 
in all high-prevalence countries. This figure is almost 
certainly an underestimate and the impact of cocaine use 
as a contributor to deaths due to cardiovascular problems 
remains unknown. The message is clear: if Europe is to 
avoid experiencing an increase in the public health costs 
associated with the use of this drug, any stabilisation in 
overall use of cocaine should not mask the need for both a 
better identification and understanding of cocaine-related 
problems and the need for investment in the development of 
effective responses.
At a glance — estimates of drug use in Europe
(Note that these estimates relate to the adult population 
and are the most recent estimates available. For complete 
data and full methodological notes see the accompanying 
statistical bulletin.)
Cannabis
Lifetime prevalence: at least 65 million, or one in fi ve 
European adults
Last year use: 22.5 million European adults or one third 
of lifetime users
Use in the past 30 days: 12 million Europeans
Country variation in last year use:
 Overall range 0.8 % to 11.3 %
 Typical range 2.8 % to 7.5 % (15 countries)
Cocaine
Lifetime prevalence: at least 10 million, or over 3 % 
of European adults
Last year use: 3.5 million European adults or one third 
of lifetime users
Use in the past 30 days: over 1.5 million
Country variation in last year use:
 Overall range 0.1 % to 2.7 %
 Typical range 0.3 % to 1.2 % (18 countries)
Ecstasy
Lifetime prevalence: about 8.5 million European adults
Last year use: 3 million or one third of lifetime users
Use in the past 30 days: more than 1 million
Country variation in last year use:
 Overall range 0.0 % to 3.5 %
 Typical range 0.3 % to 1.5 % (15 countries)
Amphetamines
Lifetime prevalence: almost 10 million or around 3 % 
of European adults
Last year use: 2 million, one fi fth of lifetime users
Use in the past 30 days: less than 1 million
Country variation in last year use:
 Overall range 0.0 % to 1.4 %
 Typical range 0.2 % to 1.1 % (16 countries)
Opioids
Problem opioid use: between 1 and 8 cases per 1 000 adult 
population (aged 15–64)
Almost 7 000 acute drug deaths, with opioids being found in 
around 70 % of them (2003 data)
Principal drug in about 60 % of all drug treatment requests
More than half a million opioid users received substitution 
treatment in 2003
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Responding to a more complex European drug problem
A common theme running through this report is the increasing 
need to develop responses that are sensitive to the complex 
and multifaceted nature of today’s drug problem. When 
prevention, treatment or harm reduction activities are 
considered, there is a need to better understand what 
constitutes good practice and evidence-based action. Among 
the total of approximately 380 000 treatment demands 
reported in 2004, cannabis was the primary reason for 
referral to treatment in about 15 % of all cases, making it the 
next most commonly reported drug after heroin. Treatment 
services are also dealing with more stimulant and polydrug 
problems, including a considerable overlap of illicit drug and 
alcohol problems. However, at the population level we do not 
know enough about the public health implications of regular 
and persistent use of these types of drugs, nor about the likely 
intervention needs of those who use them. The evidence base 
in Europe for determining the response to drug problems 
is strongest for responding to the problem of illicit opioid 
use, where a considerable body of evidence supports the 
development and targeting of services. The growing consensus 
that exists to guide policy on what is likely to constitute 
appropriate intervention for problem heroin use is matched 
by a growing need to develop the same clarity on how we 
respond to a more heterogeneous European drug problem.
The need better to define and understand polydrug use
A key issue is the need to respond to problems caused by 
the use of multiple psychoactive substances. Polydrug use 
is becoming increasingly recognised as a key area for 
service development. However, definition of the concept 
remains elusive, and in some respects nearly all those who 
use drugs can be considered polydrug users. Polydrug use 
also poses considerable challenges to drug monitoring 
systems, which tend to be based on behavioural measures 
of the use of an individual index drug. There is therefore a 
critical need to develop a better conceptual framework for 
describing different types of polydrug use as a first step to 
understanding the implications of this behaviour. This year’s 
report devotes space to presenting the analytical issues that 
must be addressed if Europe is to meet the challenge of 
better understanding the needs of the increasing number of 
individuals whose problems stem from the use of a range of 
drugs rather than a dependency on a single substance.
Drug use in Europe cheaper than ever before
In this report, for the fi rst time, a fi ve-year analysis of the street 
prices of illicit drugs is included, corrected for infl ation to allow a 
more accurate assessment of changes in the street price of illicit 
drugs over time. Data on street prices are diffi cult both to collect 
and to interpret. The purity, quantity and variety of the substance 
bought all infl uence price, as do geographical factors such as 
living in a big city or on a regular drug transit route. Drug prices 
also vary considerably between countries and are subject to 
fl uctuations over time that refl ect disruptions in supply. Despite 
these distortions in the data, across most drug types the available 
data suggest that in Europe as a whole the cost of buying drugs 
has fallen. For most countries, the predominant fi ve-year trend has 
been a decline in street price for cannabis, heroin, amphetamine, 
ecstasy and cocaine (see graphic below). Although historical 
data on street prices are largely lacking and diffi cult to interpret 
when available, worryingly this recent trend accords with the 
suggestion that prices may have been declining over the longer 
term. For example, information available from some of the high-
prevalence countries suggests that cocaine and ecstasy were 
considerably more expensive in the late 1980s and early 1990s 
than they are today.
NB:   The trends represent the available information on national street-
level prices for each drug in the EU Member States and Norway, 
weighted by country population sizes to form an overall European 
trend. Prices have been adjusted for national infl ation rates (base 
year 1999) and all series indexed to a base of 100 in 1999.
   Many countries cannot supply these data, which are diffi cult to 
obtain and often unreliable and incomplete. Countries missing drug 
price information for two or more consecutive years are not included 
in the trend calculations for the drug: the trend for heroin brown is 
based on 9 countries, amphetamine on 9, cocaine on 13, ecstasy 
on 13, herbal cannabis on 13, and cannabis resin on 14.
   Additionally, where 2004 data are missing (11 cases) 2003 prices 
are used; for missing 1999 data (1 case) 2000 prices are used; 
data missing for other years (12 cases) have been interpolated from 
adjacent years.
   For further details on 2004 prices, see Tables PPP-1 to PPP-4 in the 
2006 statistical bulletin.
Sources:  Price data: Reitox national focal points.
  Infl ation and population data: http://epp.eurostat.ec.europa.eu/
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Back to the future: anticipating threats and challenges
In this year’s report, as always, an attempt is made to identify 
emerging trends to anticipate future problems. Such analysis 
is by definition speculative and must be made with caution. 
A drug clearly associated with severe public health problems 
is methamphetamine. While globally methamphetamine 
problems continue to grow, within Europe the drug remains 
restricted to a few countries with long-established problems. 
Although the available information does not permit us to 
draw any firm conclusion on trends, more countries are 
reporting seizures or use of the drug, clearly emphasising 
the need for more intensive monitoring of those population 
groups most at risk.
In 2006, the EMCDDA published a technical paper 
on hallucinogenic mushrooms, and this issue is again 
summarised in our annual reporting. The availability and 
use of hallucinogenic mushrooms appears to have been 
increasing since the late 1990s but to a large extent has 
passed unnoticed. For the most part, use of this type of drug 
appears to be experimental and reports of problems remain 
rare. However, a growing awareness among policymakers 
of the availability of hallucinogenic mushrooms has led to the 
introduction of some actions to increase control measures.
Psilocybin and psilocin, two of the psychoactive substances 
found in hallucinogenic mushrooms, are controlled by an 
international convention. However, the fact that mushrooms 
grow naturally in many countries poses a more complex 
issue for legislation, and they are treated differently 
across Europe. More generally, vigilance on emerging 
substances that may pose a threat to public health and 
therefore require control is supported by a new Council 
decision (2005/387/JHA) on information exchange, risk 
assessment and control of new psychoactive substances. An 
example of the need for early-warning information in this 
area has been the rapid spread of mCPP (1-3-chlorophenyl 
piperazine) in 2005. The emergence of mCPP illustrates 
the fact that those involved in the production of illicit 
drugs are constantly looking for innovation in the form of 
new chemicals that can be introduced to the market — in 
this case probably to potentiate or modify the effects of 
MDMA (ecstasy). Such innovation requires a response as 
the potential for these substances to cause severe health 
problems is unknown. The early-warning system put in place 
by the Council decision therefore represents an important 
mechanism to intervene in a process in which the health of 
young Europeans is put at risk by those who pursue profit by 
avoiding existing drug control mechanisms.
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Chapter 1
Policies and laws
National drug strategies
During the reporting period, national drug strategies and 
action plans were adopted by five countries (Table 1). 
Latvia adopted a national drug strategy for the first time, for 
the period 2005–08, while new national drug strategies 
and plans were adopted in the Czech Republic, Spain, 
Luxembourg and Romania.
In addition, Finland adopted a drug strategy for the prison 
administration (2005–06), and in the United Kingdom public 
service agreements (PSAs) set out new objectives and targets in 
the field of drug policy aimed at reducing the harm caused by 
illegal drugs to individuals, their families and the community.
During the reporting period, national drug strategies were 
under preparation in Italy, Austria, Poland, Portugal, Sweden 
and Norway (Table 2).
Some countries, having first implemented national drug 
strategies and action plans some time ago (1998 onwards), 
are now reformulating their strategies or plans, placing greater 
emphasis on setting clearer and more feasible objectives. 
For example, Luxembourg reports that its new action plan 
2005–09 is simple, clearly structured and output oriented, 
setting objectives for actions, identifying responsibilities and 
specifying budgets, anticipated outcomes and deadlines 
for outcome and evaluation. In Belgium, an expert group 
was appointed by the public health authorities of the French 
Community and the Walloon Region to establish a ‘concerted 
plan of prevention, help and care in drug addiction’. The 
group recommended that ‘priorities and objectives should 
be defined more clearly by the governments’, that ‘a clear 
definition of the basic principles of a common drug policy 
should take place’ and that ‘a chronology of the chosen 
strategies should be identified’. The 2005–06 action plan 
in the Czech Republic follows a similar direction, specifying 
concrete goals and the activities needed to meet them, and 
setting out the responsibilities of individual ministers and the 
terms and indicators of fulfilment for each field.
Evaluation of national drug strategies
Many European countries automatically renew their national 
drug strategies, setting in motion a cyclical process in which 
the results of the previous strategy, or its evaluation, provide 
input for the future strategy (EMCDDA, 2004a).
During 2005, such a process was reported by Ireland, 
Luxembourg, Hungary and Romania. Evaluation of the 
implementation of the Hungarian strategy to combat the drug 
problem was undertaken externally by the Dutch Trimbos 
Institute, the first time that a country’s drug strategy has 
been assessed by foreign experts. The evaluation focused 
on the mid-term results of the drug strategy and led to a set 
of recommendations regarding future drug strategies and 
how the coordination structure in the field of drug policy 
could be strengthened. There are similarities with the 2004 
evaluation of the 1999 Portuguese national drug strategy 
and the 2001–04 action plan, conducted externally by 
the Portuguese National Institute for Public Administration 
and internally by the Institute for Drugs and Addiction (IDT). 
Table 2: Countries with drug strategies 
in preparation in 2005
Country Document Time span
Italy Action plan 2004–08
Austria National strategy
Portugal National strategic plan 
and action plan
2005–08
Sweden Action plan
Norway Action plan
Table 1: Countries adopting new drug 
strategies in 2005
Country Document Time span
Czech Republic National drug strategy
Action plan
2005–09
2005–06
Spain Action plan 2005–08
Latvia National drug strategy 2005–08
Luxembourg National strategy and 
drug action plan 
2005–09
Romania National drug strategy 2005–12
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Hungary and Portugal are the first two countries in Europe 
to have requested external assessment of their national drug 
strategies.
In 2005, the mid-term review of the Irish drug strategy 
2001–08, based on a public consultation process and 
analysis of key national and EU data, recommended 
‘refocusing’ priorities in order to address emerging trends 
in treatment, polydrug use, cocaine use and the spread 
of HIV and hepatitis C and ‘re-energising’ the roll-out and 
implementation of various key actions during the remaining 
period of the strategy. And in Romania, the national drug 
strategy 2003–04 was evaluated with the participation 
of all state institutions involved in the field of drugs with 
the findings forming the basis for the new national drug 
strategy 2005–12. In Luxembourg, 87 % of the measures 
set out in the 2000–04 national drug action plan have been 
implemented within the specified deadlines. It is reported 
that the measures not introduced (e.g. a heroin distribution 
programme) have been delayed mainly for political reasons. 
Actions not yet implemented have been included in the new 
action plan.
Furthermore, reports over the last year suggest that national 
drug strategies are beginning to have visible effects. While it 
is not yet possible to say definitively that the overall aims of 
reducing demand and supply have been achieved, there is 
no doubt that national drug strategies have reached specific 
and important targets.
Evaluation of the Portuguese drug strategy adopted in 
1999 attributes to it an increase in the availability of drug 
treatment, a reduction in drug-related deaths and HIV 
prevalence and an increase in police reports for drug 
trafficking. On the other hand, it also found that there has 
been a fall in the age at which people first experiment with 
drugs and an increase in drug-related deaths linked to 
substances other than opioids. In Spain, the evaluation of 
national strategy (2003), while recognising that the objective 
of reducing drug use has not been realised, reveals that good 
results have been achieved in the areas of assistance and 
harm reduction, and satisfactory results have been achieved 
in other areas, such as research and education, international 
cooperation and supply reduction. In addition, the Ministry of 
Health and Consumers’ Affairs has approved an action plan 
2005–08 to mobilise resources and implement initiatives 
with the aim of progressing and revitalising the national drug 
strategy. And, in Greece, a consequence of the national 
action plan 2002–06 has been an increase in the type and 
coverage of available treatment programmes.
In Sweden, the national action plan on drugs 2002–05 
resulted in drugs moving up the political agenda at the local, 
regional and national level. Most municipalities in Sweden 
now have some form of action plan on drugs, and higher 
priority is now given to coordination and cooperation between 
stakeholders in the field of drugs, resulting in improvements 
in these areas. There have also been developments in both 
the types and accessibility of treatment available for drug 
addicts. In the United Kingdom, the Audit Commission, 
while acknowledging progress in drug treatment, suggested 
that there remains room for improvement in facilities for 
reintegration and rehabilitation of drug users, such as 
housing, social care and other support services. In the future, 
the government’s success in achieving the aims of the drug 
strategy will be measured against targets set out in the PSAs, 
and by a drug harm index (DHI), which will assess the harms 
generated by problem use of any illegal drug.
Finally, evaluation is identified as a key element in the newly 
adopted national drug strategies. In Latvia, the Drug Control 
and Drug Addiction Restriction Coordination Council will 
evaluate the progress of implementation of the programme 
every year, and in Luxembourg a final external output 
evaluation will be undertaken in 2009.
Drug-related public expenditure
Although expenditure is frequently measured over differing 
time periods, and there is no common definition of drug-
related public expenditure, available estimates suggest that 
drug spending has increased in several countries, including 
the Czech Republic, Denmark, Luxembourg, Austria and 
Poland.
Countries reporting drug expenditure for the year 2004 
included the Czech Republic (EUR 11.0 million), Spain 
(EUR 302 to 325 million), Cyprus (EUR 2.8 million), Poland 
(EUR 51 million) and Norway (EUR 46 million). Two 
countries reported more recent budgeted expenditure for 
tackling drugs: Luxembourg (EUR 6 million in 2005) and the 
United Kingdom (EUR 2 billion in 2004/05).
In Slovakia, it is estimated that total public expenditure in the 
field of drugs in 2004 was EUR 14.5 million, of which law 
enforcement accounted for approximately EUR 8.4 million 
and social and healthcare for EUR 6.1 million.
In Sweden, it is estimated that drug policy expenditure 
during 2002 was around EUR 0.9 billion (lower estimate 
EUR 0.5 billion, higher estimate EUR 1.2 billion). Comparing 
the 2002 estimates with figures for 1991 shows that public 
expenditure on drug policy has increased substantially.
In Ireland, the mid-term review of the national drug strategy, 
published in June 2005, recognises that ‘a measure of the 
expenditure is vital to gauge the cost effectiveness of the 
different elements of the strategy’, and work will commence 
shortly to estimate police expenditure. In Portugal, the Institute 
for Drug and Drug Addiction (IDT) is funding research to 
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develop and test a model to estimate the costs of drug 
abuse, and in Belgium a follow-up to a 2004 study on public 
expenditure was instituted at the end of 2005. Although 
sparse, these interesting data show that research on drug 
expenditure constitutes an increasingly important part of the 
policy agenda of some Member States.
EU legal and policy developments
Action plans
At EU level, two action plans adopted in 2005 directly 
or indirectly create a new frame of reference for the 
development of EU policy in the field of drugs for the next 
few years. First, having examined the Commission’s proposal 
of February 2005, and taking fully into account the final 
evaluation of the EU drug strategy and EU action plan 
(2000–04), the Council endorsed the EU drugs action plan 
2005–08 in June 2005. The new action plan follows the 
structure and the objectives of the EU drug strategy 2005–12 
and lists around 100 specific actions to be implemented by 
the EU and its Member States by the end of 2008.
Evaluation forms a substantial part of the new EU drugs 
action plan. It is conceived as a continuous, incremental and 
participative process. It is continuous because the European 
Commission, with the support of the EMCDDA and Europol, 
will present annual progress reviews. The evaluation exercise 
will also be incremental, each annual progress review 
placing the results of the last year within the context of the 
preceding year. Finally, the process will be participative, 
involving an evaluation steering group whose task will be to 
define the methodology, output and provisional calendar. 
As in the evaluation of the EU action plan (2000–04), the 
steering group will be made up of representatives of relevant 
Commission departments, the EMCDDA and Europol, as 
well as representatives of the Member States. Consultative 
hearings for civil society representatives will also be 
organised. At the end of the 2005–08 drug action plan, and 
for the first time at European level, an impact assessment 
will be organised with a view to proposing a new action 
plan for the period 2009–12, which is intended to take 
this assessment as a starting point. A final evaluation of the 
strategy and of the action plans will then be carried out by 
the Commission in 2012.
This EU drug action plan is also a component of the action 
plan to implement the Hague programme, which sets 
objectives to be implemented in the area of freedom, security 
and justice in the European Union over the period 2005–10. 
This action plan was presented by the Commission in May 
2005 and approved by the Council in June 2005.
The EU action plan 2005–08 reflects the EU’s balanced 
approach to the drug phenomenon, i.e. a comprehensive 
multidisciplinary approach that considers the issue from every 
angle: coordination, demand reduction, supply reduction, 
international cooperation, information, research and 
evaluation.
Drug supply reduction
Two important activities in the EU in the field of drug supply 
reduction were characterised by the coming into force, on 
18 August 2005, of the two EC regulations on precursors, 
adopted in 2004. Controls on chemical precursors are 
an important aspect of drug supply reduction, as these 
substances are indispensable in the production of drugs. 
Action in this area in the EU takes two forms: first, the 
regulation of trade in certain substances between the EU and 
third countries and, second, regulation within the internal 
market.
Adopted in 1990 to comply with the provision of Article 
12 of the 1988 United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances, on 
precursors control, the first regulation laid down measures 
to be taken to discourage the diversion of certain substances 
to the illicit manufacture of narcotic drugs and psychotropic 
substances (1). It was replaced in December 2004 by a new 
regulation with an extended application framework aimed at 
countering also the manufacture of synthetic drugs (2).
A Council directive (3) issued two years later, in 1992, 
completed the system and provided for corresponding 
arrangements within the internal market (the manufacture 
and the placing on the market of certain substances used 
in the illicit manufacture of narcotic drugs and psychotropic 
substances), including the setting up of control measures. 
It has been replaced by a new regulation adopted on 
11 February 2004 (4). As a result of EU enlargement, 
Community legislators have decided to replace the 
1992 directive with a regulation as ‘each modification 
of that directive and its annexes would trigger national 
implementation measures in 25 Member States’. The new 
instrument establishes harmonised measures for intra-EU 
control and monitoring of certain substances frequently used 
in the illicit manufacture of narcotic drugs or psychotropic 
(1) (2) (3) (4) 
(1) Council Regulation (EEC) No 3677/90 of 13 December 1990, OJ L 357, 20.12.1990, p. 1.
(2) Council Regulation (EC) No 111/2005 of 22 December 2004, OJ L 22, 26.1.2005, p. 1.
(3) Council Directive (EEC) No 109/92 of 14 December 1992, OJ L 370, 19.12.1992, p. 76.
(4) Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004, OJ L 47, 18.2.2004, p. 1.
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(5) (6) (7) 
(5) Commission Regulation (EC) No 1277/2005 of 27 July 2005, OJ L 202, 3.8.2005, p. 7.
(6) Council Directive 91/308/EEC of 10 June 1991 on prevention of the use of the financial system for the purpose of money laundering, OJ L 166, 28.6.1991, 
pp. 77–83.
(7) For more information see the Commission’s website (http://ec.europa.eu/health/ph_projects/action3_en.htm).
substances, with a view to preventing the diversion of such 
substances. In particular, it obliges Member States to adopt 
the necessary measures to enable their competent authorities 
to perform their control and monitoring duties. In addition, 
a regulation laying down rules for implementing these two 
regulations came into force on 18 August 2005 (5).
These actions in the area of precursors control complete another 
part of the important activities of the EU in the field of supply 
reduction. Utilising the new opportunities provided since the 
Maastricht Treaty, the EU has developed a legal framework 
to combat drug trafficking and to improve law enforcement 
cooperation. Several joint actions in this field have been 
adopted since 1995–96, and more recently a framework 
decision to harmonise minimum sanctions against drug 
trafficking and a decision on new psychoactive substances have 
been adopted (see ‘Action on new drugs’, p. 55).
In addition to these legal instruments, a programme for police 
and judicial cooperation in criminal matters has been adopted 
and implemented. Agis is a framework programme to help the 
police, other relevant agencies and the judiciary from the EU 
Member States and candidate countries cooperate in criminal 
matters in the fight against crime. Since 2003, it has helped to 
fund many projects. International organised drug production 
and trafficking and drug precursors diversion are mentioned 
within the areas of activities and specific topics of the 2006 
Agis work programme and call for proposals (which closed 
in January 2006).
Money laundering and confiscation of assets
There have also been some modifications of legal instruments 
in the field of money laundering and confiscation. Directive 
91/308 on prevention of the use of the financial system for 
the purpose of money laundering (6), adopted in 1991 on 
the legal basis related to the internal market and modified 
in 2001, attempted to harmonise legislation in this area 
among Member States. One of the reasons for the adoption 
of this directive was to avoid the possibility that the absence 
of European Community action against money laundering 
could lead Member States to adopt protectionist measures 
that might delay the establishment and completion of the 
internal market. In June 2004, the Commission proposed a 
new directive with the same purpose but including in addition 
terrorist financing. Limiting the scope of the directive to the 
proceeds of drug trafficking was felt to be too restrictive, and 
the Commission proposed widening the range of offences 
covered. This new directive, adopted in October 2005, 
gives a precise definition of serious offences and covers 
the laundering of the proceeds of such offences, including 
financing of terrorist activities.
A framework decision on ‘the confiscation of crime-related 
proceeds, instrumentalities and property’ was also adopted 
by the Council on 24 February 2005. It aims to ensure that 
all Member States have in place effective rules governing 
the confiscation of instrumentalities and the proceeds of 
criminal offences punishable by deprivation of liberty for 
more than one year. EU legislation in this area existed 
previously but was considered insufficient. This new 
framework decision aims to achieve effective cross-border 
cooperation with regard to confiscation. The mechanism 
of confiscation is extended to other crime-related property 
when the offence was committed within the framework of a 
criminal organisation and when the offence is covered by 
one of several other EU framework decisions. Among these 
is Framework Decision 2004/757/JHA, which lays down 
minimum provisions on the constituent elements of criminal 
acts and penalties in the field of illicit drug trafficking. The 
Member States shall take the necessary measures to comply 
with this framework decision by 15 March 2007.
Public health
Demand reduction is an integral part of the European 
balanced approach to drugs. In the context of the 
implementation of the programme of community action in 
the field of public health 2003–08, in 2005 the European 
Commission selected some drug-related projects for funding 
with the objective of ‘promoting health and preventing 
disease through addressing health determinants across 
all policies and activities’. The first project to be funded in 
the drugs area, called EU-Dap 2, is the evaluation of the 
effectiveness of the EU-Dap school preventive programme, 
which aims to reduce tobacco, alcohol and drug use in the 
long term. The second project, IATPAD, aims to improve 
access to treatment for people with alcohol- and drug-related 
problems. Other horizontal projects include some aimed at 
drug prevention and should also be co-funded, for example 
‘PEER-Drive clean!’, which is an innovative project targeting 
young persons aged between 18 and 24 years and aimed 
at preventing driving while under the influence of alcohol or 
drugs. These projects have been selected for funding and 
should receive co-financing on condition that the negotiation 
procedures with the European Commission are successful 
and that the grant agreement is signed (7).
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EMCDDA regulation
Finally, on 31 August 2005, the Commission adopted a 
new proposal for the recasting of the EMCDDA founding 
regulation. The new regulation is an important instrument 
to facilitate the work of the EMCDDA because of the new 
tasks it defines. In particular, it allows the EMCDDA to take 
account of new drug use patterns and emerging trends in 
polydrug use, including the combined use of licit and illicit 
psychoactive substances; to develop tools and instruments 
to help Member States and the EU to monitor and evaluate 
their drug policies and strategies; and to cooperate with 
non-EU countries such as the candidates for EU accession or 
the countries of the western Balkans. It also contains several 
changes to the Scientific Committee and the Management 
Board. Based on Article 152 TEC, this text must now be 
adopted by the Council and the European Parliament 
according to the co-decision procedure.
New national laws
A few countries made major changes to their drug laws in the 
reporting period concerning both possession and trafficking 
offences and penalties.
In Romania, a new law and new penal code introduced 
distinctions between felonies and misdemeanours (with 
misdemeanours now punishable mainly by community work 
and day fines), between users and addicts and between 
low-risk and high-risk drugs. Exemption from penalty and 
postponing the execution of the penalty can now be applied 
to drug law offences. Treatment of addicts can now take 
place through an integrated assistance programme, overseen 
by a case manager. Prison sentences have been increased 
for offences related to providing a place for drug use, 
tolerating drug use in such a place, or encouraging drug use. 
Sentences were also increased for unlawfully administering 
high-risk drugs to a person and for supplying toxic chemical 
inhalants to a minor.
In Bulgaria, the new Narcotic Substances and Precursors 
Control Act was approved in June 2004. This act establishes 
the function of state bodies in the control of the regulatory 
procedures for drugs, in implementing measures against drug 
abuse and trafficking, and in research. A supplementary 
amendment removed the exemption of addicts from criminal 
responsibility if they were found in possession of one single 
dose (discussed further below).
In Slovakia, the new criminal code redefines the offences of 
possession of drugs for personal use and for trafficking. In 
contrast to the previous offence of possession for own use 
(defined as no more than one dose), Section 171 creates two 
offences of possession for own use, depending on the number 
of doses (see below for details). Two new penalties can also 
be imposed for these offences: monitored home imprisonment 
or community service. Possession of more than 10 doses must 
be charged under Section 172, which, depending on the 
aggravating circumstances, provides for prison sentences 
ranging from four years to life. In addition, the age of criminal 
liability has also been lowered from 15 to 14 years.
In Lithuania, handling drugs with intent to sell them can no 
longer be punished by up to 90 days in police cells; this 
offence now attracts a significantly more severe minimum 
punishment, namely a prison sentence, although the minimum 
sentence has been reduced from five to two years. The 
maximum sentence for theft of a large amount of drugs or 
theft by an organised group has been extended to 15 years.
In Italy, recent changes in legislation (February 2006) have 
reclassified drugs into two main groups rather than six (all 
substances with no therapeutic use are grouped together, 
removing any notion of hard and soft drugs); defined the 
threshold between personal use and trafficking; revised the 
sanctions to include house arrest and community service; and 
increased access to the alternatives to prison. In addition, 
all drug users now have the right to choose freely the type 
and location of treatment they receive and the institution that 
certifies their drug-addicted status, services that are no longer 
provided exclusively by the public sector.
In the United Kingdom, the Drugs Act 2005 made a number 
of substantial amendments to the national legislation 
including clarifying the classification of fungi containing 
psilocin or psilocybin as a class A drug; creating the 
presumption of intent to supply when a specified quantity 
of controlled drugs is found; allowing police to test drug 
offenders on arrest, instead of on charge, and requiring 
those testing positive to undergo assessment for drug use; 
and requiring courts to take into account aggravating factors 
(such as supplying drugs near a school) when sentencing. 
Courts may also remand in police custody for up to eight 
days (previously four days) those who swallow drugs 
packages, and a court or jury may now draw inferences if 
a person refuses to allow an intimate search or scan without 
good reason.
In general, there is a tendency across Europe to reduce or 
remove custodial penalties for personal use offences and, at 
the same time, to increase penalties for offences related to 
drug supply (8).
(8) 
(8) See 2005 annual report (http://ar2005.emcdda.europa.eu/en/page013-en.html). See also ‘Illicit drug use in the EU: legislative approaches’, an EMCDDA 
thematic paper (http://eldd.emcdda.europa.eu/?nnodeid=5175).
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Quantities
Several countries legislated on threshold quantities of drugs 
during the reporting period.
In Belgium, following the Constitutional Court’s annulment 
of Article 16 of the 2003 law, a new joint directive of the 
Minister of Justice and the Prosecutors-General dealt with 
cannabis-related infringements. It states that the possession 
of a small amount of cannabis for personal use (no more 
than three grams or one plant) by an adult should lead to a 
simple police registration only, if there are no aggravating 
circumstances.
In Slovakia, the role of quantity is central to the new penal 
code on drugs offences. Section 171 creates two offences 
of possession for own use: possession of no more than three 
doses may be punished by up to three years’ imprisonment, 
while a prison sentence of up to five years may be imposed 
for possession of ‘a larger amount’ (no more than 10 doses). 
Possession of quantities greater than this must be charged 
under Section 172. This allows a prison sentence of 
4–10 years to be imposed if there are no aggravating 
factors, and for sentences of 10–15 years for possession 
of a larger amount (with a street value of over 10 times the 
‘baseline’ amount of 8 000 Skk — approximately EUR 200), 
15–20 years for possession of drugs on a considerable scale 
(defined as over 100 times the baseline) and 20–25 years or 
life imprisonment for possession on a large scale (defined as 
over 500 times the baseline).
From 2002 to 2005, the Max Planck Institute in Germany 
carried out an evaluation of Section 31a of the German 
Narcotic Drugs Act, which permits the offence of possession 
of ‘insignificant quantities’ of drugs to be exempted from 
prosecution in certain circumstances. The evaluation found 
that, in practice, the implementation of Act §31a varies 
considerably in the 16 Länder of Germany, in part because 
of different interpretations of ‘insignificant’ (Schäfer and 
Paoli, 2006). In March 2005, the Land Berlin passed a 
revision of its ‘guideline on cannabis’, according to which 
possession of up to 10 grams of cannabis is not prosecuted if 
certain criteria are fulfilled. This amount can be increased to 
15 grams in individual cases.
The Minister of Health of Lithuania amended 
recommendations on what shall be regarded as small, 
large and very large amounts of narcotic and psychotropic 
substances, redefining these quantities. The United Kingdom 
Drugs Act 2005 now creates the presumption of intent to 
supply when a specified quantity of controlled drugs is 
found, with those quantities set out in regulations defined in 
spring 2006.
In Bulgaria, the Amendment and Supplement Act of the penal 
code (new SG 26/04) abolishes Section 354a (3), which 
exempted addicts from criminal responsibility if they were 
found in possession of a single dose. Difficulties in defining 
the quantity of a single dose and evidence that the exception 
has been misused in court to benefit drug dealers were 
among the reasons given for this measure.
In Italy, the changes implemented in February 2006 imposed 
new quantity limits to define the threshold between personal 
use and trafficking, based on the amount of active principle 
of the drug, following the removal of such limits in 1993. The 
limits are indicated in a specific Ministry of Health decree of 
April 2006.
As already shown by European Legal Databases on Drugs 
(ELDD) research (9), the role of quantity in drug laws is 
varied; in some countries (e.g. Slovakia), the quantities that 
delimit certain offences are strictly defined, while in others 
(e.g. the United Kingdom) quantities are guidelines that 
give rise to a rebuttable presumption of intent. Quantities 
may also distinguish between offences (e.g. possession 
or supply), or determine the penalty for the same offence. 
Though many countries refer to a quantity in their laws, 
quantity can be defined in different ways (weight, value) or 
even not at all. The latest, apparently contrasting, actions of 
Italy and Bulgaria continue to show only that there is no clear 
European consensus on this issue.
Sentencing statistics
Monitoring of sentences given to drug offenders has been 
discussed or implemented in several countries, and in some 
cases action has already been taken on the results.
In Ireland, approval has been given for the establishment 
of a central crime statistics unit to monitor statistics on 
arrests, prosecutions and the nature of sentences passed, in 
accordance with the national drug strategy.
The German Narcotic Drugs Act allows the prosecutor to 
discontinue proceedings for possession of drugs without 
court approval under certain circumstances. Despite 
recommendations and guidelines on these, regulations differ 
significantly between Länder. The aforementioned study 
on these differences, carried out for the Ministry of Health, 
looked at the sentencing of over 1 800 cases in six different 
Länder (Schäfer and Paoli, 2006).
(9) 
(9) See ‘The role of the quantity in the prosecution of drug offences’, an ELDD legal report, and Table 1 in ‘Illicit drug use in the EU: legislative approaches’, an 
EMCDDA thematic paper (both available at http://eldd.emcdda.europa.eu/?nnodeid=5175).
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In some provinces in Austria, there have been attempts to 
standardise implementation of Sections 12 and 35(4) of 
the Narcotics Act, which define simplified procedures to 
withdraw a report to the police in the case of the purchase or 
possession of small quantities of cannabis. Other sentencing 
statistics showed that the waiving of reports as statutory 
alternatives to punishment increased in 2004, though police 
reports and convictions increased further, while the number 
of suspended proceedings dropped slightly.
In Romania, court sentencing statistics were examined 
in order to monitor the success of social reintegration of 
drug users who commit offences other than drug use. In 
the majority of cases, the penalty was suspension of the 
sanction under surveillance. From 2004, it was noted that the 
courts less often imposed compulsory treatment, effectively 
decreasing the involvement of the probation services and thus 
their contribution to the social rehabilitation of drug users.
Statistics on sentencing, or avoidance of sentencing, give 
a far more accurate picture of the implementation of a 
country’s drug policy than does the text of the laws (see 
EMCDDA, 2002a). Although not all Member States collect 
comprehensive sentencing statistics, in contrast to arrest 
statistics, countries are starting to report a greater interest in 
monitoring this implementation, which is in line with the trend 
to evaluate policy instruments (10). The issue of collecting 
and analysing sentencing statistics was addressed by an 
EMCDDA expert meeting in 2006.
Drug-related crime
Action 25.1 of the EU drug action plan 2005–08 foresees 
the adoption by the Council, by 2007, of a common 
definition of ‘drug-related crime’, on the basis of a 
Commission proposal based on existing studies to be brought 
forward by the EMCDDA.
Although there is as yet no EU definition of drug-related 
crime, it is usually considered to mean crimes committed 
under the influence of drugs, crimes committed to finance 
drug use, crimes committed in the context of the functioning 
of illicit drug markets and offences in contravention of drug 
legislation. Routine data are available in the EU only on the 
last type of crime — drug law offences.
Data on the first three types of crime are rare or patchy in the 
EU. Some come from ad hoc local studies, which are difficult 
to extrapolate from, while others refer only to a specific type 
of drug-related crime.
Data on ‘reports’ (11) of drug law offences are available in all 
the European countries analysed in this report. They reflect 
differences in national legislation, but also the different ways 
in which the laws are applied and enforced, and differences 
in the priorities and resources allocated by criminal justice 
agencies to specific offences. In addition, there are variations 
between national information systems on drug law offences, 
especially in relation to reporting and recording practices — 
i.e. what is recorded, when and how. Because these 
differences make direct comparisons between EU countries 
rather difficult (12), it is more appropriate to compare trends 
rather than absolute numbers.
Over the five-year period 1999–2004, the number of 
‘reports’ of drug law offences increased overall in most EU 
countries (in fact in all reporting countries except Italy and 
Portugal, with particularly marked increases — twofold or 
more — in Estonia, Lithuania (13), Hungary (14) and Poland). 
In 2004, this increasing trend was confirmed in most 
(10) (11) (12) (13) (14) 
(10) See ‘National policies: evaluation of laws’ (http://ar2004.emcdda.europa.eu/en/page021-en.html).
(11) The term ‘reports’ for drug law offences is given in quotation marks because it describes different concepts in different countries. For an exact definition for 
each country, refer to the methodological notes on drug law offences in the 2006 statistical bulletin. 
(12) For a more complete discussion of methodological issues, refer to the methodological notes on drug law offences in the 2006 statistical bulletin.
(13) The increase in Lithuania is due to the implementation in May 2003 of the new criminal code.
(14) The increase in Hungary is mainly due to an amendment to the penal code and the criminal procedure.
Reports on the drugs–crime connection
In the Czech Republic in 2005, regional police headquarters 
were surveyed for the second consecutive year about drug-
related crime. It was estimated that in 2004 about 62 % 
of drug production/distribution offences, 25 % of fraud 
offences, 21 % of crimes involving misappropriation of funds/
property and 20 % of ordinary thefts were committed by 
drug users in order to fi nance their own consumption (Czech 
national report).
A survey carried out in 2004 among 15- to 16-year-olds 
in Finland showed that about 7 % of those who had used 
cannabis in the last year had fi nanced their use illegally, 
more than half by selling drugs and the rest mainly by stealing 
(Kivivuori et al., 2005, cited in the Finnish national report).
In Ireland, two studies carried out by the Garda Research Unit 
in 1996 and 2000/01 among a sample of drug users known 
to the police estimated that drug users were responsible for 
66 % of detected indictable crimes in 1996 and 28 % in 
2000/01 (Keogh, 1997; Furey and Browne, 2003, cited 
in the Irish national report). The 2000/01 survey found that 
opioid users were responsible for 23 % of detected larceny 
offences and 37 % of detected burglaries.
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(15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) 
(15) Data on ‘reports’ for drug law offences were available for 1999–2004 in all countries (although sometimes not for every year) except Cyprus, Slovakia, 
Bulgaria, Romania, Turkey and Norway; and for 2004 in all countries except Ireland, the United Kingdom and Norway.
(16) See Table DLO-1 and Figure DLO-1 in the 2006 statistical bulletin.
(17) Breakdowns by type of offence were available in all countries (although sometimes not for every year between 1999 and 2004) except Denmark, Estonia, 
Latvia, Lithuania, Hungary, Slovakia and Romania.
(18) See Table DLO-2 in the 2006 statistical bulletin.
(19) See Table DLO-4 in the 2006 statistical bulletin.
(20) See Table DLO-5 in the 2006 statistical bulletin.
(21) Breakdowns of drug law offences by substance were available in all countries (although sometimes not for every year between 1999 and 2004) except 
Denmark, Estonia, Latvia, Hungary, Finland, Romania and Norway.
(22) See Table DLO-3 in the 2006 statistical bulletin.
(23) See Figure DLO-2 in the 2006 statistical bulletin.
(24) See Table DLO-6 in the 2006 statistical bulletin.
(25) See Figure DLO-3 in the 2006 statistical bulletin.
(26) See Figure DLO-4 in the 2006 statistical bulletin.
(27) See Table DLO-7 in the 2006 statistical bulletin; note that in Sweden the proportion of heroin-related offences decreased over the period 1999–2003. 
(28) See Figure DLO-5 in the 2006 statistical bulletin.
(29) See Table DLO-8 in the 2006 statistical bulletin.
reporting countries (15), although a few countries reported a 
fall over the previous year — the Czech Republic, Greece, 
Latvia, Luxembourg, Portugal, Slovenia (since 2001), 
Slovakia, Finland and Bulgaria (16).
In most EU Member States the majority of reported drug 
law offences (17) are related to drug use or possession 
for use (18), ranging in 2004 from 61 % of all drug law 
offences in Poland to 90 % in Austria. In the Czech Republic, 
Luxembourg, the Netherlands and Turkey, most reported 
drug law offences relate to dealing or trafficking, with 
the proportion varying from 48 % of all drug offences in 
Luxembourg to 93 % in the Czech Republic.
Over the same five-year period, the number of offences for 
use/possession for use increased overall in all reporting 
countries, except Italy, Portugal, Slovenia, Bulgaria and 
Turkey, which reported a declining trend (19). The share 
of all drug law offences accounted for by these offences 
also increased in most reporting countries over the period, 
although the rate of increase was generally low, except in 
Cyprus, Poland and Finland, where more marked upward 
trends were reported. However, in Luxembourg, Portugal, 
Bulgaria and Turkey, the proportion of drug offences related 
to use/possession for use fell overall (20).
In most of the Member States, cannabis is the illicit drug most 
often involved (21) in reported drug law offences (22). In the 
countries where this is the case, cannabis-related offences 
in 2004 accounted for 34–87 % of all drug law offences. 
In the Czech Republic and Lithuania, amphetamines-related 
offences predominated, accounting, respectively, for 50 % 
and 31 % of all drug law offences; while in Luxembourg 
cocaine is the most reported substance (in 43 % of drug law 
offences).
In 1999–2004, the number of ‘reports’ of drug law offences 
involving cannabis increased overall in the majority of 
reporting countries, while decreases were evident in Italy and 
Slovenia (23). Over the same period, the proportion of drug 
offences involving cannabis increased in Germany, Spain, 
France, Lithuania, Luxembourg, Portugal, the United Kingdom 
and Bulgaria, while it remained stable overall in Ireland 
and the Netherlands, and decreased in Belgium, Italy, 
Austria, Slovenia and Sweden (24). Although in all reporting 
countries (except in the Czech Republic and Bulgaria and 
for a few years in Belgium) cannabis is more predominant in 
offences for use/possession than in other drug law offences, 
the proportion of use-related offences involving cannabis 
has decreased since 1999 in several countries — namely 
Italy, Cyprus (2002–04), Austria, Slovenia and Turkey 
(2002–04) — and has fallen over the last year (2003–04) 
in most reporting countries, possibly indicating a reduced 
targeting of cannabis users by law enforcement agencies in 
these countries (25).
Over the same five-year period, the number of ‘reports’ 
and/or the proportion of drug law offences involving heroin 
decreased in the majority of reporting countries, except 
Belgium, Austria, Slovenia and Sweden, which reported 
upward trends in the number of ‘reports’ involving heroin (26) 
and/or the proportion of drug offences that involved 
heroin (27).
The opposite trend can be observed for cocaine-related 
offences: in terms of both number of ‘reports’ (28) and the 
proportion of all drug offences (29), cocaine-related offences 
have increased since 1999 in most reporting countries. 
Bulgaria is the only country to report a downward trend in 
cocaine offences (both numbers and proportions of drug 
offences).
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European drug policies: extended beyond illicit drugs?, 
in EMCDDA 2006 annual report: selected issues
In Europe, the scope of drug policies is beginning to stretch 
beyond illicit drugs and to encompass other addictive 
substances or even types of behaviour. This is found in 
the drug policies of some Member States and in EU drug 
strategies. Increasingly, research is addressing the issue 
of addiction or addictive behaviours irrespective of the 
substances concerned. The selected issue on the increasing 
attention being given in national illicit drugs strategies or 
policy documents to licit substances or to addiction per se aims 
at presenting a fi rst insight into this emerging phenomenon in 
the European Union.
Although drug strategies do not always refer to licit drugs or 
addictions, the selected issue fi nds that prevention programmes 
and, in some countries, treatment measures apply to both licit 
and illicit drugs, targeting as a priority children and young 
people. A slow integration, strategically or institutionally, of licit 
drugs into policy and measures against illicit drugs appears to 
be more and more common.
This selected issue is available in print and on the Internet in 
English only (http://issues06.emcdda.europa.eu).
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Chapter 2
Responding to drug problems in Europe — an overview
Prevention
Experiences in some Member States suggest that drug 
prevention interventions at the individual level may be 
more effective if also supported by regulatory policies on 
legal drugs that can limit the access of young people to 
these substances and reduce their social acceptability. As 
a result, environmental prevention strategies that address 
the normative and cultural framework of substance use are 
gaining ground in parts of Europe, supported by the first 
steps taken at EU level: the tobacco advertisement directive 
and the WHO framework convention on tobacco control (see 
the section on environmental strategies in the selected issue 
on drug use in recreational settings).
The role of mass media campaigns is increasingly being 
seen as one of raising awareness (to underpin, support and 
explain to the population at large the rationale underlying 
environmental strategies) rather than one of changing 
behaviour. In this regard, a recent German review of the 
international literature (Bühler and Kröger, 2005, cited in the 
German national report) recommends that media campaigns 
be used as a supporting measure and not as the only 
measure to achieve behavioural changes.
Public health prevention
While health promotion — as a framework condition for 
prevention — strives to encourage people to adopt healthy 
lifestyles and to create healthy living conditions for all, the 
new term ‘public health prevention’ is increasingly mentioned 
by some Member States (Italy, Netherlands, Slovakia) 
and Norway. Public health prevention entails a range of 
prevention measures aimed at improving the health of 
vulnerable sections of society, among which drug prevention 
is one element. These measures are particularly suited to 
the needs of young people, whose problem behaviours, 
including drug use, are strongly conditioned by vulnerability 
(social and personal) and by living conditions. Hence, as 
selective and indicated prevention strategies target social 
and personal risk conditions, they are naturally linked to 
other youth-relevant public health policies (adolescent mental 
health strategies regarding conduct disorders, attention 
deficit disorder, etc.), social policies (the provision of 
leisure spaces and support for vulnerable youth or deprived 
families), education policies (reducing school dropout), 
etc. Thus, public health prevention targets the full set of 
vulnerability factors which are relevant for tackling drug 
problems by involving services and sectors that would not 
usually focus on drugs.
Universal school-based prevention
Programme-based prevention approaches are gaining 
ground within school-based prevention. Programme-based 
prevention implies standardised delivery in a defined number 
of sessions, each with exactly defined contents, and detailed 
teacher and pupil material. This facilitates monitoring and 
evaluation and increases the accuracy, fidelity 
and consistency of interventions, leading to high-quality 
delivery. As a result, more Member States than before are 
monitoring school-based prevention interventions (the Czech 
Republic, Greece, Spain, Ireland, Italy, Cyprus, Hungary, 
the Netherlands and the United Kingdom). The first ever 
European drug abuse prevention trial (www.eudap.net) 
has shown promising results. Funded by the European 
Commission, the project was implemented and cross-
evaluated in seven countries, nine regional centres and 
143 schools and involved 7 000 students (3 500 in a 
trial group and 3 500 in a control group). EU-Dap reports 
that, compared with the control group, students in the trial 
group had a 26 % lower probability of smoking daily, a 
35 % lower probability of being frequently drunk and a 
23 % lower probability of using cannabis. A comparable 
programme-based research approach is Blueprint in the 
United Kingdom (30). Additionally, more attention is now 
given to stricter technical guidance and to better coverage 
in the implementation of school-based prevention (e.g. in 
France and Ireland).
Police in schools
The role of the police in school-based prevention is a 
controversial issue. In Belgium, the French Community 
(30) 
(30) www.drugs.gov.uk/young-people/blueprint/
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recommends that health promotion and prevention policy 
should be implemented by school authorities and that 
the police force should not be involved in prevention 
programmes. Also, in the United Kingdom, a policy paper 
(ACPO Drugs Committee, 2002) recommended that 
the police service act only within its areas of expertise 
(security, offences, order) and not get involved in specific 
drug education. Following this line of action, Portugal 
continues to run a proximity policing programme, Escola 
Segura (safe school). During the 2004/05 school year a 
total of 320 police officers were specifically allocated to 
the school setting, with the aim of implementing proximity 
policing and offence dissuasion, both during the day and 
at night. In France, experts trained by the law enforcement 
services to liaise with youth or grown-up populations visit 
schools or other services on request. However, despite 
recommendations that drug education should not be 
delivered by police officers in uniform, as it could in some 
cases be counterproductive, activities carried out by police 
services within schools are still common in several Member 
States.
Selective prevention
With the recognition and development of the selective 
prevention approach by most Member States, vulnerable 
groups are increasingly being targeted. For example, 
Germany, Greece, Luxembourg, Austria, Finland and 
the United Kingdom report programmes targeting young 
offenders.
Several countries (e.g. Poland and Slovakia) have begun 
to put emphasis on vulnerable groups. In Sweden, the most 
obvious increase in activities compared with previous years 
has been in programmes for pre-school children at risk and 
school children with externalising behaviours. The number 
of municipalities implementing these programmes has 
approximately doubled. In addition, Norway is developing a 
national strategy for early intervention against problem drug 
and alcohol use in which prevention efforts will specifically 
target risk groups. Approaches not based on abstinence are 
effective in reducing not only consumption but also initiation 
among those groups in which incipient drug use is already 
occurring. Thus, Poland has a nationwide programme to 
change the drug-related behaviour of vulnerable children or 
children who are in the early stages of drug use. The specific 
objective of the Polish programme is to support the family 
in solving drug problems. In this regard, it is helpful that 
the concept of selective prevention does not focus on drug 
use and does not stigmatise drug use; rather, its focus is on 
vulnerability in a broader sense.
Member States increasingly report targeting of specific 
ethnic groups in their selective prevention policies, with 
four countries (Belgium, Germany, Italy and Luxembourg) 
reporting on new projects in this area. In Italy, the priority 
of many projects is now to protect children, mothers and 
immigrant families or those belonging to ethnic minorities. 
Luxembourg reports that special attention is given to young 
people and to the biggest immigrant community, focusing on 
linguistic and sociocultural specificities.
Selective prevention in schools
Young people at risk of dropping out of school and/or with 
behavioural problems are increasingly being addressed 
by selective drug prevention, for instance in Italy, where 
some 15 % of prevention interventions in schools are 
aimed at vulnerable subgroups of students (selective and 
indicated prevention). The main subgroups at which selective 
prevention in schools is aimed are students with social 
behavioural problems, school problems or family problems, 
immigrant students and those belonging to ethnic minorities. 
In fact, academic performance and school attendance are 
good predictors for drug problems, and monitoring these 
enables early and accurate intervention.
School dropout is the focus of drug prevention programmes 
in several Member States. The HUP project in Storstrom 
County, Denmark, aims to increase the average rate of 
school completion from 75 % towards the national target of 
95 % by focusing on vulnerable students. Similar projects 
are reported in Ireland, Portugal (47 projects), Romania (one 
project) and Norway (brochures for teachers). Reducing 
early school leaving is an official aim of Ireland’s national 
strategy, with the target of a 10 % reduction compared with 
2005/06 rates in LDTF (local drug task force) areas. Students 
most at risk are targeted by selective prevention programmes 
in Malta, while in France and Slovakia counselling services 
are provided in schools on the basis of (self-)referral.
Family-based prevention
With growing numbers of younger children initiating drug 
use, the improvement and intensification of family-based 
prevention are of increasing importance. In pre-teenagers, 
family influence prevails over peer influence. The role of 
the family in establishing norms and support for children is 
more relevant to prevention than imparting information on 
substances.
Family-based prevention in the EU is becoming more targeted 
and more firmly needs-based. Several Member States 
(Germany, Spain, Ireland, Italy and the United Kingdom) 
have acknowledged that it can be difficult for institutions to 
contact problem families. As a result, in the United Kingdom 
the FRANK campaign has developed an action pack for 
drug and alcohol action teams and prevention practitioners 
on how to reach the family, and in several other Member 
States selective prevention programmes targeted at families 
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at risk are now being implemented. These programmes 
employ several techniques to attract at-risk families (e.g. 
providing food, financial incentives, babysitting) mostly 
based on Kumpfer’s ‘strengthening families programme’ 
(Kumpfer et al., 1996).
The ‘strengthening families programme’ (SFP) is being 
implemented in Spain (Palma de Mallorca and Barcelona), 
the Netherlands (two cities, evaluation study) and Sweden 
(two cities). Training in Ireland and Italy is under way and it 
is envisaged in the latter that coverage will extend to several 
cities. Norway is evaluating the similar MST programme in 
a randomised controlled trial. These selective family-based 
programmes have similar features in all Member States 
where they have been implemented.
Programmes for neglected children and young people from 
dysfunctional families are being run in Poland and in some 
provinces in Austria. These programmes are implemented 
in local community-based venues such as socio-therapeutic 
common rooms, upbringing facilities, youth clubs and 
prevention centres.
Some countries are focusing increasingly on the children 
of alcoholics (Belgium, Germany, Austria). The remaining 
countries still focus solely on the children of drug users.
Community-located prevention
Most selective prevention programmes are operated at the 
level of the community. Partly, this is because the various 
social services involved are usually coordinated at this 
level. However, in countries where communities have the 
power and will to enforce local norms, the community is a 
natural unit for environmental strategies. Community-based 
selective prevention is common in the Nordic countries and in 
Belgium, the Netherlands, Poland and the United Kingdom, 
and is increasing in countries that have made less use of this 
approach in the past (France, Italy, Hungary, Portugal).
By establishing community norms on the availability and 
methods of consumption of legal drugs, and by optimising 
local services, local environmental prevention strategies 
are a good starting point for effective drug prevention 
programmes.
Quality control in prevention
Quality control in prevention is of increasing importance, 
especially as many Member States have devolved the 
competences and responsibilities for prevention to the local 
level (Denmark, Italy, the Netherlands, Poland, Portugal 
and Slovenia) and/or delegated responsibility for drug 
prevention to non-governmental organisations (NGOs) or 
semi-independent associations (Belgium, Germany, France, 
Hungary and Finland). Accordingly, some Member States 
report on strategies to provide common quality criteria, 
standards and technical advisory services at the local level, 
supporting schools or communities in developing school 
policies (Belgium, Denmark, the Netherlands and the United 
Kingdom), implementing adequate prevention programmes 
and assuring minimum quality criteria (Denmark, France, 
Lithuania, Hungary, Slovakia, the United Kingdom, Romania 
and Norway).
Greece and Austria are leading the way in defining 
specifications for the accreditation of prevention agencies or 
prevention professionals.
Treatment and harm reduction responses
The context for EMCDDA data collection on harm reduction 
and treatment responses to the drug problem is provided by 
two main EU instruments:
• the EU drug strategy 2005–12 and its first action plan 
2005–08, which present a framework for national 
policies as well as detailed recommendations for actions 
in the Member States aiming at the prevention of drug use 
and at increasing the coverage and quality of treatment 
and harm reduction services;
• the Council Recommendation of 18 June 2003 (31), which 
gives further specific recommendations on measures that 
Member States should consider implementing, in order 
to prevent and reduce health-related harm associated 
with drug dependence and to provide for a high level 
of health protection. This recommendation has been 
reinforced by its inclusion in the EU action plan as 
objective 14.
In order to evaluate the level of implementation of the 
strategy, it is important to determine levels of service 
provision and the extent to which the services are being used. 
Ultimately, however, sound estimates of the coverage — the 
extent to which the intended target group is reached by 
treatment and harm reduction measures — will be needed to 
evaluate the action plan objectives and for creating a basis 
for assessing the impact of the strategy.
Throughout the eight-year implementation period of the 
strategy, the EMCDDA supports the Commission in the 
evaluation process by providing data from the EU system 
of epidemiological indicators and by developing and 
implementing a number of specific data collection tools to 
determine service provision and utilisation of treatment and 
harm reduction services. Compared with the good overview 
(31) 
(31) Council Recommendation 2003/488/EC.
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of the epidemiological situation that has been achieved 
by the EMCDDA-driven development and implementation 
of indicator-based monitoring, standardised reporting on 
responses is limited.
Opioid substitution treatment
Methadone maintenance treatment for heroin users was 
pioneered in Europe by Sweden (in 1967), the Netherlands 
and the United Kingdom (1968) as well as by Denmark 
(1970), but its use remained limited for many years.
Following the discovery of the extent to which the HIV 
epidemic had spread among drug users in western European 
countries, therapeutic goals and approaches began to shift 
in many countries from abstinence as the primary goal to 
the adoption of interventions more oriented towards the 
reduction of the harms associated with drug use. The need 
for repeated treatment interventions was accepted and the 
benefits of drug maintenance treatment for the stabilisation 
and improvement of opioid users’ health and social situation 
as well as for society as a whole was recognised.
After the late 1980s, the rate at which methadone 
maintenance was introduced as a treatment modality 
accelerated. By 2001, 24 EU countries as well as Bulgaria, 
Romania and Norway had introduced it (Figure 1). However, 
scale and coverage differ considerably between countries 
(see Chapter 6).
In 1996, the legal basis for the use of medication containing 
buprenorphine in the treatment of heroin users was first 
established in an EU Member State (see the selected issue 
on buprenorphine in the 2005 annual report). It is now 
available and used in the majority of Member States. As 
buprenorphine is controlled under a less stringent schedule of 
UN drug conventions, countries are given greater possibilities 
for its prescription. In some countries, this treatment option 
has led to rapid increases in the number of clients treated. 
New pharmacotherapy treatment modalities beyond agonist 
substitution are being explored, and research attention is 
now turning towards developing treatment responses for 
cocaine and crack users, many of whom also use heroin or 
have used it in the past (see also Chapter 5).
It is estimated that in the EU more than half a million opioid 
users received substitution treatment in 2003, which represents 
one third of the currently estimated 1.5 million problem 
opioid users (EMCDDA, 2005a). The new Member States 
and candidate countries account for only a small fraction of 
the clients in substitution treatment in the European region, 
which can partly be explained by lower levels of opioid use in 
these countries. Although the overall provision of substitution 
treatment remains low in these countries, there are some 
indications of increases in Estonia, Lithuania and Bulgaria.
The information provided shows that in some countries 
there have been further increases in methadone treatment 
provision, but that in eight countries the numbers of people 
Figure 1: Introduction of methadone maintenance and high-dose buprenorphine treatment in EU Member States, 
candidate countries and Norway
Sources:  National focal points.
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receiving such treatment stabilised or decreased (32). Four 
of these countries — Denmark, Spain, Malta and the 
Netherlands — have a profile of long-standing heroin use 
and highly accessible methadone substitution programmes. 
The other four countries, Latvia, Hungary, Poland and 
Romania, are characterised by low geographical coverage 
of methadone substitution, and in some places there is a 
waiting list for treatment.
It is difficult to determine if decreasing numbers of clients 
receiving methadone treatment means that such clients are 
switching to buprenorphine treatment when available. The 
extent to which drug dependence treatment is delivered by 
GPs is often not known at national level.
Provision and type of drug dependence treatment
A survey conducted among national focal points (NFPs) 
in 2005 assessed the general characteristics of treatment 
provision in Europe. National experts were asked whether 
the majority of opioid users were treated in drug-free or 
medically assisted programmes or whether both modalities 
were equally prevalent.
The results show a ratio largely in favour of medically assisted 
treatment, with the main substance used being methadone 
(except in the Czech Republic and France; for more details 
see Chapter 6). The results further show that drug-related 
treatment in most countries is predominantly provided in 
outpatient settings — only Latvia and Turkey provide most 
treatment in inpatient settings. Traditional psychotherapeutic 
treatment modalities (psychodynamic, cognitive-behavioural, 
systemic/family therapy or Gestalt therapy) are the most 
frequently used modalities in outpatient treatment in Ireland, 
Latvia, the United Kingdom, Bulgaria and Turkey. Nine 
countries report the provision of predominantly ‘supportive’ 
methods (which can include counselling, socio-educative 
and environmental therapy, motivational interviewing or 
relaxation techniques and acupuncture), and 10 countries 
combine the different methods in their outpatient work.
Concerning inpatient care, the 12-step Minnesota model 
is frequently used in residential care in Ireland, Lithuania, 
Hungary and Turkey, while six countries predominantly 
apply psychotherapeutic treatment modalities, five countries 
‘supportive’ methods and 10 countries a combination of such 
approaches.
Over the last decade, but even more so in the last five years, 
many European countries have ‘opened the doors’ to treatment 
by expanding their provision of substitution treatment and 
reducing access limitations. Never before have such large 
numbers of drug users been reached by the system of care. 
Many but not all require assistance beyond the treatment of 
their dependency, and many seem to need low-threshold care 
as well as substantial support for their reintegration.
Harm reduction responses
At the same time as reaching clients and maintaining contact 
became an objective in itself, outreach and low-threshold 
service provision gained recognition and support and have 
now become essential parts of a comprehensive response in 
many Member States. Common response profiles are visible 
in Europe with regard to the prevention of infectious diseases 
among drug users and the reduction of drug-related deaths 
(see also Chapter 7).
The reduction of drug-related deaths was defined for the 
first time as a European drug policy objective six years ago, 
and it is an objective of the current EU action plan (33). The 
number of countries which include a direct reference to 
the target of reducing drug-related deaths in their national 
policies has continued to increase in recent years, with eight 
countries adopting such strategies during 2004 and 2005 
(bringing the total number to 15). Besides national policies, 
complementary approaches at city level are common: several 
capital cities (including Athens, Berlin, Brussels, Lisbon and 
Tallinn) but also wider semi-urban regions (e.g. the eastern 
region of Ireland, around Dublin) have their own strategies 
for reducing drug-related deaths. In the Czech Republic, Italy, 
the Netherlands and the United Kingdom, local or regional 
policies are reported to exist, and in Bulgaria strategies have 
been drawn up at local level in nine cities.
As in the previous European Union drug strategy and 
action plan, prevention of the spread of infectious diseases 
remains an important goal in the current strategy and is 
specified as objective 16 in the action plan for 2005–08. 
This emphasises the continued importance that European 
governments and the Commission place on the health-related 
consequences of drug use (34).
A large majority of EU countries and Norway have clearly 
spelled out their approach to the prevention of infectious 
(32) (33) (34) 
(32) See Table NSP-7 in the 2006 statistical bulletin.
(33) Objective 17 of the EU action plan 2005–08 calls for the reduction of drug-related deaths to be included as a specific target at all levels, with interventions 
specifically designed for this purpose.
(34) In particular, objective 16 of the EU action plan 2005–08 refers to infectious disease prevention. Objective 14 calls for the implementation of a Council 
recommendation on prevention and reduction of health-related harm associated with drug dependence, adopted in 2003 (Council Recommendation 2003/488/
EC). A report by the Commission on the implementation of this recommendation, including information collected from policymakers and Reitox national focal points, 
is foreseen in 2007 as a contribution to the evaluation of the EU drug strategy.
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diseases among drug users and have included concrete 
objectives or tasks in their national drug strategy documents 
or have adopted a separate policy text that specifies how 
infectious disease prevention among drug users shall be 
tackled (Spain, Latvia, Luxembourg, Sweden), or have done 
both (Estonia, France, the United Kingdom). Malta and 
Austria are planning to draw up specific policies for their 
approach in this area.
In Germany and Greece, concrete measures aimed at the 
prevention of infectious diseases form part of the national 
drug strategy, while infectious disease prevention is not 
explicitly identified as an objective.
These infectious disease prevention strategies are in most 
cases quite recent, and the timing of their adoption coincides 
in a number of countries with the previous EU drug strategy 
(2000–04), in which a reduction in the incidence of 
infectious diseases among drug users became a European 
target for the first time.
According to the reports by NFPs (35), objectives and target 
groups in national strategies also show a high level of 
synergy at the European level. Besides drug injectors, target 
groups include sex workers and prisoners. In the new central 
European Member States in particular, but also in Norway, 
young people and non-injectors are clearly addressed as 
further important target groups for action to prevent infectious 
disease. Danish and Estonian policies widen the target 
groups even more and include groups in close contact with 
drug users.
In many EU countries, strategies aimed at reducing infectious 
disease are clearly geared towards HIV/AIDS, particularly 
Estonia, Spain, Cyprus, Latvia and Lithuania. However, in 
10 countries (37 %), infectious disease strategies explicitly 
mention the prevention of hepatitis C infection among drug 
users (36). Ireland launched a consultation process in 2004, 
preparing such a strategy, and in Germany recommendations 
on prevention and treatment were issued. Professional and 
(35) (36) 
(35) This analysis is largely based on national reporting with a structured questionnaire (SQ 23), updated with information provided by national focal points in their 
national reports. 
(36) Including France and England, both of which have established full-blown hepatitis C prevention strategies: Plan national hepatites virales C et B (2002–05) 
(http://www.sante.gouv.fr/htm/actu/hepatites/situation.htm) and Hepatitis C: action plan for England, 2004 (http://www.dh.gov.uk/) respectively. 
Actions and interventions concerning drug users in prisons 
in the new Member States
The present data are based on a joint EMCDDA–WHO/Europe 
data collection project that was conducted in 2005 (1).
Drug testing in prisons is reported in the majority of new Member 
States. However, countries vary in terms of their drug testing 
schemes. Inmates are tested upon admission only in the Czech 
Republic, Malta and Slovenia. Malta and Slovenia are also the 
only countries to test prisoners before they go on leave. Random 
drug testing is carried out in all prisons in the Czech Republic, 
Malta, Slovenia and Slovakia and in less than 50 % of prisons in 
Hungary.
Drug-free treatment approaches dominate the interventions in 
prisons in the new Member States, but the coverage of such 
interventions is limited. Drug-free treatment with psychological 
support is reported to be available in less than 50 % of prisons 
in the Czech Republic, Estonia, Lithuania, Hungary, Poland and 
Slovakia. Drug-free units exist in most countries, but only the 
Czech Republic and Slovenia report such facilities in more than 
50 % of prisons. Brief detoxifi cation with medication is more 
widely available (all prisons in Latvia, Hungary, Malta, Slovenia 
and Slovakia).
The number of prisoners in new Member States having access to 
treatment with antagonists and substitution treatment is generally 
low. Except in emergency cases, treatment with antagonists does 
not appear to exist, and few countries report the availability of 
opioid substitution treatment for acute detoxifi cation in prison 
(Hungary, Malta, Poland and Slovenia). Drug-related pre-release 
interventions mainly take the form of counselling and information 
provision (Czech Republic, Latvia, Lithuania, Hungary, Poland, 
Slovenia and Slovakia). Substitution treatment as a pre-release 
intervention is available in all prisons in Slovenia and in less than 
50 % of prisons in Poland.
Few prisons in the new Member States report harm reduction 
measures for injecting drug users. Needle and syringe exchange 
programmes are not implemented in prisons in any of the new 
Member States, and only Estonia, Lithuania and Slovenia report 
the provision of disinfectants for cleaning syringes. Nevertheless, 
drug-related infectious diseases are being tackled in prisons. 
Vaccinations against hepatitis B are available in all prisons in 
six new Member States (Czech Republic, Estonia, Hungary, 
Malta, Slovenia and Slovakia), and fi ve countries report the 
availability of antiviral treatment for hepatitis C-positive prisoners 
in all prisons (Czech Republic, Lithuania, Poland, Slovenia and 
Slovakia). Antiretroviral treatment for HIV-positive prisoners is 
reported by all new Member States (2).
(1) Data were provided by the Czech Republic, Estonia, Latvia, Lithuania, 
Hungary, Malta, Poland, Slovenia and Slovakia. For further references see 
EMCDDA (2005c).
(2) No data are available for Cyprus.
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public discussion in Austria was boosted by an international 
conference on the topic held in Vienna in 2005.
Harm reduction strategies form an important part of the 
European response to drug use today, and improving access 
to services for the prevention and reduction of health-related 
harm is a main priority of the EU drug strategy 2005–12. 
The common strategic platform on the reduction of health-
related harm that the EU drug strategy provides is mirrored 
in many national policies across the EU and has supported a 
mainstreaming of evidence-based responses in this area.
In 2004, an improvement in the monitoring of syringe 
availability at European level was documented. However, 
information on the provision, utilisation and coverage of the 
wide range of further important services delivered by low-
threshold agencies is barely recorded at national level in 
most countries. A European picture cannot easily be drawn. 
A project to improve the data situation is described in the box 
‘Low-threshold agencies as an important data source’.
Targeted treatment and quality management
The current EU action plan also calls for high-quality 
treatment and harm reduction services.
The use of quality management tools at the level of the 
treatment and harm reduction planning has resulted in 
services being more target group specific, e.g. respecting the 
different needs of gender groups (see also the selected issue 
on gender).
Treatment units or programmes that exclusively service 
one specified target group are a common phenomenon 
across the EU. Children and young people under the age of 
18 are treated in specialised agencies in 23 countries; the 
treatment of drug users with psychiatric co-morbidity takes 
place in specialised agencies in 18 countries; and women-
specific services are reported to exist in all countries except 
Cyprus, Latvia, Lithuania, Bulgaria and Turkey. Services 
designed to meet the needs of immigrant drug users or of 
groups with specific language requirements or religious 
or cultural backgrounds are less common but have been 
reported from Belgium, Germany, Greece, Spain, Lithuania, 
the Netherlands, Finland, Sweden and the United Kingdom.
Units that specialise in treating cannabis or cocaine users 
have been reported from 13 countries, and specific treatment 
programmes for these groups in drugs agencies exist in 
eight countries. However, the availability and accessibility of 
such services are rated to be low in most of these countries. 
A similar specialised programme for amphetamine users is 
reported from Spain, Slovakia and the United Kingdom.
Further concrete steps towards enhancement of quality 
in treatment and care are individual case management, 
mediation of the provision of specialist services (i.e. treatment 
of co-morbidities) and pretreatment client assessments to 
better match client profiles with the treatment on offer with the 
aim of achieving longer retention and increased treatment 
effectiveness.
Despite the overall expansion of treatment options, 
engaging with some groups of drug users, particularly those 
with long-term and chronic problems, remains a challenge 
for drug services. Outreach and low-threshold interventions 
are common approaches to attempting to make contact 
and engage with these hard-to-reach populations. A 
more controversial approach is the development in some 
countries of supervised drug consumption rooms mostly 
targeting drug injectors but now sometimes also extending 
provision to crack cocaine or heroin smoking (see 
EMCDDA, 2004c). Another controversial area of service 
development and experimentation is the use of heroin by 
a few countries as an agent for drug substitution treatment. 
Although, overall, activities in this area remain very limited 
Low-threshold agencies as an important data source
Low-threshold agencies play a crucial role in increasing drug 
users’ access to care. For populations of drug users that are 
‘hidden’ or more diffi cult to reach or have lost contact with the 
care system, these agencies can provide a point of contact 
and a setting for delivering medical and social services.
Although all low-threshold agencies have in place some 
system for documenting their service delivery, and monitoring 
and reporting can be extensive, these activities are primarily 
orientated towards accountability to funding bodies and less 
towards internal quality management or service planning 
and evaluation. All too often, valuable information that 
is collected remains at the level of the agency. Despite its 
potential importance for monitoring drug use patterns and 
trends as well as service access, the low-threshold setting 
appears to be largely underused. One main obstacle is 
lack of standardisation and comparability of the collected 
information.
It is important for improving the quality of data available on 
the provision and utilisation of harm reduction services that a 
data collection tool exists that is appropriate for agencies and 
at the same time produces relevant results for national and 
European monitoring purposes. An initiative in this direction is 
the joint EMCDDA–Correlation project, supported by experts 
from the national focal points of France, Ireland, Hungary 
and Norway. The Correlation network (European Network 
for Social Inclusion and Health, www.correlation-net.org) 
represents governmental and non-governmental organisations 
from 27 European countries and is funded under the public 
health programme of the European Commission (Health and 
Consumer Protection DG).
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compared with other treatment options, some studies have 
suggested that heroin prescribing may have potential 
benefits for clients where methadone maintenance treatment 
has failed. For example, a recent German randomised 
controlled trial of heroin-assisted treatment (Naber and 
Haasen, 2006) reported positive outcomes in terms of both 
health and reductions in use of illicit drugs. Nonetheless, no 
clear consensus currently exists across Europe on the cost 
and benefits of this approach and it remains an area where 
there is considerable political and scientific debate.
With the increasing availability and quality of treatment, 
emphasis in some European cities has also shifted towards 
reducing the impact of drug use on the community. Assertive 
outreach work and an attractive range of low-threshold 
services have shown promise in some local contexts (see 
‘Harm reduction approaches’ in Chapter 5) and might be 
valuable and effective models to be used more broadly to 
re-establish communication with marginalised groups and 
eventually channel them into treatment.
The development of ‘safer’ substitution products (i.e. 
substances less likely to be diverted into the black market) 
makes it likely that drug dependency treatment will move 
even further towards the GP’s surgery. This is also a process 
of normalisation, which allows drug dependency to be 
treated like a chronic disease such as diabetes.
Some countries report that the large groups of heroin users 
in substitution treatment create a corresponding demand for 
social reintegration support, especially for paid work. Under 
the current economic circumstances, many countries may find 
it difficult to meet the vocational reintegration needs of older 
heroin users, even if they are stabilised in drug maintenance 
treatment. This situation is aggravated by the high levels of 
morbidity among this group.
Social reintegration
All the available literature and facts and figures from 
Member States converge towards the same truth: the life 
situations of drug users are far more problematic and 
precarious than those of the general population. Thus, in the 
last two EU drug action plans, social reintegration has been 
one of the ultimate aims in order to improve the health and 
social status of drug users.
The 2005–08 action plan calls on Member States to 
‘improve access to and coverage of rehabilitation and social 
reintegration programmes’. Although social measures are 
still a less well-established response to problem drug use than 
treatment, interventions combining treatment, health and 
social actions are recognised by professionals as the best 
response to achieve drug user rehabilitation.
Data on social reintegration (37) are scarce in Europe, mostly 
because of the obstacles to collecting quantitative information 
in this field. Hence, most of the information related below 
is based on a qualitative assessment focusing on policy, 
implementations and quality assurance within the Member 
States (38).
In 2004/05, in response to the EU action plan, 20 of the 
28 reporting countries (39) had a strategy for drug-related 
social reintegration; a further four countries, although they do 
not address this issue explicitly in their national drug strategy 
or other drug policy documents, have regional or local 
strategies in place; three have neither.
The main provider of funds is to be found at state/national 
level in 11 countries, whereas funding is predominantly 
at regional/local level in eight countries. In another eight 
countries, the funding comes from both levels, with no 
apparent predominant provider, or through health insurance 
schemes.
In the EU Member States, problem drug users can access 
social measures through facilities either exclusively dedicated 
to drug users or targeting socially deprived groups. Among 
these measures, housing is one of the key pillars. The service 
most commonly offered to homeless problem drug users is 
access to ‘generic housing services’ (in 21 countries), while 
18 countries offer housing facilities solely for problem drug 
users and 13 countries combine the two systems. However, 
there are doubts about the effective access of homeless 
problem drug users to these facilities. Low availability, 
local resistance to providing drug users with new facilities, 
restricted criteria for access and difficulties for homeless 
problem drug users in sticking to the rules are among the 
problems reported.
Getting homeless problem drug users into stable 
accommodation is the first step towards stabilisation and 
rehabilitation. Based on the estimated numbers of problem 
drug users and the proportion of homeless people among 
(37) (38) (39) 
(37) Social reintegration is defined as ‘any social intervention with the aim of integrating former or current problem drug users into the community’. The three 
‘pillars’ of social reintegration are housing, education and employment (including vocational training). Other measures, such as counselling and leisure activities, 
may also be used.
(38) For more information see http://www.emcdda.europa.eu/?nnodeid=1573
(39) Member States plus Bulgaria, Romania, Turkey and Norway, but no information available for Estonia.
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clients in treatment, there are approximately 75 600 to 
123 300 homeless problem drug users in Europe. As 
facilities are currently available in most countries, and 
as some countries continue to implement new structures, 
the effect of these measures will depend on ensuring that 
homeless problem drug users can access these services.
A gender perspective on drug use and responding to drug 
problems, in EMCDDA 2006 annual report: selected issues
Generally among drug users, males far outnumber females. In 
the EU Member States, not only is the use of illicit drugs more 
common in males, but men are much more likely to develop 
problems, seek treatment and die from drug use.
This selected issue looks at drug use and related problems 
from a gender perspective. Among the important questions 
addressed are: What differences exist between the use of drugs 
by men and women and is the gender gap narrowing? How 
have Member States developed gender-specifi c approaches 
to drug prevention, treatment, social rehabilitation and harm 
reduction? Are gender-specifi c responses equally important for 
males and females?
This selected issue is available in print and on the Internet in 
English only (http://issues06.emcdda.europa.eu).
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Chapter 3
Cannabis
Supply and availability
Production and trafficking
Cannabis continues to be the most widely produced and 
trafficked plant-based illicit drug worldwide (CND, 2006).
Large-scale production of cannabis resin is concentrated in a 
few countries, in particular Morocco, but also Pakistan and 
Afghanistan. Total global production of cannabis resin is 
estimated to be 7 400 tonnes annually (CND, 2006). Most 
cannabis resin consumed in the EU originates in Morocco; 
it is smuggled mainly via the Iberian peninsula, although the 
Netherlands seems to represent a secondary distribution centre 
for further transport to EU countries. Cannabis cultivation in 
Morocco was surveyed for the second time in 2004, and 
the findings revealed a 10 % decline compared with 2003, 
largely as a result of intervention by the government. In 2004, 
the total area under cultivation amounted to 120 500 hectares 
in the Rif region, which corresponds to a potential production 
of 2 760 tonnes of cannabis resin (UNODC and Government 
of Morocco, 2005).
Other countries also mentioned in 2004 as source countries 
for the cannabis resin seized in the EU include Albania, 
Portugal, Senegal, Afghanistan, Pakistan and countries in 
central Asia (Reitox national reports, 2005; WCO, 2005; 
INCB, 2006a).
Global potential herbal cannabis production was estimated 
at over 40 000 tonnes in 2003 (CND, 2005), with source 
countries throughout the world. Herbal cannabis seized in 
the EU in 2004 is reported to have originated from a variety 
of countries, mainly the Netherlands and Albania, but also 
Angola, South Africa, Jamaica and Thailand (Reitox national 
reports, 2005; WCO, 2005; INCB, 2006). In addition, local 
(indoor or outdoor) cultivation and production of cannabis 
products takes place in most of the EU Member States.
Seizures
Worldwide, a total of 1 471 tonnes of cannabis resin and 
6 189 tonnes of herbal cannabis was seized in 2004. 
Western and central Europe (74 %) and south-west Asia 
and the Near and Middle East (19 %) continued to account 
for most cannabis resin seized, while quantities of herbal 
cannabis seized remained concentrated in North America 
(54 %) and Africa (31 %) (UNODC, 2006).
In 2004, an estimated 275 000 seizures of cannabis resin 
amounting to 1 087 tonnes were made in the EU. Most 
seizures continued to be reported by Spain (which accounts 
for about half of all seizures and about three quarters of the 
total quantity seized in the EU), followed by France and the 
United Kingdom (40). Although the number of resin seizures 
in the EU as a whole declined between 1999 and 2003, 
trends in reporting countries indicate an increase at EU level 
in 2004 (41). The total amount of resin intercepted in the EU 
(40) (41) 
(40) This should be checked against missing 2004 data when available. Data on both number of cannabis seizures and quantities of cannabis seized in 2004 
were not available for Ireland and the United Kingdom; data on number of cannabis seizures were not available for the Netherlands in 2004. For estimating 
purposes, 2004 missing data were replaced by 2003 data. Data on quantities seized in 2004 provided by the Netherlands were only estimates, which could not 
be included in the analysis of trends to 2004.
(41) See Table SZR-1 in the 2006 statistical bulletin.
Interpreting seizures and other market data
Drug seizures in a country are usually considered an indirect 
indicator of the supply and availability of drugs, although 
they also refl ect law enforcement resources, priorities 
and strategies, as well as the vulnerability of traffi ckers to 
national and international supply reduction activities, and 
reporting practices. Quantities seized may fl uctuate widely 
from one year to the next, for example if in one year a few 
of the seizures are very large. For this reason, the number 
of seizures is sometimes a better indicator of trends. In all 
countries, the number of seizures includes a major proportion 
of small seizures at the retail (street) level. Where known, 
origin and destination of drugs seized may indicate traffi cking 
routes and producing areas. The price and purity/potency 
of drugs at retail level are reported by most of the Member 
States. However, data come from a range of different 
sources, which are not always comparable, making accurate 
comparisons between countries diffi cult.
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shows a continuous increase over the period 1999–2004, 
although in 2004 a majority of countries (but not Spain) 
reported a decline (42).
Herbal cannabis is less seized in the EU; in 2004 there were 
an estimated 130 000 seizures, amounting to 71 tonnes, 
with most seizures occurring in the United Kingdom (43). 
The numbers of herbal cannabis seizures in the EU have 
increased consistently since 1999 (44), although the quantities 
seized have been decreasing in reporting countries since 
2001 (45). This picture is preliminary as data from the United 
Kingdom for 2004 are not yet available.
In 2004, an estimated 12 800 seizures in the EU and 
candidate countries resulted in the recovery of about 
22 million cannabis plants and 9.5 tonnes of cannabis 
plants, with Turkey accounting for the greatest quantities 
seized (46). The number of seizures of cannabis plants has 
increased since 1999 and, based upon data from reporting 
countries, continued to increase in 2004.
Price and potency
In 2004, the average retail price of cannabis resin in the 
EU varied from EUR 2.30 per gram in Portugal to over 
EUR 12 per gram in Norway, while the price of herbal 
cannabis ranged from EUR 2.70 per gram in Portugal to 
EUR 11.60 per gram in Malta, with a majority of countries 
reporting prices for cannabis products of between EUR 5 and 
EUR 10 per gram (47).
Average prices of cannabis resin, corrected for inflation (48), 
fell over the period 1999–2004 in all reporting countries (49) 
except Germany and Spain, where prices remained stable, 
and Luxembourg, where a slight increase occurred. Average 
prices of herbal cannabis, corrected for inflation (50), of 
type unspecified or imported, also decreased over the same 
period in most of the reporting countries, but remained stable 
in Spain and the Netherlands and increased in Germany, 
Latvia, Luxembourg and Portugal. Only two countries, the 
Netherlands and the United Kingdom, have reported on the 
average price of locally produced herbal cannabis, and in 
both cases it has declined.
The potency of cannabis products is determined by their 
content of delta-9-tetrahydrocannabinol (THC), the primary 
active constituent (EMCDDA, 2004b). In 2004, the reported 
average THC content of cannabis resin at retail level varied 
from less than 1 % (Bulgaria) to 16.9 % (the Netherlands), 
while herbal cannabis potency ranged from 0.6 % (Poland) 
to 12.7 % (England and Wales) (51). The potency of locally 
produced herbal cannabis was reported at 17.7 % in the 
Netherlands (52).
Prevalence and patterns of cannabis use
Cannabis is the illegal substance most frequently used in 
Europe. Its use increased in almost all EU countries during the 
1990s, in particular among young people, including school 
students.
It is estimated that about 65 million European adults, that is 
about 20 % of those aged 15–64, have tried the substance 
at least once (53), although it should be remembered that most 
of these will not be using the substance at the present time. 
National figures vary widely, ranging from 2 % to 31 %, 
with the lowest figures in Malta, Bulgaria and Romania, and 
the highest in Denmark (31 %), Spain (29 %), France (26 %) 
and the United Kingdom (30 %) (54). Of the 25 countries 
for which information is available, 13 presented lifetime 
prevalence rates in the range 10–20 % (55).
(42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) 
(42) See Table SZR-2 in the 2006 statistical bulletin.
(43) See footnote (40). Data on number of herbal cannabis seizures in 2004 were not available for Poland.
(44) See Table SZR-3 in the 2006 statistical bulletin.
(45) See Table SZR-4 in the 2006 statistical bulletin.
(46) See footnote (40).
(47) See Table PPP-1 in the 2006 statistical bulletin.
(48) Taking 1999 as the base year for the value of money in all countries.
(49) Over the period 1999–2004, data on cannabis resin/herb prices were available for at least three consecutive years in Belgium, the Czech Republic, 
Germany, Spain, France, Ireland, Cyprus, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Portugal, Slovenia, Sweden, the United Kingdom, Bulgaria (herb 
only), Romania, Turkey and Norway. However, trends in the Czech Republic were not analysed due to methodological limitations affecting the data submitted. 
(50) Taking 1999 as the base year for the value of money in all countries.
(51) See Figure PPP-2 in the 2006 statistical bulletin.
(52) See Table PPP-5 in the 2006 statistical bulletin.
(53) The average proportion was computed as the average of national prevalence rates weighted according to the population of the relevant age group in each 
country. Total numbers were computed by multiplying prevalence among the population concerned in each country and, in countries for which no information was 
available, imputing the average prevalence. Figures here are probably a minimum, as there could be some under-reporting.
(54) In this text, United Kingdom figures are based on the 2005 British Crime Survey (England and Wales), for practical reasons. There are additional estimates for 
Scotland, Northern Ireland and a combined estimate for the United Kingdom is available (presented in the statistical bulletin). 
(55) See Table GPS-1 in the 2006 statistical bulletin.
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Last year use is clearly lower than lifetime experience. It is 
estimated that about 22.5 million European adults have used 
cannabis in the last year, about 7 % of those aged 15–64. 
National figures range between 1 % and 11 %, with the 
lowest figures reported by Greece, Malta and Bulgaria, and 
the highest by Spain (11.3 %), France (9.8 %) and the United 
Kingdom (9.7 %) (56).
Estimates of last month prevalence will more closely represent 
regular use of the drug. It is estimated that 12 million 
European adults have used the drug in the last 30 days, 
about 4 % of adults. Country figures range between 0.5 % 
and 7.5 %, a 15-fold difference. The lowest figures were 
reported from Lithuania, Malta, Sweden and Bulgaria, and 
the highest from the Czech Republic (4.8 %), Spain (7.6 %) 
and the United Kingdom (5.6 %) (57).
Use of illegal drugs, including cannabis, is concentrated 
mainly among young people. In 2004, between 3 % and 
44 % of Europeans aged 15–34 reported having tried 
cannabis, 3–20 % had used it in the last year, and 1.5–13 % 
had used it in the last month, with the highest figures again 
coming from the Czech Republic, Spain and the United 
Kingdom. The European averages for this age group are 
32 % for lifetime use, 14 % for last year use (compared with 
2 % for 35- to 64-year-olds) and over 7 % for last month use 
(compared with 1 % for 35- to 64-year-olds) (58).
Cannabis use is even higher among 15- to 24-year-olds, with 
lifetime prevalence ranging between 3 % and 44 % (most 
countries report figures in the range 20–40 %), last year 
use ranging from 4 % to 28 % (in most countries 10–25 %) 
(Figure 2) and last month use ranging from 1 % to 15 % (in 
most countries 5–12 %), with higher rates among males than 
females. In the new Member States levels of cannabis use 
among young adults aged 15–24 are typically in the same 
range as those in the EU-15 Member States, but among older 
age groups rates of use drop substantially (59).
By contrast, in the 2004 US national survey on drug use and 
health (60), 40.2 % of adults (defined as aged 12 years and 
older) reported lifetime use, compared with the EU average 
of about 20 %. This is higher even than in those European 
countries with the highest lifetime rates (Denmark 31.3 % and 
the United Kingdom 29.7 %) although differences in last year 
use estimates are less marked: this figure is 10.6 % in the 
United States compared with a European average of 7 %, 
(56) (57) (58) (59) (60) 
(56) See Table GPS-3 in the 2006 statistical bulletin.
(57) See Table GPS-5 in the 2006 statistical bulletin.
(58) See Tables GPS-2, GPS-4 and GPS-6 in the 2006 statistical bulletin.
(59) See Tables GPS-14, GPS-15 and GPS-16 and Figures GPS-2, GPS-3, GPS-11, GPS-12, GPS-13 and GPS-26 in the 2006 statistical bulletin.
(60) Source: SAMHSA, Office of Applied Studies, 2004 national survey on drug use and health (http://oas.samhsa.gov/nsduh.htm#nsduhinfo). Note that the age 
range for ‘all adults’ in the US survey (12 years and over) is wider than the age standard range for European surveys (15–64).
Estimating drug use in the population
Cannabis use in the general or school population is assessed 
through surveys, which provide estimates of the proportion of 
people that declare having used drugs over defi ned periods 
of time: lifetime, last year or last month.
The EMCDDA, in association with national experts, has 
developed a set of common core items (the ‘European model 
questionnaire’, EMQ) for use in adult surveys, and this has 
been implemented in most EU Member States. Details of the 
EMQ are included in a handbook for surveys about drug use 
among the general population (http://www.emcdda.europa.
eu/?nnodeid=1380). However, there are still differences 
between countries in methodology and year of data 
collection, and small differences between countries should be 
interpreted with caution (1).
‘Lifetime use’ is of limited value in assessing current drug use 
among adults (although it is considered to be a reasonable 
indicator among schoolchildren), but it can provide insight 
into patterns of use. ‘Last year use’ and ‘last month use’ refl ect 
the current situation more accurately, with the latter weighted 
more heavily towards people who use the drug frequently.
The European school survey project on alcohol and other 
drugs (ESPAD) is an important source of information on drug 
and alcohol use among European school students and is 
invaluable for recording trends over time. ESPAD surveys 
were conducted in 1995, 1999 and 2003. The next survey 
will take place in 2007.
ESPAD uses standardised methods and instruments among 
nationally representative samples of school students aged 
15–16 years, to allow comparability of results. Participation 
in ESPAD has grown with each survey, with 26 European 
countries participating in 1995, 30 in 1999 and 35 in 
2003, including 22 EU Member States and four candidate 
countries (Bulgaria, Croatia, Romania and Turkey). The survey 
questions focus on alcohol consumption and use of illicit 
drugs, with the standard time frames, and frequency of use.
Information on ESPAD and the availability of reports can be 
found on the ESPAD website (www.espad.org).
(1) For more information about methodology of population surveys and 
the methodology used in each national survey, see the 2006 statistical 
bulletin.
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and several European countries reported figures similar to 
those found in the United States.
Five EU Member States (Belgium, Spain, Italy, Cyprus and 
the United Kingdom) reported new data from national 
school surveys, and Bulgaria reported data from school 
surveys conducted in two major cities. Overall, the picture 
of cannabis use among school students in Europe remains 
unchanged. The highest lifetime prevalence of cannabis 
use among 15- and 16-year-old school students is in the 
Czech Republic and Spain (44 % and 41 % respectively). 
Countries where the rate is higher than 25 % include 
Germany, Italy, the Netherlands, Slovenia and Slovakia 
(27–28 %) and Belgium, France, Ireland and the United 
Kingdom, where lifetime prevalence ranges from 32 % to 
40 %. The lowest lifetime prevalence estimates (less than 
10 %) occur in Greece, Cyprus, Sweden, Romania, Turkey 
and Norway (61).
Prevalence estimates for 15- to 16-year-old students should 
not be generalised to older students because large increases 
in prevalence may occur with small increases in age. Among 
17- and 18-year-olds lifetime prevalence estimates reach over 
50 % in the Czech Republic, Spain and France (62). And in 
Sweden, where prevalence is low compared with many other 
Member States, estimated lifetime use of cannabis among 
17- and 18-year-old students, at 14 %, is more than double 
that among 15- to 16-year-olds (6 %) (63).
Patterns of cannabis use
Cannabis use tends to be occasional or discontinued some 
time after its initiation. On average, 33 % of Europeans 
who have ever tried cannabis have also used it in the last 
year, whereas only 16 % have used it in the last 30 days. 
These proportions, known as ‘continuation rates’, vary 
across countries, ranging from 20 % to 45 % for last year 
(61) (62) (63) 
(61) See Table EYE 1 in the 2006 statistical bulletin.
(62) ESCAPAD youth survey including 17- to 18-year-olds not attending school.
(63) See Table EYE 3 and Figure EYE 1 (part i) in the 2006 statistical bulletin.
Figure 2: Last year prevalence of cannabis use among young adults (aged 15–34 and 15–24)
NB:   Data are from the most recent national surveys available in each country at the time of reporting. See Tables GPS-8, GPS-11 and GPS-18 in the 2006 statistical bulletin 
for further information.
Sources:  Reitox national reports (2005), taken from population surveys, reports or scientific articles.
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continuation and from 10 % to 25 % for last 30 days 
continuation (64).
Although cannabis use is largely concentrated among young 
people, there is some suggestion from data from Spain and 
the United Kingdom that people may be continuing to use the 
drug into their 30s or 40s. This could represent an important 
long-term change in cannabis use patterns that merits further 
attention.
Use of cannabis, like that of other illegal drugs, is notably 
higher among males than among females. The difference is 
more marked in the case of last year or last month use than 
it is for lifetime use, but the differences are smaller among 
young people than among older adults (see the selected issue 
on gender). Cannabis use is also more common in urban 
areas or areas with a high population density. It has been 
hypothesised that use may be spreading to smaller towns or 
rural areas, and Poland documented this trend in its 2005 
national report.
Despite increasing concerns about regular or intensive 
forms of cannabis use (65), there is very limited information 
at European level. A crude estimate drawn in the 2004 
annual report (EMCDDA, 2004a) suggests that 1 % of 
European adults, about 3 million people, could be daily 
or almost daily cannabis users. Several countries reported 
increases in regular or intensive cannabis use, but only Spain 
reported similar data on daily use, with an increase between 
1997–99 (0.7–0.8 % of adults) and 2001 (1.5 %), followed 
by stabilisation in 2003 (1.5 %). It would be valuable to 
have information from other countries and by specific age 
groups (e.g. 15–24 years). The French 2003 ESCAPAD 
study found that 14 % of 17- to 18-year-olds (9 % of girls and 
18 % of boys) could be considered to be at risk of problem 
use, according to a specific scale (CAST). Other countries 
are also working on scales to assess intensive forms of 
cannabis use (Germany, Netherlands, Poland and Portugal), 
and the EMCDDA is promoting collaboration in this area.
Trends in cannabis use among adults
Tracking long-term trends in drug use in Europe is made 
difficult by the absence of reliable time-series data. However, 
an increasing number of countries have launched surveys 
from the early 1990s onwards, and some of these are now 
beginning to provide valuable insights into trends over time.
It is generally considered that cannabis use started to spread 
in some European countries in the 1960s and became popular 
in the 1970s and 1980s. Recent national surveys show 
significant lifetime experience among 45- to 54-year-olds in 
Denmark, Germany, Spain, France, the Netherlands, Sweden 
and the United Kingdom, suggesting significant cannabis 
initiation during the late 1960s and 1970s. An analysis of 
initiation to cannabis use found a marked expansion of use in 
Spain during the 1970s, in Germany (West) during the 1980s 
and in Greece during the 1990s (66). Swedish data document 
a relatively high level of experimentation in the 1970s among 
conscripts (15–20 %).
National or local household, conscript and school surveys 
have shown that cannabis use increased markedly during the 
1990s in almost all EU countries, particularly among young 
people. This increase has continued until recently in almost 
all countries, although there are signs of stabilisation or even 
decreases in some cases.
(64) (65) (66) 
(64) See Figure GPS-24 in the 2006 statistical bulletin.
(65) There is as yet no universally accepted definition of ‘intensive cannabis use’; rather the definition varies across different studies. It is, however, a broad term 
meaning use of cannabis that exceeds a certain threshold of frequency. It does not necessarily imply the existence of ‘dependence/abuse’ or other problems, but 
it is considered to increase the risk of negative consequences, including dependence. In this chapter, figures refer to ‘daily or almost daily use’ (defined as use 
on 20 or more days out of the last 30 days). This benchmark has often been used in studies and can be derived from the European model questionnaire. Risk of 
dependency among less frequent users is lower.
(66) See Figure 4 in the 2004 annual report. 
Health effects of cannabis use
In recent years there has been a surge in the level of concern 
about potential social and health outcomes of cannabis use. 
Although the available evidence does not provide a clear-
cut understanding of the issues, some conclusions may be 
drawn. It is, for instance, evident that intensive cannabis use is 
correlated with mental illness, but the question of co-morbidity 
is intertwined with the questions of cause and effect. The 
complexities of this correlation are explored and discussed in 
a forthcoming EMCDDA monograph.
The fact that intensive cannabis use often co-occurs with non-
drug-specifi c mental problems has practical implications. 
When forming a treatment plan for cannabis users it may be 
diffi cult for clinicians to know whether to start with the drug 
use or the mental health problem. Studies of the effects of 
treatment for problem cannabis use are still scarce, and the 
few that exist cover only specifi c psychosocial treatments. 
All other treatment modalities have either not been studied 
at all or insuffi ciently studied; thus evidence for effi cacy and 
effectiveness is lacking.
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In the United Kingdom, recent cannabis use among young 
adults (aged 15–34) was the highest in Europe in the early 
1990s but slowly declined from 1998 to 2004/05 (67), while 
in Spain and France rates have recently (2002 or 2003) 
reached those found in the United Kingdom (Figure 3). 
Similar high prevalence levels are also reported for the 
Czech Republic.
Levels of use are lower in Denmark, Germany, Estonia, Italy, 
the Netherlands and Slovakia, but all these countries have 
reported increases in last year use among young adults, as 
has Hungary, although to a lesser extent. It should be noted 
that the Danish (2000) and Dutch (2001) data are now 
relatively old and the current situation is therefore less clear.
In Finland and Sweden prevalence rates are relatively low but 
also appear to be increasing; however, the difference observed 
in Sweden between 2000 (1.3 %) and 2004 (5.3 %) is difficult 
to interpret because of methodological changes (68).
Estimates of last month prevalence also generally increased 
in the past decade, although pronounced increases occurred 
only in Belgium and Spain. The United Kingdom has recently 
reported a decrease in last month use, having previously 
presented the highest levels in Europe since the early 1990s. 
In addition, Slovakia reported a decrease between 2002 
and 2004. In the Czech Republic and France it was not 
possible to assess the trend.
In addition, school surveys can give valuable information 
about trends in drug use among the younger members of the 
population, which may predict future trends among young 
adults. In most countries, since 1995, there has been an 
overall increase in the number of school students who have 
ever tried cannabis. However, geographical variations in 
trends are marked. Trends in lifetime prevalence of cannabis 
use among school students aged 15–16 years can be 
categorised into three geographical groups. In Ireland and 
the United Kingdom, which have long histories of cannabis 
use, lifetime prevalence is high but has remained stable 
during the last decade (around 37–39 %). In the eastern and 
central European Member States, together with Denmark, 
Spain, France, Italy and Portugal, lifetime prevalence of 
cannabis use in 2003 was substantially higher than it was 
in 1995. In the third group of Member States (Finland and 
Sweden in the north and Greece, Cyprus and Malta in the 
south) plus Norway, estimates of lifetime prevalence among 
school students have remained at relatively low levels 
(around 10 % and below) (69).
Treatment demand data (70)
Among the total of approximately 380 000 treatment 
demands reported in 2004 (data from 19 countries 
available), cannabis was the primary reason for referral to 
treatment in about 15 % of all cases, making it the next most 
commonly reported drug after heroin (71).
Overall, cannabis is also the second most frequently cited 
drug in reports on those entering treatment for the first time, 
representing 27 % of new clients reported in 2004, although 
there are considerable variations between countries with 
cannabis being cited by only less than 5 % of new clients 
in Lithuania, Malta and Romania but by more than 40 % of 
new clients in Denmark, Germany, Hungary and Finland (72). 
(67) (68) (69) (70) (71) (72) 
(67) Since 1994, the first year with information based on the British Crime Survey for England and Wales.
(68) See Figures GPS-4 and GPS-14 in the 2006 statistical bulletin.
(69) See Table EYE-5 (part i) and Figure EYE-1 (part ii) in the 2006 statistical bulletin. 
(70) The analysis of the general distribution and the trends is based on the data on clients demanding treatment in all treatment centres; the analysis of the profile of 
clients and the patterns of drug use is based on the data from outpatient treatment centres. A specific analysis on gender breakdown can be found in the selected 
issue on gender published with the 2006 EMCDDA annual report.
(71) See Figure TDI-2 in the 2006 statistical bulletin.
(72) See Table TDI-4 (part ii) in the 2006 statistical bulletin.
Figure 3: Trends in last year prevalence of cannabis use among 
young adults (aged 15–34)
NB:   Data are from the most recent national surveys available in each country 
at the time of reporting. See Table GPS-4 in the 2006 statistical bulletin for 
further information.
Sources:  Reitox national reports (2005), taken from population surveys, reports or 
scientific articles.
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Over the period 1999–2004, the proportion of all new 
clients seeking treatment for cannabis increased in most 
countries that reported data (73).
In almost all countries for which data are available, the 
proportion of new clients reported as seeking treatment for 
cannabis use is higher than the proportion of all clients; 
in a few countries the proportions are roughly equal (74). 
The greatest demand for treatment for cannabis use is in 
outpatient settings (75).
A number of factors are likely to be associated with the 
increased demand for cannabis treatment, and this remains 
an area requiring research scrutiny. Possible reasons for an 
increase include an escalation in intensive cannabis use and 
related problems in the population, an increased perception 
of the risks of cannabis use, an increase in the number of 
referrals to treatment from the criminal justice system, clearly 
important in some countries, and changes in the reporting 
system and/or its coverage (76).
Overall, cannabis clients can be divided into three groups: 
those who use it occasionally (34 %), those using it once 
to several times a week (32 %) and those using it daily 
(34 %). There are marked differences between countries in 
the frequency of cannabis use among new clients, with the 
highest proportion of daily cannabis users being reported in 
the Netherlands and Denmark and the highest proportions of 
occasional users or those who have not used cannabis in the 
month prior to treatment being found in Germany, Greece 
and Hungary. This variation probably reflects differences in 
referral to treatment (e.g. more referrals from the criminal 
justice system or from social networks) (77).
The extent to which cannabis users in treatment meet 
diagnostic criteria for either dependence or harmful drug use 
is an important question. Currently, this is an area requiring 
further investigation. As referral practices differ between 
countries, there is a need for studies to document the differing 
clinical characteristics of those receiving treatment for 
cannabis use.
Some clients seek treatment for cannabis use in combination 
with other drug or alcohol problems, and sometimes the 
request for treatment is related to more general problems, 
such as conduct disorder among young people. Furthermore, 
some recent studies also report that there has been an 
increase in adolescents seeking treatment for cannabis 
use who have coexisting mental health problems, and that 
this may be an important factor influencing demand for 
treatment (78).
It is also important to understand better the needs of cannabis 
users at the population level. The EMCDDA estimates there 
are around 3 million intensive cannabis users (defined as 
daily or almost daily cannabis use) in the EU. Although the 
number of these requiring interventions is unknown, the 
number of cannabis-related treatment demands is small in 
relation to this figure.
The available data suggest that cannabis clients in outpatient 
treatment centres tend to be relatively young: virtually all 
cannabis clients new to treatment are under 30 years old. 
Teenagers in specialised drug treatment are more likely to 
be recorded as having a primary cannabis problem than 
are clients in other age groups, with cannabis accounting 
for 75 % of treatment demands among those younger than 
15 years and 63 % among those aged 15–19 years (79).
Most clients report having first used cannabis when in the 
youngest age groups, with 36.8 % using the drug for the first 
time before the age of 15. Almost no one seeking treatment 
reports having used cannabis for the first time after the age of 
29 years (80).
Prevention
Well-implemented universal prevention programmes can 
delay or reduce the initiation of young people into the use 
of substances such as tobacco, alcohol and cannabis. The 
importance of this is underlined by evidence that early-onset 
users (pre- to mid-adolescence) have a significantly higher 
risk of developing drug problems, including dependence 
(Von Sydow et al., 2002; Chen et al., 2005). An additional 
consideration in striving to prevent or delay the onset of 
initiation into cannabis use is the fact that adolescents are 
more vulnerable to cannabis toxicity.
The profiles of young cannabis users, at least in the early 
stages of consumption, do not differ from those of young 
alcohol or tobacco users. This supports the idea that universal 
(73) (74) (75) (76) (77) (78) (79) (80) 
(73) See Figure TDI-1 in the 2006 statistical bulletin.
(74) See Tables TDI-3 (part iii) and TDI-4 (part iii) in the 2006 statistical bulletin.
(75) See Table TDI-25 in the 2006 statistical bulletin.
(76) An EMCDDA monograph on cannabis will be published in 2007; three chapters of the monograph will target the issue of the increase in cannabis treatment 
demand.
(77) See Table TDI-18 in the 2006 statistical bulletin.
(78) http://www.addaction.org.uk/Drugcannabis.htm#top
(79) See Table TDI-10 (part i) and (part ii) in the 2006 statistical bulletin.
(80) See Table TDI-11 (part ii) and (part ix) in the 2006 statistical bulletin.
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prevention for young people should not focus on cannabis 
alone, but should be aimed at preventing use of alcohol and 
tobacco too.
Gender is an important issue in cannabis prevention (see 
the selected issue on gender). Boys are at more risk of 
progression to more intensive use, perhaps because girls 
are more responsive to parental disapproval and are more 
cautious in the selection of their peers. However, this is 
changing as the traditional roles of males and females 
change in modern societies. In several European countries 
projects aimed at preventing cannabis as well as alcohol 
use (Bagmaendene, Denmark; Beer-Group, Germany; 
and Risflecting, Austria) attempt to address boys’ lack of 
communication skills. It is known that one reason for intensive 
consumption of alcohol and cannabis among boys is that 
they find it difficult to approach girls, and thus these projects 
offer training in flirting.
Selective prevention in schools targets risk factors associated 
with drug use such as early school leaving, antisocial 
behaviour, academic underachievement, low bonding, 
and infrequent attendance at school and impaired learning 
because of drug use.
The German project Stoned at School aims to train teachers 
in early detection and early intervention, prevention of 
cannabis consumption, and establishing contact between 
schools and drug counselling facilities. Like similar projects 
in Austria, it is a 10-module training scheme to increase 
teachers’ awareness of cannabis consumption and identify 
pupils at risk.
Specific drug counselling centres are frequent in Germany, 
France and the Netherlands. Since January 2005, more 
than 250 ‘cannabis consultation’ clinics have been set up 
throughout the French territories. Aimed at teenagers who are 
experiencing difficulties as a result of their use of cannabis 
or other drugs, as well as their parents, these facilities are 
anonymous, free and open to all. They are located in the 
major French cities for easy access. Consultations are carried 
out by professionals trained in the use of evaluation tools 
and brief interventions that deal with addictions, and are 
also able to identify social, medical or psychiatric services 
appropriate for clients needing specialised care. This new 
type of structure is to be subjected a follow-up study. The first 
available data from the first two or three months of operation 
show attendance figures of 3 500–4 000 individuals 
per month, of whom 2 000–2 500 were cannabis users 
(the others being parents, relatives and youth workers). 
Alternative strategies are to offer short but structured courses 
with around 10 group sessions (Germany, Denmark, the 
Netherlands, Austria). An accompanying manual, SKOLL 
(self-control training), has been launched by a Dutch–German 
Euregio project.
Often, cannabis-specific ‘training courses’ rely on the fact 
that cannabis use or possession is illegal and participants 
are referred via the criminal justice system. Motivation to 
participate largely comes from the fact that attendance at 
such courses is an obligatory part of a judicial sentence. 
Nonetheless, these methods enable contact to be established 
with at least part of the group at risk.
Many European selective prevention interventions tend 
towards the provision of information on cannabis. Several 
more evidence-based approaches, including normative 
restructuring (e.g. learning that most peers disapprove of 
use), assertiveness training, motivation and goal-setting, 
as well as myth correction (on value associations with 
cannabis), have yet to become established as standard 
elements of cannabis prevention programmes. A recent 
meta-analysis of prevention programmes for vulnerable 
young people (Roe and Becker, 2005) found that 
information-based approaches have little or no impact on 
consumption behaviours or attitudes, whether in universal 
prevention or selective prevention. The same authors found 
that comprehensive social influence programmes have an 
important effect on vulnerable young people.
An important point emerging from the few available 
evaluations of European selective cannabis prevention 
projects (FRED, Way-Out, Sports for Immigrants and others; 
see above and EDDRA at http://eddra.emcdda.europa.eu) 
is the efficacy of comprehensive social influence techniques. 
Among the positive effects achieved by these techniques 
are a reduction in consumption levels, an increase in the 
self-perception of problem use, a reduction in the main risk 
factors and associated problems, as well as increased self-
control and motivation.
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Brief intervention for cannabis users
Brief intervention is an approach that aims to make people refl ect 
on their use of drugs and to provide them with skills to control 
it. The concept is largely based on motivational interviewing, a 
non-judgemental, non-confrontational approach that explores 
the client’s values, objectives, self-assessment of use and gives 
feedback on discrepancies between the client’s self-image and 
actual status.
Brief intervention is often targeted at an early stage of a person’s 
alcohol or drug use to prevent the development of serious drug 
problems later on. There is evidence for the effectiveness of brief 
intervention in preventing alcohol and tobacco misuse, and 
there is growing interest in the value of this approach for other 
substances.
Brief intervention has been found to be very useful in selective 
prevention measures targeted at cannabis users who would not 
normally come into contact with treatment settings. In the case 
of intensive cannabis users, education-based programmes that 
emphasise abstinence may not be effective.
Brief interventions are cost-effective and may be particularly 
appropriate to cannabis users, as they are found to work well 
with drug users who:
• are experiencing few problems with their drug use;
• have low levels of dependence;
• have a short history of drug use;
• have stable backgrounds (social, academic, family);
• are unsure or ambivalent about changing their drug use.
This kind of approach is now used in several countries, including 
Germany, the Netherlands, Austria and the United Kingdom, 
where interventions may take the form of counselling, ‘cannabis 
courses’ or even self-help websites. For example, the German 
website-based counselling programme, Quit the Shit 
(www.drugcom.de), is an innovative approach, using telematics, 
for cannabis users who want to reduce or stop their drug use. 
Similar websites with self-help components include www.jellinek.
nl/zelfhulp/cannabis/frameset.html by Jellinek (the Netherlands) 
and www.knowcannabis.org.uk/ by HIT (United Kingdom).
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Amphetamines, ecstasy and other psychotropic drugs
In many European countries the second most commonly used 
illegal substance is some form of synthetically produced 
drug. The use of these substances among the general 
population is typically low, but prevalence rates among 
younger age groups are significantly higher, and in some 
social settings or cultural groups the use of these drugs may 
be particularly high. Globally, amphetamines (amphetamine 
and methamphetamine) and ecstasy are among the most 
prevalent synthetic drugs.
Amphetamine and methamphetamine are central nervous 
system stimulants. Of the two drugs, amphetamine is by 
far the more commonly available in Europe. Worldwide, 
increasing levels of use of methamphetamine are a cause 
for considerable concern, as the drug is associated with a 
range of severe health problems. Within Europe, significant 
methamphetamine use appears to be restricted to the Czech 
Republic.
Ecstasy refers to synthetic substances that are chemically 
related to amphetamines but which differ to some extent in 
their effects. The best-known member of the ecstasy group 
of drugs is 3,4-methylenedioxy-methamphetamine (MDMA), 
but other analogues are also occasionally found in ecstasy 
tablets (MDA, MDEA, etc.). These drugs are sometimes 
known as entactogens, a reference to their very specific 
mood-altering effects. Sometimes they provoke effects more 
typically associated with hallucinogenic substances.
Historically, lysergic acid diethylamide (LSD) has been by far 
the best-known hallucinogenic drug, but overall consumption 
levels have been low and somewhat stable for a considerable 
time. Recently, evidence of increased availability and use of 
naturally occurring hallucinogenic substances, hallucinogenic 
mushrooms in particular, has emerged.
To detect new drugs emerging on the European drug scene, 
the EU has in place an early-warning system. This system 
also monitors potentially harmful new trends in the use of 
psychoactive substances.
Supply and availability (81)
The production of amphetamines and ecstasy is difficult to 
quantify because ‘it starts with readily available chemicals, in 
easily concealed laboratories’ (UNODC, 2003a). The most 
recent estimate of annual global production of amphetamines 
and ecstasy is about 520 tonnes (UNODC, 2003b). Global 
seizures of these substances peaked in 2000 at 46 tonnes. 
Following a decline in 2001 and 2002, seizures increased 
again to 34 tonnes in 2003, and declined slightly to 29 tonnes 
in 2004. In 2004, the share of global amphetamines and 
ecstasy seizures accounted for by methamphetamine fell to 
38 % (from 66 % in 2003), with ecstasy accounting for 29 % 
and amphetamine 20 % (CND, 2006).
Amphetamine
Worldwide, amphetamine production remains concentrated 
in western and central Europe, in particular in Belgium, 
the Netherlands and Poland. In this subregion, Estonia, 
Lithuania and Bulgaria also play a significant role in the 
illicit manufacture of amphetamine, and to a lesser extent 
Germany, Spain and Norway, as shown by the dismantling 
of amphetamine laboratories in 2004 in these countries 
(UNODC, 2006) (82). Outside Europe, amphetamine is 
mainly manufactured in North America and Oceania (CND, 
2006). Trafficking in amphetamine in 2004 remained mainly 
intraregional. Most amphetamine found on European illicit 
markets comes from Belgium, the Netherlands and Poland, 
and also from Estonia and Lithuania (in the Nordic countries) 
(Reitox national reports, 2005; WCO, 2005).
Of the six tonnes of amphetamine seized worldwide in 2004, 
about 97 % was seized in Europe, mostly in western/central 
Europe and south-eastern Europe (accounting respectively for 
67 % and 26 % of the global amount seized) (CND, 2006).
In 2004, an estimated 33 000 seizures of amphetamine, 
amounting to 5.2 tonnes and 9.6 million units, were made 
in the EU. In terms of number of seizures and weight of 
(81) (82) 
(81) See ‘Interpreting seizures and other market data’, p. 37.
(82) The number of laboratories dismantled reported in different countries reflects, in addition to the number of production sites, law enforcement activities and 
priorities as well as reporting practices.
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(83) (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) 
(83) This situation should be checked against 2004 data for the United Kingdom when available. Data on both number of amphetamine seizures and quantities of 
amphetamine seized in 2004 were not available for Ireland and the United Kingdom; data on quantities of amphetamine seized were not available for Slovenia in 
2004; data on number of amphetamine seizures were not available for the Netherlands in 2004. For estimating purposes, 2004 missing data were replaced by 
2003 data. Data on quantities seized in 2004 provided by the Netherlands were only estimates, which could not be included in the analysis of trends to 2004.
(84) See Table SZR-11 in the 2006 statistical bulletin.
(85) See Table SZR-12 in the 2006 statistical bulletin.
(86) See Table PPP-4 in the 2006 statistical bulletin.
(87) Taking 1999 as the base year for the value of money in all countries.
(88) Over the period 1999–2004, data on amphetamine prices were available for at least three consecutive years in Belgium, Germany, Spain, France, Ireland, 
Latvia, Lithuania, Poland, Sweden, the United Kingdom, Bulgaria, Turkey and Norway.
(89) See Table PPP-8 in the 2006 statistical bulletin. Note that the reported average levels of amphetamine purity may conceal wide variation in the purity of 
samples analysed.
(90) Over the period 1999–2004, data on amphetamine purity were available for at least three consecutive years in Belgium, Germany, Estonia, France, Italy, 
Latvia, Lithuania, Luxembourg, Hungary, the Netherlands, Poland, Portugal, Finland, the United Kingdom, Turkey and Norway.
(91) Data for 2004 provided by Germany, Italy, Luxembourg and the Netherlands do not allow methamphetamine and amphetamine seizures to be distinguished, 
while Ireland and the United Kingdom did not provide 2004 data on drug seizures, making it difficult to know whether any methamphetamine seizures occurred in 
these five countries in 2004.
(92) See Table PPP-4 in the 2006 statistical bulletin.
(93) See Table PPP-8 in the 2006 statistical bulletin.
amphetamine seized, the United Kingdom has consistently 
been the main amphetamine-seizing country in the EU (83). 
Turkey reported the interception of 9.5 million units of 
amphetamine in 2004. Despite some fluctuations, at EU level 
both the overall number of amphetamine seizures (84) and 
quantities seized (85) have increased since 1999 and, based 
on the findings from reporting countries, this upward trend 
seems to have continued in 2004.
In 2004, the average retail price of amphetamine ranged 
from EUR 4 per gram in Slovenia to EUR 64 per gram in 
Malta (86). Over the period 1999–2004, amphetamine 
prices, corrected for inflation (87), decreased overall in 
Germany, Spain, Ireland, Latvia, Lithuania, Sweden, the 
United Kingdom, Bulgaria, Turkey and Norway (88).
The average purity of amphetamine in 2004 varied from 
5–6 % in Bulgaria to 44 % in Norway (89). Available data (90) 
on average amphetamine purity for the period 1999–2004 
reveal overall downward trends in Latvia, Lithuania, 
Luxembourg, Finland and Norway and upward trends in 
Belgium, Germany, France, Italy, Hungary and Austria.
Methamphetamine
Worldwide, in terms of quantities manufactured and 
trafficked, methamphetamine continues to be more 
important than amphetamine or ecstasy, although its share 
in global seizures fell in 2004. It continues to be mostly 
manufactured in East and South-East Asia (China, the 
Philippines, Myanmar, Thailand), followed by North and 
Central America (United States, Canada, Mexico). In 2004, 
11 tonnes of methamphetamine was seized worldwide, of 
which 59 % was seized in East and South-East Asia and 
37 % in North America (CND, 2006). In Europe, production 
of methamphetamine is largely limited to the Czech Republic, 
where it has been produced since the mid-1980s under the 
local name of ‘pervitin’. In 2004, however, manufacture was 
also reported in Slovakia and Bulgaria, where laboratories 
were dismantled (Reitox national reports, 2005; UNODC, 
2006). Most of the Czech production of methamphetamine 
is destined for the local market, although some is smuggled 
to Germany, Austria and Slovakia (Reitox national reports, 
2005). In 2004, methamphetamine seizures were reported 
in Belgium, the Czech Republic, Denmark, Estonia, Greece, 
France, Latvia, Lithuania, Hungary, Austria, Slovakia, 
Sweden, Romania and Norway, the last accounting for both 
the highest number of seizures and the greatest quantities 
recovered (91).
In 2004, the price (92) of methamphetamine at retail level in 
the Czech Republic was reported to vary between EUR 12 
and EUR 63 per gram, while its average purity (93) ranged 
between 43 % in Slovakia and 50 % in the Czech Republic.
Ecstasy
Globally, Europe remains the main centre of ecstasy 
production, although its relative importance appears 
to be declining as ecstasy manufacture has spread in 
recent years to other parts of the world, notably to North 
America (United States, Canada) and East and South-
East Asia (China, Indonesia, Hong Kong) (CND, 2006; 
UNODC, 2006). Although the Netherlands remained in 
2004 the main source of ecstasy for Europe and the world 
as a whole, ecstasy laboratories were also uncovered 
in Belgium, Estonia, Spain and Norway (Reitox national 
reports, 2005; UNODC, 2006). The ecstasy seized in 
the EU is reported to originate from the Netherlands and 
Belgium, and to a lesser extent Poland and the United 
Kingdom (Reitox national reports, 2005).
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Ecstasy trafficking is still strongly concentrated in western 
Europe, although, like production, it has spread throughout 
the world in recent years. Of the 8.5 tonnes (weight 
equivalent) of ecstasy seized globally in 2004, 50 % was 
recovered in western and central Europe, 23 % in North 
America and 16 % in Oceania (CND, 2006).
An estimated 24 000 seizures led to the confiscation of 
about 28.3 million ecstasy tablets in the EU in 2004. Up to 
2003, the largest quantities of ecstasy were seized by the 
United Kingdom, followed by Germany, France and the 
Netherlands (94).
After a rapid increase over the period 1999–2001, the 
number of ecstasy seizures (95) at EU level declined in 
2002–03; but data from reporting countries indicate an 
increase again in 2004. Quantities of ecstasy (96) intercepted 
increased from 1999 to 2002; after a steep decline to a low 
point in 2003, the available data for 2004 suggest that they 
again reached the 2002 level.
In 2004, the average retail cost of ecstasy tablets ranged 
from less than EUR 3 each in Lithuania and Poland to 
EUR 15–25 in Greece and Italy (97). During 1999–2004, 
average retail prices of ecstasy, corrected for inflation (98), 
fell in most reporting countries (99).
Generally in Europe, most tablets sold as ecstasy contained 
MDMA or another ecstasy-like substance (MDEA, MDA), 
usually as the only psychoactive substance present. In the 
Czech Republic, Greece, Latvia, Lithuania, Hungary, the 
Netherlands, Slovakia, Finland, the United Kingdom and 
Norway, such tablets accounted for more than 95 % of the 
total number of tablets analysed in 2004. An exception to 
this finding occurred in Bulgaria, where a high percentage 
(61 %) of tablets analysed contained amphetamine and/or 
methamphetamine as the only psychoactive substances. 
The MDMA content of ecstasy tablets varies greatly 
between batches (even between those with the same logo) 
both between and within countries. In 2004, the average 
content of active substance (MDMA) per ecstasy tablet was 
reported to range from 30 to 82 mg (100) (Reitox national 
reports, 2005).
LSD
LSD is manufactured and trafficked to a much smaller 
extent than other synthetic drugs. In 2004, an estimated 
700 seizures of 220 000 LSD units were made in the EU. 
Since 2002, Germany has been the country seizing the 
largest quantities of LSD per year, followed by the United 
Kingdom (101). Between 1999 and 2002, at EU level, both 
the number of LSD seizures (102) and quantities seized (103) 
decreased. However, in both 2003 and 2004, the available 
data suggest that numbers of LSD seizures and amounts 
intercepted increased for the first time in nine years, with 
relatively large amounts of the drug seized in Germany, 
France, Lithuania, the Netherlands and Poland in 2004.
In 2004, the average cost to users of an LSD unit ranged 
from EUR 2.50 in Portugal to EUR 11.60 in Malta (104). 
Average prices of LSD, corrected for inflation (105), showed an 
overall downward trend (106) between 1999 and 2004 in the 
Czech Republic, Ireland, Poland, Slovenia and Sweden, but 
increased in Germany and France.
(94) (95) (96) (97) (98) (99) (100) (101) (102) (103) (104) (105) (106) 
(94) This situation should be checked against 2004 data for the United Kingdom when available. Data on both number of ecstasy seizures and quantities of ecstasy 
seized in 2004 were not available for Ireland and the United Kingdom; data on number of ecstasy seizures were not available for the Netherlands in 2004. For 
estimating purposes, 2004 missing data were replaced by 2003 data. Data on quantities seized in 2004 provided by the Netherlands were only estimates, which 
could not be included in the analysis of trends to 2004.
(95) See Table SZR-13 in the 2006 statistical bulletin.
(96) See Table SZR-14 in the 2006 statistical bulletin.
(97) See Table PPP-4 in the 2006 statistical bulletin.
(98) Taking 1999 as the base year for the value of money in all countries.
(99) Over the period 1999–2004, data on ecstasy prices were available for at least three consecutive years in Belgium, Czech Republic, Germany, Spain, France, 
Ireland, Cyprus, Latvia, Lithuania, Luxembourg, Poland, Portugal, Slovenia, Sweden, the United Kingdom, Bulgaria, Turkey and Norway.
(100) This range is based on data from a few countries only, namely Denmark, Germany, France, Luxembourg and the Netherlands.
(101) This situation should be checked against 2004 data for the United Kingdom when available. Data on both the number of LSD seizures and quantities of LSD 
seized in 2004 were not available for Ireland and the United Kingdom; data on the number of LSD seizures seized were not available for Cyprus, the Netherlands, 
Poland and Bulgaria. For estimating purposes, 2004 missing data were replaced by 2003 data. Data on quantities seized in 2004 provided by the Netherlands 
were only estimates, which could not be included in the analysis of trends to 2004.
(102) See Table SZR-15 in the 2006 statistical bulletin.
(103) See Table SZR-16 in the 2006 statistical bulletin.
(104) See Table PPP-4 in the 2006 statistical bulletin.
(105) Taking 1999 as the base year for the value of money in all countries.
(106) Over the period 1999–2004, data on LSD prices were available for at least three consecutive years in the Czech Republic, Germany, Spain, France, Ireland, 
Lithuania, Poland, Portugal, Slovenia, Sweden, the United Kingdom, Romania and Norway.
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International action against production and trafficking 
of amphetamines and ecstasy
In the area of synthetic drugs, Europol has been running 
Project Synergy since December 2004 (107). It is supported by 
20 EU Member States and some third countries, and includes 
an analytical work file (AWF) with operational sub-projects 
carried out throughout the EU across several countries, as 
well as a number of instruments used for analytical and 
strategic purposes, such as the Europol ecstasy logo system 
(EELS) (including the ecstasy logo catalogue) and the 
Europol illicit laboratory comparison system (ELICS). Europol 
continues to support the CHAIN project (108) on amphetamine 
profiling and the European Joint Unit on Precursors (EJUP). 
Besides on-the-spot expert assistance in dismantling illicit 
synthetic drug production, recent sub-projects have focused 
on comparing the laboratories dismantled, on uncovering 
chemical dump sites as starting points for investigations, 
on back-tracking tablet machines, and on investigating 
trafficking in precursor chemicals to the EU countries.
Project Prism is the international initiative set up to prevent 
the diversion of precursor chemicals used in the illicit 
manufacture of synthetic drugs, through a system of pre-
export notifications for licit trade to the International 
Narcotics Control Board (INCB) and the reporting of 
shipments stopped and seizures made when suspicious 
transactions occur.
Ephedrine and pseudo-ephedrine are key precursors 
for methamphetamine, while 1-phenyl-2-propanone 
(P-2-P) is also used to manufacture amphetamine; 
3,4-methylenedioxyphenyl-2-propanone (3,4-MDP-2-P), 
safrole and safrole-rich oils are used in the illicit manufacture of 
MDMA, while piperonal is also used to synthesise MDA (109).
Licit trade of ephedrine and pseudo-ephedrine amounted 
to a total of 526 and 1 207 tonnes respectively in 2004. 
The largest seizures of these chemicals were reported in 
North America and South-East Asia, but there is concern that 
seizures have spread to all regions. Smuggling of ephedrine 
and pseudo-ephedrine to Europe originates mainly in 
western Asia. In 2004, 2.6 tonnes of ephedrine and 1 kg of 
pseudo-ephedrine were seized in Europe (110); the seizures 
were mostly small seizures and came from many different 
laboratories, a majority in the Czech Republic, although 
there was a large seizure in Greece of ephedrine from 
Pakistan.
The activities of Project Prism in Europe have focused 
on preventing the smuggling of 3,4-MDP-2-P and P-2-P 
into the EU for use in the illicit manufacture of MDMA 
and amphetamine respectively. In 2004, seizures of 
3,4-MDP-2-P and P-2-P were the largest ever reported 
globally, Europe accounting for the greatest quantities 
of 3,4-MDP-2-P seized and the United States for the 
greatest quantities of P-2-P seized. In 2004, seizures in 
Europe totalled 10 161 litres of 3,4-MDP-2-P (mostly in 
the Netherlands and Belgium) and 9 297 litres of P-2-P 
(mostly in Poland and the Netherlands) (111).
Piperonal has many licit uses but may also be used as a 
precursor in the manufacture of 3,4-MDP-2-P, MDA or 
MDMA (INCB, 2006b). Between November 2004 and 
October 2005, over 150 shipments of 3 800 tonnes were 
reported to the INCB (2006b). In 2004, the greatest seizures 
of piperonal were reported by China (13 tonnes); 2.4 tonnes 
was seized in Europe, nearly all of it in Romania (112).
Seizures of safrole are reported from all regions worldwide 
but quantities remain small, except in China, which reports 
seizures over 100 kg. In Europe 122 litres of safrole was 
seized in 2004, mainly in Latvia but also in Lithuania.
Prevalence and patterns of use
Traditionally, population surveys have shown that, next 
to cannabis, amphetamines and ecstasy are the illegal 
substances most commonly used, albeit the overall 
prevalence of their use is lower than that of cannabis. Use 
of ecstasy became popular during the 1990s, whereas 
amphetamines have been used for much longer.
Among EU Member States, use of amphetamines (113) and 
ecstasy appears to be relatively high in only a few countries, 
namely the Czech Republic, Estonia and the United Kingdom.
Recent surveys among the adult population (15–64 years) 
report that lifetime prevalence of amphetamine use in 
Europe ranges from 0.1 % to 5.9 %, except in the United 
Kingdom (England and Wales), where it reaches 11.2 %. 
On average about 3.1 % of all European adults have used 
amphetamines at least once. After the United Kingdom, the 
(107) (108) (109) (110) (111) (112) (113)
(107) Project Synergy merged Projects CASE and Genesis, which commenced in 2002.
(108) The ‘collaborative harmonised amphetamine initiative’ (CHAIN) is a forensic profiling initiative which has superseded the CASE pilot project.
(109) All scheduled under Table I of the 1988 convention.
(110) Seizure data do not include quantities involved in stopped shipments.
(111) Seizure data do not include quantities involved in stopped shipments.
(112) Seizure data do not include quantities involved in stopped shipments.
(113) Within the framework of population surveys, data on ‘amphetamine use’ include use of both ‘amphetamine’ and ‘methamphetamine’ under one category.
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countries with the next highest figures are Denmark (5.9 %), 
Norway (3.6 %) and Germany (3.4 %). Last year use is 
much lower: 0.6 % on average (range 0–1.4 %). Based on 
general population surveys, it has been estimated that almost 
10 million Europeans have tried this substance, and more 
than 2 million will have used amphetamine in the previous 
12 months (114).
Among young adults (15–34 years) experience of 
amphetamine use is reported by 0.1–9.6 %, with the 
United Kingdom (England and Wales) reporting a lifetime 
prevalence rate of 16.5 % (which may reflect a historical 
phenomenon, see below). Half of the countries providing 
data have prevalence rates below 4 %, with the highest rates 
after the United Kingdom reported by Denmark (9.6 %), 
Norway (5.9 %) and Germany (5.4 %). An average of 
4.8 % of young Europeans have tried amphetamine. 
Denmark (3.1 %) and Estonia (2.9 %) report the highest last 
year prevalence rates (115). It is estimated that, on average, 
1.4 % of young Europeans have used amphetamine in the 
last year (see also Figure 4).
Ecstasy has been tried by 0.2–7.1 % of all adults (average 
2.6 %). Half of the countries report prevalence rates of 1.8 % 
or lower, with highest prevalence rates being reported by the 
Czech Republic (7.1 %) and the United Kingdom (6.7 %). 
The prevalence of last year use of ecstasy ranges from 0.2 % 
to 3.5 %, but half of the countries report prevalence rates of 
0.5 % or below. It has been estimated that almost 8.5 million 
Europeans have tried ecstasy, and almost 3 million have used 
it in the last year.
Among young adults across the European countries, the 
prevalence of lifetime use of ecstasy is 5.2 %, ranging 
from 0.5 % to 14.6 %, although rates of less than 3.6 % 
are reported by half of the countries. The Czech Republic 
(14.6 %), the United Kingdom (12.7 %) and Spain (8.3 %) 
report the highest prevalence rates.
Ecstasy use is predominantly a youth phenomenon. In the 
15–24 years age group, lifetime use ranges from 0.4 % 
to 18.7 %, with the highest figures reported by the Czech 
Republic (18.7 %) (116) and the United Kingdom (10.7 %), 
and with higher rates among males (0.3–23.2 %) than 
among females (0.4–13.9 %). Use in the last year ranges 
from 0.3 % to 12 %, with the Czech Republic (12 %) and 
Estonia (6.1 %) reporting the highest figures (Figure 5). 
Last month prevalence rates lower than 3 % are reported 
by seven countries. Prevalence rates are typically higher in 
urban areas, and in particular among people frequenting 
discos, clubs or dancing events (see the selected issue on 
drug use in recreational settings).
Among 15- to 16-year-old school students, surveys show that 
overall lifetime prevalence of ecstasy use increased over the 
period 1995–2003, with the greatest increases occurring 
in the Czech Republic and most of the new EU Member 
States (117). In the 2003 ESPAD school surveys (Hibell 
et al., 2004), lifetime prevalence estimates for amphetamines 
remained between 1 % and 3 % higher than those for 
ecstasy in six Member States (Germany, Denmark, Estonia, 
Lithuania, Austria and Poland) (118).
For comparison, in the 2004 US national survey on drug use 
and health, 4.6 % of adults (defined as 12 years and older) 
reported lifetime experience with ecstasy and 0.8 % reported 
last year use (the corresponding figures for the EU are 2.6 % 
and 0.9 %). Among young adults aged 16–34 years, lifetime 
experience was 11.3 %, and last year use 2.2 % (5.2 % and 
1.9 % respectively in Europe) (119).
Lifetime experience of the use of LSD among adults ranges 
from 0.2 % to 5.9 %, with two thirds of countries reporting 
prevalence rates between 0.4 % and 1.7 %. Among young 
adults (15–34 years), lifetime prevalence of LSD use ranges 
from 0.3 % to 9 %, and among the 15–24 years age group 
it does not exceed 4.5 %. The prevalence of last year use of 
this drug in the 15–24 years age group is over 1 % only in 
the Czech Republic, Estonia, Latvia, Hungary, Poland and 
Bulgaria.
Trends
There is evidence from new population surveys that 
amphetamine and ecstasy consumption, which has shown an 
increasing trend in recent years, may be stabilising or even 
decreasing. In the United Kingdom, as well as in two other 
Member States where consumption of these drugs has been 
relatively high (the Czech Republic and Spain), last year use 
of amphetamines among young adults is now reported to be 
(114) (115) (116) (117)(118)(119) 
(114) For the method of computation see footnote (53). 
(115) See Figures GPS-15 and GPS-16 in the 2006 statistical bulletin.
(116) In the Czech Republic, the age group surveyed was 18–24 years.
(117) See Figure EYE-2 (part i) in the 2006 statistical bulletin. 
(118) See Figure EYE-2 (part vi) in the 2006 statistical bulletin.
(119) Source: SAMHSA, Office of Applied Studies, 2004 national survey on drug use and health (http://oas.samhsa.gov/nsduh.htm#nsduhinfo). Note that the age 
range in the US survey (12 years and over) is wider than the age range reported by the EMCDDA for EU surveys (15–64 years). The figures for ‘young adults’ 
(16–34 years) for the US survey were recomputed by the EMCDDA.
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stabilising or even decreasing (120). And, similarly, ecstasy 
use appears to be levelling off or even declining in two 
high-prevalence countries, Spain and the United Kingdom, 
although not in the Czech Republic (121).
Treatment demand data — 
amphetamines and ecstasy (122)
Although the number of demands for treatment relating 
to the use of amphetamines and ecstasy is increasing, in 
general, this form of drug use is rarely the primary reason for 
attending drug treatment in most countries (123). An important 
exception is that a few countries do report a substantial 
proportion of treatment requests related to amphetamine 
or methamphetamine use. In the Czech Republic, Slovakia, 
Finland and Sweden these drugs account for anything from a 
quarter to around a half of all treatment demands (124). In the 
Czech Republic and Slovakia, a large proportion of reported 
treatment demands relate to a primary methamphetamine 
problem (see box on methamphetamine). In those countries 
where amphetamines users account for a substantial portion 
of treatment requests, between one third and two thirds of 
amphetamines clients inject the drug (125).
Demands for treatment related to ecstasy use are reported to 
account for less than 1 % of all treatment demands in most 
countries, with the exception of Cyprus, Hungary, Ireland 
and Turkey, where ecstasy clients constitute between 4 % and 
6 % of all clients seeking treatment.
(120) (121) (122) (123) (124) (125) 
(120) See Figures GPS-6 and GPS-17 in the 2006 statistical bulletin.
(121) See Figures GPS-8, GPS-18 and GPS-30 in the 2006 statistical bulletin.
(122) See footnote (70).
(123) See Figure TDI-1 in the 2006 statistical bulletin.
(124) See Table TDI-5 in the 2006 statistical bulletin.
(125) See Table TDI-17 (part iii) in the 2006 statistical bulletin.
Figure 4: Last year prevalence of amphetamine use among young adults (aged 15–34)
NB:   Data are from the most recent national surveys available in each country at the time of reporting. See Tables GPS-8 and GPS-11 in the 2006 statistical bulletin for further 
information.
Sources:  Reitox national reports (2005), taken from population surveys, reports or scientific articles.
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Figure 5: Last year prevalence of ecstasy use among young adults (aged 15–34)
NB:   Data are from the most recent national surveys available in each country at the time of reporting. See Tables GPS-8 and GPS-11 in the 2006 statistical bulletin for further 
information.
Sources:  Reitox national reports (2005), taken from population surveys, reports or scientific articles.
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Methamphetamine use and related problems
Signifi cant problems with methamphetamine use have been 
reported in many parts of the world, including the USA, 
South-East Asia and the Pacifi c, and Africa (UNODC, 2006). 
Methamphetamine use can lead to serious medical problems, 
including psychosis and dependence, and may be associated 
with risky behaviours, including some that could lead to HIV 
transmission.
Historically, methamphetamine use in Europe has been 
concentrated in the Czech Republic, where there are estimated 
to be twice as many problem methamphetamine (pervitin) users 
(20 300) as problem opioid users (9 700). In recent years, 
methamphetamine has become the most frequent primary drug 
among those demanding treatment for the fi rst time in Slovakia, 
and high levels of methamphetamine use have also been 
found among some subpopulations in Hungary. In their 2005 
Reitox reports, seven other countries (Denmark, France, Latvia, 
Slovenia, the United Kingdom, Bulgaria and Norway) reported 
an increase in seizures and/or use of this drug, mainly among 
frequent attendees at clubs and parties. Currently, the available 
information does not allow us to draw any fi rm conclusions on 
trends in methamphetamine use in these countries. Nevertheless, 
the spread of methamphetamine elsewhere in the world and the 
potential for this drug to cause signifi cant health problems means 
that this is an area in which continued vigilance is required.
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New and emerging drug trends
Prevalence estimates for the use of new or emerging drugs 
are much lower than those for the use of more established 
illicit drugs. New forms of drug use are likely to be adopted 
initially by a few individuals, among small subpopulations or 
in limited geographical locations or settings. Consequently, 
the identification and monitoring of emerging trends 
demands a different type of approach from that used for 
monitoring the main types of drug use.
Hallucinogenic mushrooms: an emerging trend case study
Until recently, LSD was the most commonly used 
hallucinogenic substance. This may now be changing as 
the use of hallucinogenic mushrooms (126) has become 
increasingly reported. The availability of hallucinogenic 
mushrooms appears to have increased since the late 
1990s, when they began to be marketed alongside other 
‘natural’ products in ‘smart shops’ in the Netherlands and 
elsewhere (127). For example, in the United Kingdom, during 
the early 2000s, the number of shops selling hallucinogenic 
mushrooms increased, and by 2005 it was estimated that 
they were being sold in about 300 shops and market stalls 
across the country. The sale of hallucinogenic mushrooms 
through the Internet also emerged, with sites, mainly based in 
the Netherlands, selling fresh mushrooms, growing kits and 
spore prints. Online marketing of hallucinogenic mushrooms 
is conducted in a variety of languages, mainly English, 
French and German, implying a wide international consumer 
base.
Recent adult and school population surveys in the EU indicate 
that, among young people aged 15–24 years, lifetime use 
of hallucinogenic mushrooms ranges from less than 1 % 
to 8 % (128). Lifetime prevalence estimates for the use of 
hallucinogenic mushrooms among school students aged 
15–16 years are equal to, or higher than, lifetime prevalence 
estimates for ecstasy use in nine of the EU Member States 
(Hibell et al., 2004). However, there are indications that 
continuation rates are lower for hallucinogenic mushrooms 
than for most other drugs. This is a common feature of 
hallucinogenic drug use and reflects the fact that young 
people generally choose to confine this type of drug use 
to experimenting and rarely go on to develop patterns of 
regular use.
Reports about acute or chronic health problems requiring 
medical interventions relating to the use of hallucinogenic 
mushrooms are rare. However, some countries changed their 
laws in response to the use of such hallucinogenic substances 
by young people. Although the active ingredients of 
mushrooms, psilocybin and psilocin, are already controlled 
at international level by the 1971 UN Convention on 
Psychotropic Substances, until recently it has often been left to 
prosecutors to interpret whether and when these substances 
are prohibited when inside a mushroom, to avoid penalising 
the owners of land on which such mushrooms grow 
naturally. Six countries have tightened up their legislation 
on mushrooms in the last five years (Denmark, Germany, 
Estonia, Ireland, the Netherlands and the United Kingdom). 
The changes made by these countries extend prohibition to 
include hallucinogenic mushrooms, although legal controls 
do not always apply to exactly the same mushrooms or states 
of preparation.
In 2004, seizures of hallucinogenic mushrooms were 
reported in the Czech Republic, Germany, Estonia, Greece, 
Lithuania, Hungary, the Netherlands, Poland, Portugal, 
Slovenia, Slovakia, Sweden and Norway (129). The number 
and quantity of law enforcement seizures of hallucinogenic 
mushrooms are generally low and no clear trends emerge 
from these data.
GHB and ketamine
Both gamma-hydroxybutyrate (GHB) and ketamine are being 
monitored following EU concerns arising in 2000 about 
the misuse of these drugs for recreational purposes (130). In 
March 2001 the UN drug control system added GHB to 
the list of internationally controlled drugs, and as a result 
all EU Member States have been updating their legislation 
on this substance. More recently, in March 2006, the INCB 
recommended that the WHO expedite its review to determine 
whether ketamine should be placed under international 
control (INCB, 2006a). At national level, ketamine is 
controlled under drug legislation, as opposed to medicine 
regulations, in almost half of the EU Member States.
(126 (127) (128) (129) (130) 
(126) In this report, the term hallucinogenic mushrooms refers only to fungi containing the psychoactive substances psilocybin and psilocin. Species of fungi 
containing other psychoactive substances are more rarely used. See the EMCDDA thematic paper on hallucinogenic mushrooms for more information 
(www.emcdda.europa.eu/?nnodeid=400).
(127) These shops sell legal and predominantly natural products, including hallucinogenic mushrooms. 
(128) EMCDDA data from the European model questionnaire. Eleven Member States provide data on hallucinogenic mushrooms (Czech Republic, Denmark, 
Germany, France, Ireland, Lithuania, Hungary, Netherlands, Poland, Finland, United Kingdom).
(129) Reitox national reports (Germany, Estonia, the Netherlands, Norway) and EMCDDA early-warning system network questionnaire (Czech Republic, Greece, 
Hungary, Poland, Portugal, Slovenia, Slovakia, Sweden).
(130) Joint action risk assessment report 2000.
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The shortage of prevalence data on GHB and ketamine 
suggests that use of these substances has stabilised at 
low levels in most countries. Studies of high-prevalence 
populations suggest that even among regular recreational 
drug users both of these drugs may be less commonly used 
than other substances such as amphetamines, ecstasy, LSD 
and hallucinogenic mushrooms.
Deaths and non-fatal emergencies reported to be associated 
with the use of GHB and ketamine are very rare. However, 
the absence of accurate and comparable systems for 
recording deaths and non-fatal emergencies related to 
the use of these substances limits the data available in this 
area. Two countries have reported deaths related to GHB, 
usually in association with other drugs. The municipal 
health service in Amsterdam recorded an increase in the 
annual number of non-fatal emergencies attributable to the 
use of GHB from 25 in 2000 to 98 in 2004, more than 
the number of medical emergencies attributed to use of 
ecstasy, amphetamine, LSD or hallucinogenic mushrooms. 
In Sweden, detections of GHB (or its precursors GBL and 
1,4-BD) in body fluid specimens increased from 24 in 
1997 to 367 in 2004. Deaths associated with GHB have 
also been reported in Sweden: between 1996 and 2004 
the drug was detected in 36 drug-related deaths, with 
nine of these occurring in 2004. In England and Wales in 
2003, GHB was mentioned in the coroner’s report of three 
deaths, in one of which GHB was the only drug mentioned 
(ONS, 2006). However, toxicological information from one 
hospital in the United Kingdom, covering a large region, 
indicates that GHB was detected in five deaths between 
May and December 2005 (131).
As GHB is water/alcohol-soluble, and because of its 
potentially incapacitating effects, often followed by 
amnesia, there have been concerns that it is being used 
in drug-facilitated sexual assaults (so-called ‘date rapes’). 
However, as cases may remain unreported, and because 
forensic evidence is scarce and such crimes are difficult 
to prove, there is no sound evidence on the extent of this 
phenomenon. Further research is therefore needed to 
determine the nature and extent of this potentially worrying 
development.
Action on new drugs
There was a smooth transition, with no disruption in 
information exchange, in 2005 when the 1997 joint 
action was superseded by the new Council Decision 
(2005/387/JHA). A total of 14 new psychoactive 
substances were officially notified for the first time to the 
EMCDDA and Europol. They are all psychotropic (synthetic) 
drugs, similar to those listed in Schedules I and II of the 
1971 UN Convention on Psychotropic Substances. The 
newly notified substances belonged to three major chemical 
groups — phenethylamines, tryptamines and piperazines. 
Various substances from these groups have been previously 
notified through, and are currently being monitored by, the 
early-warning system (EWS) (132).
The most significant new development in 2005 was the 
appearance and rapid spread of the new psychoactive 
(131) (132) 
(131) Information from the EWS. The relatively high number of deaths related to GHB in this report is likely to reflect the research interest in GHB by the hospital 
laboratory.
(132) Of the nine new synthetic drugs that underwent risk assessment between 1997 and 2004 under the joint action, all six substances that were subsequently 
controlled at EU level were phenethylamines.
Council decision on new psychoactive substances
Council Decision 2005/387/JHA of 10 May 2005 on the 
information exchange, risk assessment and control of new 
psychoactive substances (1) establishes a mechanism for 
the rapid exchange of information on new psychoactive 
substances that may pose public health and social threat, 
thus allowing the EU institutions and Member States to act on 
both new narcotic and new psychotropic drugs that appear 
on the European drug scene. The EMCDDA and Europol, in 
close cooperation with their networks — the Reitox national 
focal points (NFPs) and Europol national units (ENUs) 
respectively — have been assigned a central role in detecting 
and notifying new psychoactive substances. The decision 
also provides for an assessment of the risks associated with 
these new substances so that measures applicable in the 
Member States for the control of narcotic and psychotropic 
substances (2) can also be applied to new psychoactive 
substances if appropriate. The decision broadens the scope 
of, and replaces, the 1997 joint action (3), which was devoted 
exclusively to new synthetic drugs. The decision, however, 
maintains the three-step approach piloted by the joint action: 
information exchange/early warning, risk assessment and 
decision-making.
(1) Council Decision 2005/387/JHA on information exchange, risk 
assessment and control of new psychoactive substances was published 
in the Offi cial Journal of the European Union (OJ L 127, 20.5.2005, 
pp. 32–37) and took effect on 21 May 2005. The decision applies to 
substances currently not listed in any of the schedules to the 1961 and 
1971 UN drug control conventions.
(2) In compliance with the provisions of the 1961 UN Single Convention 
on Narcotic Drugs and the 1971 UN Convention on Psychotropic 
Substances.
(3) Joint action of 16 June 1997 concerning the information exchange, risk 
assessment and control of new synthetic drugs (OJ L 167, 25.6.1997).
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substance 1-(3-chlorophenyl)piperazine (mCPP). mCPP is an 
aryl-substituted piperazine, as is benzylpiperazine (BZP), 
a substance monitored by the EWS since 1999. The first 
official notifications of the detection of mCPP were received 
by the EMCDDA and Europol in February/March 2005, 
concerning samples collected in France and Sweden. 
By the end of 2005, mCPP-containing tablets had been 
seized by the law enforcement authorities or found in the 
context of various recreational activities (open-air dance/
music festivals, dance clubs, etc.) in almost all Member 
States. They are almost always designed to look like, 
and presumably marketed as, ecstasy. The drug is chiefly 
available in tablet form, and the subjective effects of mCPP 
and MDMA are partially comparable (Bossong et al., 
2005). In addition, mCPP is often found in combination with 
MDMA. Since this is unlikely to be the result of accidental 
contamination, it suggests that the deliberate addition of 
mCPP may be intended to potentiate or modify the effects of 
MDMA. There seems to be little specific demand or market 
for mCPP in its own right in the EU.
Since the EWS started to monitor new (synthetic) drugs in 
1997, mCPP has been more widely identified by Member 
States than any other new psychoactive substance. It has 
been identified within the space of a year in 20 Member 
States as well as in Romania and Norway.
In a joint report, the EMCDDA and Europol recommended, 
in line with the provisions of the Council decision, that no 
formal risk assessment be carried out as there is evidence that 
mCPP is used in the manufacture of at least one medicinal 
product. However, it was also noted that, despite the fact that 
at present there is little evidence of significant public health or 
social risks related to mCPP, this question must remain open 
in the absence of a thorough scientific risk assessment.
Developments in drug use within recreational settings, 
in EMCDDA 2006 annual report: selected issues
Drug use and the recreational activities of young people are 
often linked. In particular, studies targeted at young people 
attending music and dance events consistently report much higher 
prevalence estimates for drug use than those found in general 
population surveys, with particularly high levels of stimulant drug 
use often being reported. Can differences between countries 
be explained in terms of the variety of commercial nightlife 
settings available, music culture, drug availability and disposable 
incomes? These questions are explored in this selected issue.
New developments in the promotion of recreational drugs 
via the Internet and in recreational drug use itself bring with 
them new challenges in the fi elds of policy, prevention and 
risk reduction. These are explored in this selected issue, which 
also reviews in detail the innovative drug prevention and risk 
reduction initiatives that have been introduced in the EU over 
the past decade in response to the complex problem of the 
interaction of leisure activities and drug use by young people.
This selected issue is available in print and on the Internet in 
English only (http://issues06.emcdda.europa.eu).
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Chapter 5
Cocaine and crack cocaine
Cocaine supply and availability (133)
Production and trafficking
Cocaine is the most trafficked drug in the world after herbal 
cannabis and cannabis resin. In terms of volume seized — 
578 tonnes worldwide in 2004 — trafficking continued to be 
predominantly in South America (44 %) and North America 
(34 %), followed by western and central Europe (15 %) 
(CND, 2006).
Colombia is by far the largest source of illicit coca in the 
world, followed by Peru and Bolivia. Global production 
of cocaine in 2004 is estimated to have increased to 
687 tonnes, of which Colombia contributed 56 %, Peru 28 % 
and Bolivia 16 % (UNODC, 2005). Most of the cocaine 
seized in Europe comes directly from South America (mainly 
Colombia) or via Central America and the Caribbean. In 
2004, Suriname, Brazil, Argentina, Venezuela, Ecuador, 
Curaçao, Jamaica, Mexico, Guyana and Panama were 
reported as transit countries for cocaine imported into the EU 
(Reitox national reports, 2005; WCO, 2005; CND, 2006; 
INCB, 2006a; Europol, 2006). Some also passed through 
Africa, increasingly through western Africa and countries in 
the Gulf of Guinea (mainly Nigeria), but also eastern Africa 
(Kenya) and north-western Africa through the islands off 
the coast of Mauritania and Senegal (CND, 2006; INCB, 
2006a). The main points of entry in the EU remain Spain, the 
Netherlands and Portugal, as well as Belgium, France and 
the United Kingdom (Reitox national reports, 2005; CND, 
2006; Europol, 2006). Although Spain and the Netherlands 
still play an important role as distribution points for the 
cocaine entering the EU, the intensified controls along the 
Spanish north coast (Galicia) and the 100 % controls policy 
on flights from specific countries (134) at Schiphol Airport 
(Amsterdam) may have played a part in the development 
of alternative routes, increasingly, for example, via Africa, 
but also via eastern and central Europe and secondary 
distribution from there to western Europe (Reitox national 
reports, 2005; WCO, 2005; INCB, 2006a).
Seizures
In 2004, an estimated 60 000 seizures of 74 tonnes of 
cocaine were made in the EU. Most seizures of cocaine are 
reported in western European countries, especially Spain, 
which accounts for about half the seizures and amounts 
recovered in the EU in the last five years (135). Over the 
period 1999–2004, the number of cocaine seizures (136) 
increased overall at EU level, while quantities (137) seized 
fluctuated within an upward trend. However, based on 
reporting countries, quantities appear to have declined in 
2004 — perhaps in comparison with the exceptional amount 
recovered in Spain the year before.
Price and purity
In 2004, the average retail price of cocaine varied widely 
across the EU, from EUR 41 per gram in Belgium to over 
EUR 100 per gram in Cyprus, Romania and Norway (138). The 
average prices of cocaine, corrected for inflation (139), showed 
an overall downward trend over the period 1999–2004 in all 
reporting countries (140) except Luxembourg, where it declined 
(133) (134) (135) (136) (137) (138) (139) (140) 
(133) See ’Interpreting seizures and other market data’, p. 37.
(134) All flights from the Netherlands Antilles, Aruba, Suriname, Peru, Venezuela and Ecuador are 100 % controlled; in 2004, 3 466 drug couriers were arrested as 
a result of such controls and 620 as a result of regular controls (Dutch national report).
(135) This should be checked against missing 2004 data when available. Data on both number of cocaine seizures and quantities of cocaine seized in 2004 were 
not available for Ireland and the United Kingdom; data on number of cocaine seizures were not available for the Netherlands in 2004. For estimating purposes, 
2004 missing data were replaced by 2003 data. Data on quantities seized in 2004 provided by the Netherlands were only estimates, which could not be included 
in the analysis of trends to 2004.
(136) See Table SZR-9 in the 2006 statistical bulletin.
(137) See Table SZR-10 in the 2006 statistical bulletin.
(138) See Table PPP-3 in the 2006 statistical bulletin.
(139) Taking 1999 as the base year for the value of money in all countries.
(140) Over the period 1999–2004, data on cocaine prices were available for at least three consecutive years in Belgium, the Czech Republic, Germany, Spain, 
France, Ireland, Cyprus, Latvia, Lithuania, Luxembourg, Poland, Portugal, Slovenia, Sweden, the United Kingdom, Bulgaria, Turkey and Norway.
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until 2002 and then increased, and Norway, where prices 
rose sharply in 2001 and then stabilised.
Compared with heroin, the average purity of cocaine at 
user level is high, varying in 2004 from 24 % in Denmark 
to 80 % in Poland, with most countries reporting purities of 
40–65 % (141). Data available for 1999–2004 indicate an 
overall decrease in the average purity of cocaine in most 
reporting countries (142), although it increased in Estonia 
(since 2003), France and Lithuania, and remained stable in 
Luxembourg and Austria.
International action against cocaine production 
and trafficking
Project COLA, run by Europol, aims at identifying and 
targeting Latin American and associated criminal groups 
operating towards and within the EU and engaged primarily 
in the trafficking of cocaine. In particular, it provides 
operational support to live investigations in participating 
Member States and enhances the strategic intelligence 
picture. It is complemented by the Europol cocaine logo 
system, which collates, in an annually updated catalogue, 
modi operandi and photographic and other information 
on cocaine seizures and on logos/markings on the drugs 
and their packaging, in order to identify matches between 
seizures and promote international law enforcement 
cooperation and information exchange (Europol, 2006).
Operation Purple, running since 1999, is designed to 
prevent the diversion of potassium permanganate (143) 
from licit trade for use in the illicit manufacture of cocaine, 
in particular in the Americas. The licit trade in potassium 
permanganate is large: since 1999, 30 exporting 
countries/territories have provided 4 380 pre-export 
notifications to the INCB involving over 136 560 tonnes 
of potassium permanganate. Since 1999, 233 shipments 
involving over 14 316 tonnes of the substance have been 
stopped or seized because of concerns over the legitimacy 
of the orders or the end-users, and diversions were 
identified. In 2004, 1.4 tonnes of potassium permanganate 
was seized in Europe, mainly in the Russian Federation, 
followed by Romania and Ukraine (144) (INCB, 2006b).
Traffickers appear to have found ways to avoid controls 
and monitoring mechanisms introduced under Operation 
Purple. Indeed, although the illicit manufacture of cocaine 
is not associated with Asia, there is growing concern that 
traffickers may be targeting the region for diverting potassium 
permanganate from licit trade. There is also concern that 
traffickers may be diverting potassium permanganate to the 
Andean subregion through the Caribbean islands. Thus, 
while acknowledging some success in identifying suspicious 
transactions and in stopping shipments, the INCB (2006b) 
has urged governments to develop operating procedures to 
backtrack information from cocaine laboratory seizures in 
order to trace the chemicals back to the source, identify transit 
countries and investigate trade companies, so that traffickers 
may experience more difficulties in relocating their activities.
Prevalence and patterns of cocaine use
Based on recent national population surveys, it is estimated 
that about 10 million Europeans (145) have tried cocaine at 
least once (lifetime prevalence), representing over 3 % of all 
adults (146). National figures on reported use range between 
0.5 % and 6 %, with Italy (4.6 %), Spain (5.9 %) and the 
United Kingdom (6.1 %) at the upper end of this range. It is 
estimated that about 3.5 million adults have used cocaine in 
the last year, representing 1 % of all adults. National figures 
in most countries range between 0.3 % and 1 %, although 
prevalence levels are higher in Spain (2.7 %) and the United 
Kingdom (2 %).
As with other illegal drugs, cocaine use is concentrated 
among young adults. Lifetime experience is highest among 
young adults aged 15–34 years, although last year use 
is slightly higher among 15- to 24-year-olds. Cocaine 
seems to be predominantly a drug used by those in their 
20s, but, compared with cannabis use, cocaine use is less 
concentrated among younger people. Lifetime experience 
among 15- to 34-year-olds ranges from 1 % to 10 %, with 
the highest levels again found in Spain (8.9 %) and the 
United Kingdom (10.5 %). Last year use ranges between 
0.2 % and 4.8 %, with the figures for Denmark, Ireland, 
Italy and the Netherlands being around 2 %, and for Spain 
and the United Kingdom over 4 % (Figure 6). Data from 
school surveys show very low lifetime prevalence for the 
use of cocaine, ranging from 0 % in Cyprus, Finland and 
Sweden to 6 % in Spain, with even lower lifetime prevalence 
rates for use of crack cocaine, ranging from 0 % to 3 % 
(Hibell et al., 2004).
(141) (142) (143) (144) (145) (146) 
(141) See Table PPP-7 in the 2006 statistical bulletin.
(142) Over the period 1999–2004, data on cocaine purity were available for at least three consecutive years in Belgium, the Czech Republic, Denmark, Germany, 
Estonia, Spain, France, Ireland, Italy, Latvia, Lithuania, Luxembourg, Hungary, the Netherlands, Austria, Portugal, Slovakia, the United Kingdom and Norway.
(143) Precursor used in the manufacture of cocaine and scheduled under Table I of the 1988 convention.
(144) These data do not include quantities involved in stopped shipments.
(145) Based on a weighted average of national figures; more details in footnote (53).
(146) For detailed figures for each country, see the table in ’General population surveys of drug use’ in the 2006 statistical bulletin.
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Cocaine consumption is higher among young males. For 
instance, among males aged 15–34 years, surveys from 
Denmark, Germany, Spain, Italy, the Netherlands, the United 
Kingdom and Norway found that lifetime experience was 
between 5 % and 14 %. Last year use was lower, but four 
countries reported figures higher than 3 %, with Spain and 
the United Kingdom reporting figures of about 6–7 % (147), 
suggesting that in these countries about 1 in 15 young 
males has used cocaine recently. This proportion will be 
substantially higher in urban areas.
Among the general population, cocaine use seems to 
be occasional, occurring mainly at weekends and in 
recreational settings (bars and discos), where it can reach 
high levels. Research studies conducted among young 
people in dance and music settings in different countries 
reveals prevalence estimates for cocaine use that are much 
higher than those found in general populations, with lifetime 
prevalence ranging from 10 % to 75 % (see the selected 
issue on drug use in recreational settings). For instance, 
the British Crime Survey 2004/05 reported a prevalence 
estimate for the use of ‘class A’ drugs among people going 
to discos or nightclubs that was at least two times higher than 
the rate among those who did not go to these venues (Chivite-
Matthews et al., 2005) (see also the selected issue on drug 
use in recreational settings). On average, about one third of 
all European adults who have ever used cocaine have used 
it in the previous 12 months; for comparison, only 13 % 
report having used it in the previous 30 days. For instance, 
2–4 % of males aged 15–24 years in Spain, Italy, the United 
Kingdom and Bulgaria (148) report having used cocaine in 
(147) (148) 
(147) See Figure GPS-9 in the 2006 statistical bulletin.
(148) 2001 survey. In the 2003 survey, gender breakdown was not reported by10-year age groups.
Figure 6: Last year prevalence of cocaine use among all adults (aged 15–64) and young adults (aged 15–34 and 15–24)
NB:   Data are from the most recent national surveys available in each country at the time of reporting. See Tables GPS-8, GPS-11 and GPS-18 in the 2006 statistical bulletin 
for further information.
Sources:  Reitox national reports (2005), taken from population surveys, reports or scientific articles.
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the previous 30 days. A rough estimate of current cocaine 
use in Europe would be about 1.5 million adults aged 
15–64 years (80 % in the age range 15–34 years). This 
can be considered as a minimum estimate, given probable 
under-reporting.
Patterns of cocaine use are very different in different groups 
of users. In a European multi-city study, it was found that 
socially integrated cocaine users mainly snorted (95 %) the 
substance, while only a small fraction had smoked or injected 
it, but combined use of cannabis and alcohol was very 
common (Prinzleve et al., 2004). Among users in addiction 
treatment settings or in socially marginalised groups, 
injection was frequent, and crack use was usual in Hamburg, 
London and Paris, and to a lesser extent in Barcelona and 
Dublin. Crack use among the European general population 
seems to be low. For instance, lifetime prevalence of crack 
use was reported to be 0.5 % in Spain (2003) and 0.8 % in 
the United Kingdom (Chivite-Matthews et al., 2005). In three 
countries, lifetime prevalence of crack use was surveyed in 
club settings and found to be even lower than heroin use (the 
Czech Republic 2 %, the United Kingdom 13 % and France 
21 %). However, use of crack among marginalised groups 
or opioid users is a cause for concern in some cities. For 
example, among a targeted group of 94 female street sex 
workers in Amsterdam, the prevalence estimate for lifetime 
use of crack cocaine was extremely high at 91 % (Korf, 
2005, cited in the Dutch national report).
For comparison, according to the 2004 United States national 
survey on drug use and health, 14.2 % of adults (defined as 
12 years or older) reported lifetime experience with cocaine, 
which contrasts with a European average of 3 %. Last year 
use was 2.4 %, compared with a European average of 1 %, 
although in some EU countries, e.g. Spain (2.7 %) and the 
United Kingdom (2 %), reported figures are in the same range 
as in the United States (149). The comparatively higher lifetime 
figures in the United States may be in part related to earlier 
spread of cocaine use in that country.
Among young adults (aged 16–34), US figures were 
14.6 % (lifetime), 5.1 % (last year) and 1.7 % (last month), 
whereas the EU average figures for 15- to 34-year-olds were, 
respectively, about 5 % (lifetime), 2 % (last year) and 1 % 
(last month).
Trends in cocaine use
For several years, there have been warnings about the 
possibility of increasing cocaine use in Europe, based on 
data from diverse sources (e.g. market indicators, treatment 
demands, deaths). Although the available information 
on cocaine trends among the population is improving as 
more countries carry out repeated surveys, the data are still 
limited. In the case of cocaine, added difficulties are the 
lower prevalence levels and the probable under-reporting 
of use.
Recent cocaine use (last year) increased markedly in 
the second half of the 1990s among young adults in the 
United Kingdom, until 2000, and in Spain, until 2001, 
with an apparent stabilisation in recent years. In Germany, 
a moderate increase was observed over the 1990s, but 
the figures have remained stable in recent years, at levels 
clearly lower than in Spain and the United Kingdom 
(Figure 7).
Moderate increases in last year use have been observed 
in Denmark (up to 2000), Italy, Hungary, the Netherlands 
(up to 2001) and Norway. This trend needs to be interpreted 
carefully as it is based on only two surveys in each country.
In the case of cocaine and other substances (e.g. ecstasy, 
amphetamines, hallucinogenic mushrooms), trends could be 
(149) 
(149) Source: SAMHSA, Office of Applied Studies, 2004 national survey on drug use and health (http://oas.samhsa.gov/nsduh.htm#nsduhinfo). Note that the age 
range for ‘all adults’ in the US survey (12 years and over) is wider than the age standard range for European surveys (15–64). The figures for the 16–34 years 
group in the United States have been recomputed by the EMCDDA. 
Figure 7: Trends in last year prevalence of cocaine use among young 
adults (aged 15–34)
(1)   In Denmark, the value for 1994 corresponds to ‘hard drugs’.
NB:   Data are taken from the most recent national surveys available in each country 
at the time of reporting. See Table GPS-4 in the 2006 statistical bulletin for 
further information.
Sources:  Reitox national reports (2005), taken from population surveys, reports or 
scientific articles.
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better identified by focusing the analysis on groups in which 
drug use is concentrated, in particular young people living in 
urban areas. These populations are explored in more depth 
in the selected issue on drug use in recreational settings. In 
addition, survey information should be complemented by 
focused studies among young people in selected groups 
(nightlife settings).
Treatment demand data (150)
After opioids and cannabis, cocaine is the drug most 
commonly reported as the reason for entering treatment and 
accounts for about 8 % of all treatment demands across the 
EU in 2004 (151). It should be noted that Spain, a country 
usually reporting high treatment demands for cocaine, has 
not yet provided data. This overall figure reflects a wide 
variation between countries: in most countries treatment 
demands related to cocaine use are quite low, but in the 
Netherlands (37 %) and, historically, Spain (26 % in 2002) 
the proportion of all clients who ask for treatment for cocaine 
use is far higher. In the most recent data available, a group 
of countries report percentages of cocaine clients among 
all treatment clients between 5 % and 10 % (Denmark, 
Germany, France, Ireland, Italy, Cyprus, Malta, the United 
Kingdom and Turkey), whereas in the remaining countries 
the proportions are very low (152). In several countries, 
compared to all clients, there are higher percentages of new 
clients demanding treatment for primary cocaine use (153) 
and overall around 12 % of all new treatment demands are 
reported as cocaine related. Cocaine is also reported as a 
secondary drug by around 12 % of new clients (154).
The increasing trends among clients seeking treatment for 
cocaine use reported in previous years is continuing; from 
1999 to 2004, an analysis that interpolates for unreported 
data suggests that the proportion of new clients demanding 
treatment for cocaine use grew from around 10 % to 20 % 
during this period (based on 17 EU countries and Bulgaria 
and Romania) (155).
Overall, most cocaine treatment demands in Europe 
are not related to crack cocaine: around 80 % of new 
outpatient cocaine clients are reported to be using cocaine 
hydrochloride (cocaine powder), with less than 20 % using 
crack cocaine. However, crack cocaine users may pose 
particular challenges for treatment services as they tend 
to have a more marginalised social profile than users of 
cocaine powder. A European study on cocaine use (powder 
and crack cocaine) found an association between crack use 
and social and mental health problems; however, the study 
also reported that crack cocaine use itself is not sufficient 
to explain the social or mental health problems (Haasen 
et al., 2005). A recent study of 585 cocaine and crack 
clients in Scotland found that the crack users are more likely 
to have a longer history of problematic drug use and more 
involvement in criminal activities (Neale and Robertson, 
2004, cited in the United Kingdom national report).
Looking at the profile of cocaine clients in outpatient settings, 
it appears that new clients using cocaine as their primary 
drug are usually older than other drug consumers: 70 % are 
in the 20–34 years age group with a smaller group (13 %) 
aged between 35 and 39 years (156).
Cocaine is often used in combination with another illicit 
or licit subsidiary drug, often cannabis (31.6 %), opioids 
(28.6 %) or alcohol (17.4 %) (157). Local studies of drug 
injectors suggest that, in some areas, the combination of 
heroin and cocaine within an injection may be becoming 
more popular (sometimes referred to by drug injectors as 
‘speedballing’). The combination of opioids and cocaine is 
currently more apparent in the treatment data. Among clients 
reporting primary use of opioids, 31 % in Italy, 42 % in 
the Netherlands and 44 % in the United Kingdom report a 
secondary cocaine use. Among primary cocaine users, 28 % 
in Italy and 38 % in the United Kingdom report secondary 
use of opioids.
Treatment of cocaine dependence
There is not enough evidence to support pharmacological 
treatment for cocaine or other psychostimulant dependence. 
However, in their comprehensive review of the use of 
pharmacotherapies for psychostimulant users, Shearer and 
Gowing (2004) conclude that substitution therapy, which 
is successful in the case of opioid and nicotine dependence 
and has the potential for attracting and retaining users in 
treatment, has not yet been adequately tested in stimulant 
(150) (151) (152) (153) (154) (155) (156) (157) 
(150) See footnote (70).
(151) See Figure TDI-2 in the 2006 statistical bulletin.
(152) See Table TDI-5 in the 2006 statistical bulletin; for Spain data refer to the 2002 reporting year.
(153) See Table TDI-4 in the 2006 statistical bulletin.
(154) See Table TDI-23 in the 2006 statistical bulletin.
(155) See Figure TDI-1 in the 2006 statistical bulletin.
(156) See Table TDI-10 in the 2006 statistical bulletin.
(157) See Table TDI-24 in the 2006 statistical bulletin.
kg609922insideEN.indd   62 27/10/06   10:13:56
63
Chapter 5: Cocaine and crack cocaine
users. A review of the literature on the responses to and 
effectiveness of cocaine treatment, including responses to 
mental health disorders among crack cocaine users, has 
been published recently by the EMCDDA (158).
In some countries, including the United States and the 
United Kingdom, there is currently substantial investment in 
building up immunotherapy treatment options by developing 
antibodies that can intercept cocaine in the bloodstream 
before it reaches the central nervous system (see box on 
immunotherapy for cocaine addicts).
Combining several specific psychosocial treatment 
interventions is currently considered the most promising 
treatment option for cocaine and other psychostimulant users. 
The combination of the community reinforcement approach 
(CRA) with contingency management has been shown to 
reduce cocaine use in the short term (Higgins et al., 2003; 
Roozen et al., 2004).
CRA is an intensive treatment method that involves family, 
friends and other members of the client’s social network 
throughout the treatment and consists in training the clients to 
make social contacts, to improve their self-image, and to find 
work and rewarding leisure activities in order to establish 
a different lifestyle (Roozen et al., 2004). In combination 
with contingency management — a method that aims to 
influence clients’ behaviour by offering meaningful incentives, 
e.g. presents, vouchers or privileges for cocaine-free urine 
samples — positive effects on drug use and psychosocial 
functioning have been achieved during the treatment 
phase and post-treatment follow-up in cocaine-dependent 
outpatients, although effects on cocaine use appeared to be 
limited to the treatment period (Higgins et al., 2003).
New approaches to the highly problematic groups of 
cocaine- and crack-using heroin users focus on harm 
reduction as primary treatment goal and apply behavioural 
therapies, in particular contingency management 
approaches, in combination with methadone maintenance 
programmes or heroin-assisted treatment (Schottenfeld 
et al., 2005; van den Brink, 2005; Poling et al., 2006).
Harm reduction approaches
In Europe, the development of harm reduction approaches 
that target cocaine use has been limited. This might now be 
beginning to change as increased awareness of both the 
extent of cocaine use and the problems associated with it 
stimulates interest in developing responses to address the 
needs of cocaine users. The value of prevention and harm 
reduction approaches to reducing the risks associated with 
cocaine use remains largely unexplored, but a number of 
areas may have potential for the development of this kind 
of approach. For example, it is possible that cocaine users 
may benefit from interventions that address issues such as 
the increased toxicity of cocaine and alcohol combinations, 
the potential association of cocaine use with cardiovascular 
problems or behavioural links that may put the users at 
increased risk of HIV infection or becoming the victim of 
an accident or violent crime. As cocaine use can escalate 
quickly, brief interventions that can alert users to the fact that 
they may be beginning to experience negative consequences 
due to their use of the drug may also be worth exploring.
(158)
(158) www.emcdda.europa.eu/?nnodeid=400
Immunotherapy for cocaine addicts
In contrast to heroin addiction, which can be treated 
with agonists such as methadone or antagonists such 
as naltrexone, there are currently no medical treatments 
available for cocaine addiction. The reason for this would 
appear to be the mechanism of action through which cocaine 
exerts its effects on the brain neurotransmitters dopamine and 
serotonin. Whereas heroin binds to brain opioid receptors, 
such as the mu receptors, and therefore mimics the action of 
the brain’s own endorphins, cocaine inhibits the reabsorption 
of dopamine (and indeed serotonin) from the neuronal 
synapse once it has had its effect, leading to a build-up of the 
transmitter, thus prolonging and strengthening its effect.
This does not necessarily mean that it is not possible to 
develop a medical treatment for cocaine addiction, only that 
it may be more diffi cult to do so and may involve different 
concepts from those used in the development of treatments for 
heroin dependence.
One exciting strand of research is the use of immunotherapy, 
i.e. the development of a vaccine that would effectively 
‘neutralise’ the action of cocaine by preventing the drug from 
reaching the brain. The basic concept has undergone limited 
testing. A vaccine developed in the United Kingdom was 
tested in a small number of cocaine addicts, 18 in total, over 
a period of 14 weeks. It was found that three quarters of the 
vaccinated cohort of cocaine addicts were able to remain 
drug free for a period of three months with no untoward side-
effects. In addition, after six months, both those who relapsed 
and those who did not stated that the feelings of euphoria 
were not as potent as prior to vaccination. As a result of 
these fi ndings, the vaccine, known as drug–protein conjugate 
TA-CD, is undergoing phase 2 clinical trials. An alternative 
immunotherapeutic approach involves the development of 
monoclonal antibodies to cocaine, but this has only been 
tested preclinically.
The potential benefi t of the cocaine vaccine TA-CD has raised 
ethical concerns about the use of a vaccine: who would receive 
it, who would make the decision and on what criteria, etc.
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As a result of the serious health and social problems 
associated with crack cocaine use, there is more experience 
of developing services for this group, although activities 
are limited to those relatively few cities in Europe that have 
experienced a significant crack cocaine problem. In a 
number of cities crack cocaine users have been targeted by 
outreach schemes that attempt to engage with what is often 
viewed as a difficult group to work with. Although overall the 
evidence base remains relatively weak, some studies have 
suggested that benefits can accrue. For example, one study 
of an innovative outreach treatment programme in Rotterdam 
(Henskens, 2004, cited in the Dutch national report) 
identified factors that were observed to be important for 
treating this group of clients, who are often difficult to engage 
in conventional drug services.
Compulsive patterns of crack and cocaine use may be 
associated with an increase in sexual health risk-taking, 
and some low-threshold programmes specifically target 
crack-using sex workers to transmit safer sex and drug use 
messages and to distribute condoms and lubricants (see 
selected issue on gender).
A more controversial approach has been adopted in some 
cities in Europe, where the concept of safe consumption 
rooms, usually targeting drug injection, has been extended 
to drug inhalation. Rooms for supervised inhalation have 
been opened in several Dutch, German and Swiss cities 
(EMCDDA, 2004c). Although the supervision of consumption 
hygiene is a main objective of such services, there is some 
evidence that they could also act as a conduit to other care 
options; for example, monitoring of one service in Frankfurt, 
Germany, reported that, during a six-month evaluation 
period in 2004, more than 1 400 consumptions were 
supervised, while 332 contact talks, 40 counselling sessions 
and 99 referrals to other drugs services were documented.
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Heroin supply and availability (159)
In Europe, two forms of imported heroin are found: the 
commonly available brown heroin (its chemical base form) 
and the less common and usually more expensive white 
heroin (a salt form), which typically originates from South-East 
Asia. In addition, some opioid drugs are produced within 
the EU, but manufacture is mainly confined to small-scale 
production of home-made poppy products (e.g. poppy straw, 
poppy concentrate from crushed poppy stalks or heads) in a 
number of eastern EU countries, for example Lithuania, where 
the market for poppy stalks and concentrate seems to have 
stabilised, and Poland, where production of ‘Polish heroin’ 
might be decreasing (CND, 2006).
Production and trafficking
Heroin consumed in Europe is predominantly manufactured 
in Afghanistan, which remains the world leader in illicit 
opium supply and in 2005 accounted for 89 % of global 
illicit opium production, followed by Myanmar (7 %). 
Global production of illicit opium remained relatively stable 
between 1999 and 2004, except in 2001, when a ban on 
opium poppy cultivation enforced by the Taliban regime in 
Afghanistan resulted in a dramatic but short-lived decline; it 
is estimated that about 4 670 tonnes was produced in 2005, 
a 4 % decline compared with 2004 (CND, 2006). Global 
potential production of heroin was estimated at 472 tonnes 
in 2005 (495 in 2004) (UNODC, 2006).
Heroin enters Europe by two major trafficking routes. The 
historically important Balkan route continues to play a crucial 
role in heroin smuggling. Following transit through Pakistan, 
Iran and Turkey, the route then diverges into a southern 
branch through Greece, the former Yugoslav Republic of 
Macedonia (FYROM), Albania, Italy, Serbia, Montenegro 
and Bosnia-Herzegovina and a northern branch through 
Bulgaria, Romania, Hungary, Austria, Germany and the 
Netherlands, the latter operating as a secondary distribution 
centre to other western European countries. Heroin seizures 
in 2004 suggest that the southern branch has now gained the 
same importance as the northern branch in terms of volume 
smuggled (WCO, 2005; INCB, 2006a). Since the mid-
1990s, heroin has been increasingly (but to a lesser extent 
than through the Balkan routes) smuggled to Europe through 
the ‘silk route’ via central Asia (in particular Turkmenistan, 
Tajikistan, Kyrgyzstan and Uzbekistan), the Caspian Sea and 
the Russian Federation, Belarus or Ukraine, to Estonia, Latvia, 
some of the Nordic countries and Germany (Reitox national 
reports, 2005; CND, 2006; INCB, 2006a). Although these 
routes are the most important, countries in the Arabian 
peninsula (Oman, United Arab Emirates) have become transit 
sites for heroin consignments from South and South-West 
Asia destined for Europe (INCB, 2006a). In addition, heroin 
destined for Europe (and North America) was seized in 
2004 in East and West Africa, the Caribbean, and Central 
and South America (CND, 2006).
Seizures
In 2004, 210 tonnes of opium (or 21 tonnes of heroin 
equivalent), 39.3 tonnes of morphine and 59.2 tonnes of 
heroin were seized worldwide. Asia (50 %) and Europe 
(40 %) continued to account for the greatest quantities of 
heroin seized worldwide. Europe’s share is increasing, 
largely as a result of increased seizures in south-eastern 
European countries (Turkey), which for the first time 
surpassed the volume intercepted in western and central 
Europe (CND, 2006).
In 2004, an estimated 46 000 seizures resulted in the 
recovery of about 19 tonnes of heroin in the reporting 
countries. The United Kingdom continued to account for 
the highest number of seizures, followed by Germany and 
Italy, while Turkey seized the largest quantities (followed by 
Italy and the United Kingdom), accounting for nearly half of 
the total amount intercepted in 2004 (160). Over the period 
(159) (160) 
(159) See ‘Interpreting seizures and other market data’, p. 37.
(160) This should be checked against missing 2004 data when available. Data on both number of heroin seizures and quantities of heroin seized in 2004 were not 
available for Ireland and the United Kingdom; data on number of heroin seizures were not available for the Netherlands in 2004. For estimating purposes, 2004 
missing data were replaced by 2003 data. Data on quantities seized in 2004 provided by the Netherlands were only estimates, which could not be included in the 
analysis of trends to 2004.
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1999–2004, seizures of heroin fluctuated, and based on 
data from reporting countries it seems that the decrease 
observed in 2002–03 was followed by an increase in 
2004 (161). Over the five-year period 1999–2004, total 
quantities seized steadily increased, reaching a record 
level in 2004, largely because the quantity of heroin seized 
in Turkey nearly doubled in 2004 compared with the 
previous year (162).
Price and purity
In 2004, the average retail price of brown heroin varied 
widely across Europe, from EUR 12 per gram in Turkey to 
EUR 141 per gram in Sweden, while that of white heroin 
varied between EUR 31 per gram in Belgium and EUR 202 
per gram in Sweden, and the price of heroin of type 
undistinguished ranged from EUR 35 per gram in Slovenia 
to EUR 82 per gram in the United Kingdom (163). Data 
available for 1999–2004 show a decrease in the average 
price of heroin, corrected for inflation (164), in most reporting 
countries (165).
The average purity of brown heroin at user level varied in 
2004 from 10 % in Bulgaria to 48 % in Turkey, while that 
of white heroin varied between 20 % in Germany and 63 % 
in Denmark, and that of heroin of type undistinguished 
ranged from 16 % in Hungary to 42–50 % (166) in the 
Netherlands (167). The average purity of heroin products has 
been fluctuating in most reporting countries (168) since 1999, 
making it difficult to identify any overall trend.
International action against the manufacture 
and trafficking of heroin
Acetic anhydride (169) is an important precursor used in 
the illicit manufacture of heroin. Operation Topaz is an 
international initiative to monitor licit trade in acetic anhydride 
and to investigate methods and routes of diversion (INCB, 
2006b). There is considerable licit trade in acetic anhydride, 
making it difficult to control. This is illustrated by the fact that, 
since 2001, 22 exporting countries/territories have provided 
7 684 pre-export notifications to the INCB involving over 
1 350 000 tonnes of acetic anhydride. Seizures in Turkey 
(1 600 litres in 2004) have significantly declined in recent 
years, perhaps indicating that traffickers have developed new 
routes and methods of diversion. In 2004, for the first time, 
seizures in Europe (Bulgaria) were identified as having come 
from south-western Asia (INCB, 2006b).
Although aspects of Operation Topaz related to monitoring 
international trade have proved to be successful, little progress 
has been made in identifying and dismantling routes used 
for smuggling acetic anhydride within Afghanistan and in its 
neighbouring countries (INCB, 2006b).
Project Mustard, run by Europol, aims at identifying and 
targeting Turkish and associated criminal groups operating 
towards and within the EU and engaged in the trafficking of 
drugs, primarily heroin. It provides operational support to 
live investigations in participating states and enhances the 
strategic intelligence picture by providing insight into the 
activities of Turkish organised crime and associated groups 
(Europol, 2006).
Prevalence estimates 
of problem opioid use
Data in this section are derived from the EMCDDA problem 
drug use (PDU) indicator, which covers ‘injecting drug use 
or long duration/regular use of heroin, cocaine and/or 
amphetamines’. Historically, problem drug use estimates 
have principally reflected heroin use, although in a few 
countries, as discussed elsewhere in the report, amphetamine 
users are an important component.
When interpreting the estimates of problem opioid use it 
should be kept in mind that patterns of use are becoming 
more diverse. For example, polydrug use problems have 
become progressively more important in most countries, 
whereas some countries where opioid problems have 
(161) (162) (163) (164) (165) (166) (167) (168) (169) 
(161) See Table SZR-7 in the 2006 statistical bulletin.
(162) See Table SZR-8 in the 2006 statistical bulletin.
(163) See Table PPP-2 in the 2006 statistical bulletin.
(164) Taking 1999 as the base year for the value of money in all countries.
(165) In the period 1999–2004, data on heroin prices were available for at least three consecutive years: for brown heroin in Belgium, the Czech Republic, Spain, 
France, Ireland, Luxembourg, Poland, Portugal, Slovenia, Sweden, the United Kingdom, Bulgaria, Romania, Turkey and Norway; for white heroin in the Czech 
Republic, Germany, France, Latvia and Sweden; and for heroin of type undistinguished in Lithuania and the United Kingdom.
(166) These two figures correspond to data from two different monitoring systems (see Table PPP-6 (part iii) in the 2006 statistical bulletin); caution is required as the 
figure 50 % is based on one sample only. 
(167) See Table PPP-6 in the 2006 statistical bulletin.
(168) In the period 1999–2004, data on heroin purity were available for at least three consecutive years: for brown heroin in the Czech Republic, Denmark, Spain, 
Ireland, Italy, Luxembourg, Austria, Portugal, Slovakia, the United Kingdom, Turkey and Norway; for white heroin in Denmark, Germany, Estonia, Finland and 
Norway; and for heroin of type undistinguished in Belgium, Lithuania, Hungary and the Netherlands.
(169) Scheduled under Table I of the 1988 convention.
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historically predominated now report changes towards 
other drugs. Most heroin users are now believed to use 
stimulants and other drugs besides opioids, but reliable 
data on polydrug use are very hard to obtain at the EU level 
(see Chapter 8).
Despite the general trend towards diversification of the 
phenomenon, in many countries estimates of problem drug 
use are exclusively based on problem use of heroin or other 
opioids as the primary substance. This can be seen in the 
estimated rates of problem opioid use (see Figure 8), which 
for the most part are very similar to those of PDU (170). It is 
not clear whether in the other countries the prevalence of 
non-opioid problem use is almost negligible or, possibly, 
significant but too difficult to estimate.
Estimating the number of problem opioid users is difficult, 
and analyses of a sophisticated nature are required to 
obtain prevalence figures from the available data sources. 
Moreover, estimates are often localised geographically, and 
extrapolation to form national estimates are not necessarily 
reliable.
Estimates of the prevalence of problem opioid use at 
national level over the period 2000–04 range between 
one and eight cases per 1 000 population aged 15–64 
(based on midpoints of estimates). Estimated prevalence 
rates of problem opioid use differ greatly between 
countries, although when different methods have been 
used within one country the results are largely consistent. 
Higher estimates of problem opioid use are reported by 
Ireland, Italy, Luxembourg, Malta and Austria (5–8 cases 
per 1 000 inhabitants aged 15–64 years), and lower rates 
are reported by the Czech Republic, Germany, Greece, 
Cyprus, Latvia and the Netherlands (fewer than four cases 
per 1 000 inhabitants aged 15–64 years) (Figure 8). Some 
of the lowest well-documented estimates now available 
(170) 
(170) See Figure PDU-1 (part i) in the 2006 statistical bulletin.
Figure 8: Estimates of the prevalence of problem opioid and stimulant use, 2000–04 (rate per 1 000 population aged 15–64)
NB:   ■ indicates stimulant use, other estimates are opioid use.
   MM, mortality multiplier; CR, capture–recapture; TM, treatment multiplier; PM, police multiplier; MI, multivariate indicator; TP, truncated Poisson; CM, combined methods. 
For more information see Tables PDU-1, PDU-2 and PDU-3 in the 2006 statistical bulletin. The symbol indicates a point estimate, a bar indicates an uncertainty interval, 
which can be either a 95 % confidence interval or an interval based on sensitivity analysis. Target groups may vary slightly owing to different methods and data sources, 
therefore comparisons should be made with caution.
Sources:  National focal points.
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are from the new countries of the EU, but in Malta a 
higher prevalence has been reported (5.4–6.2 cases 
per 1 000 aged 15–64). One can derive from the limited 
data a general EU prevalence of problem opioid use of 
between two and eight cases per 1 000 of the population 
aged 15–64. However, these estimates are still far from 
robust and will need to be refined as more data become 
available.
Local and regional estimates specifically of problem 
opioid use are not available; however, the available data 
regarding problem drug use (including use of stimulants 
and other drugs) suggest that there is a large variation in 
prevalence among cities and regions. The highest local 
prevalence estimates in the period 2000–04 are reported 
from Ireland, Portugal, Slovakia and the United Kingdom, 
reaching rates of between 15 and 25 per 1 000 (171). 
Geographic variability is, as might be expected, also 
marked at the local level; for example, the prevalence in 
different parts of London varies between 6 and 25 cases 
per 1 000. The wide variation in local prevalence rates 
makes generalisation difficult.
Time trends in problem opioid use
A lack of reliable and consistent historical data complicates 
the assessment of trends over time in problem opioid use. 
The evidence that has been collected suggests that the 
prevalence of problematic opioid use differs widely between 
countries, and that trends are not consistent across the EU. 
Reports from some countries, supported by other indicator 
data, suggest that problem opioid use continued to increase 
during the latter half of the 1990s (Figure 9) but appears to 
have stabilised or declined somewhat in more recent years. 
Repeated estimates on problem opioid use for the period 
between 2000 and 2004 are available from seven countries 
(the Czech Republic, Germany, Greece, Spain, Ireland, 
Italy, Austria): four countries (the Czech Republic, Germany, 
Greece, Spain) have recorded a decrease in problem opioid 
use, while one reported an increase (Austria — although this 
is difficult to interpret as the data collection system changed 
during this period). Evidence from people entering treatment 
for the first time suggests that the incidence of problem opioid 
use may in general be slowly declining; therefore in the near 
future a decline in prevalence is to be expected.
(171) 
(171) See Figure PDU-6 (part i) in the 2006 statistical bulletin.
Drug users in prisons
Information on drug use among prisoners is patchy. Many of the 
data available in Europe come from ad hoc studies, sometimes 
carried out at local level in establishments not representative of 
the national prison system, and using samples of prisoners that 
vary considerably in size. As a result, differences in terms of the 
characteristics of the populations studied limit comparisons of 
data between surveys — within and between countries — as well 
as extrapolation of results and trend analysis.
Data on drug use among the prison population in the last fi ve 
years (1999–2004) were provided by most European countries (1). 
They show that, compared with the general population, drug users 
are overrepresented in prison. The proportion of detainees who 
report ever having used an illicit drug varies among prisons and 
detention centres, but average rates range from one third or less 
in Hungary and Bulgaria to two thirds or more in the Netherlands, 
the United Kingdom and Norway, with most countries reporting 
lifetime prevalence rates of around 50 % (Belgium, Greece, Latvia, 
Portugal, Finland). Cannabis remains the most frequently used 
illicit drug, with lifetime prevalence rates among prisoners ranging 
between 4 % and 86 %, compared with lifetime prevalence rates 
of 3–57 % for cocaine, 2–59 % for amphetamines and 4–60 % 
for heroin (2).
Regular drug use or dependence prior to imprisonment is 
reported by 8–73 % of inmates, while the lifetime prevalence of 
drug injection among the prison population is 7–38 % (3).
Although the majority of drug users reduce or stop their drug 
use after incarceration, some detainees continue and others start 
using drugs (and/or injecting drugs) while in prison. According 
to available studies, 8–51 % of inmates have used drugs within 
prison, 10–42 % report regular drug use and 1–15 % have 
injected drugs while in prison (4). This raises issues around the 
potential spread of infectious diseases, in particular in relation to 
access to sterile injection equipment and sharing practices among 
the prison population.
Repeated surveys carried out in the Czech Republic 
(1996–2002), Denmark (1995–2002), Lithuania (2003/04), 
Hungary (1997–2004), Slovenia (2003/04) and Sweden 
(1997–2004) show an increase in the prevalence of various 
types of drug use among detainees, whereas France (1997–
2003) reports a signifi cant decrease in the proportion of injectors 
among the prison population (5).
(1) Countries reporting studies carried out in the last fi ve years (1999–
2004) and providing data on drug use patterns in prison populations were 
Belgium, the Czech Republic, Denmark, Germany, Greece, France, Ireland, 
Italy, Latvia, Lithuania, Hungary, Malta, the Netherlands, Austria, Portugal, 
Slovenia, Slovakia, Finland, Sweden, the United Kingdom, Bulgaria and 
Norway.
(2) See Table DUP-1 and Figure DUP-1 in the 2006 statistical bulletin.
(3) See Tables DUP-2 and DUP-5 in the 2006 statistical bulletin.
(4) See Tables DUP-3 and DUP-4 in the 2006 statistical bulletin.
(5) See Table DUP-5 in the 2006 statistical bulletin.
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Injecting drug use
Injecting drug users (IDUs) are at very high risk of 
experiencing adverse consequences such as serious 
infectious diseases or overdoses. It is therefore important to 
consider drug injection separately.
Despite their importance for public health, few countries 
provide estimates of injecting drug use at national 
or subnational level (172). In this section, IDU estimates 
are not categorised by primary drug, given the scarcity of 
data, although the trends in the proportion of IDUs among 
treated heroin users (see below) are of course specific for 
heroin injecting.
Most available estimates of injecting drug use are derived 
from either fatal overdose rates or data on infectious diseases 
(such as HIV). Available estimates vary considerably between 
countries: since 2000, estimates at national level have mostly 
ranged between one and six cases per 1 000 population 
aged 15–64, with some higher estimates existing prior to 
2000. Since 2000, the highest national prevalence rates of 
injecting drug use, among the countries where estimates are 
available, have been reported by Luxembourg and Austria, 
with a rate of about six cases per 1 000 population aged 
15–64. The lowest estimates are from Cyprus and Greece, at 
just over one case per 1 000.
Where time trends are available they do not show a general 
pattern, suggesting declines in some countries and regions 
(for example in Scotland, United Kingdom) and increases in 
others. However, the lack of data in this area means that it is 
not possible to draw a clear picture.
Monitoring the proportion of current injectors among heroin 
users entering treatment forms an important complement 
to monitoring the prevalence of injecting drug use in the 
general population. However, it is important to remember 
that the observed proportions do not necessarily reflect trends 
in the prevalence of all injecting drug use. For example, in 
countries with a high proportion of stimulant users (the Czech 
Republic, Slovakia, Finland, Sweden), the rates of injecting 
among heroin users might not be representative of the overall 
situation.
The proportion of IDUs among primary heroin users entering 
drug treatment again suggests marked differences in 
levels of injecting drug use between countries as well as 
varying trends over time (173). In some countries (Spain, the 
Netherlands and Portugal), a relatively small proportion 
of treated heroin users inject, whereas in other countries 
injection appears to be still the main form of heroin use. In 
some EU-15 Member States from which data are available 
(Denmark, Greece, Spain, France, Italy and the United 
Kingdom), rates of injecting among heroin users in treatment 
have declined. However, in most of the new Member States, 
at least where data exist, a large proportion of heroin users 
entering treatment are injectors.
Treatment demand data (174)
In many countries, opioids (largely heroin) remain the 
principal drug for which clients seek treatment. Of the total 
treatment requests reported for 2004 under the treatment 
demand indicator, opioids were recorded as the principal 
drug in about 60 % of cases — and just over half (53 %) 
of these clients reported injecting the drug (175). It should be 
noted that the treatment demand indicator does not cover 
all people in opioid treatment, which is a considerably 
greater number, only clients requesting treatment during the 
reported year.
(172) (173) (174) (175)
(172) See Figure PDU-7 in the 2006 statistical bulletin.
(173) See Figure PDU-3 (part i) in the 2006 statistical bulletin.
(174) See footnote (70).
(175) See Figure TDI-2 and Table TDI-5 in the 2006 statistical bulletin.
Figure 9: Trends in the prevalence of problem opioid use, 
1995–2004 (rate per 1 000 population aged 15–64)
(1)  Estimates for the 18–64 age group.
(2)  Computed from data for the 15–54 age group.
NB:   Time series are combined where methods are similar over the time span. For 
more information see Tables PDU-1, PDU-2 and PDU-3 in the 2006 statistical 
bulletin.
Sources:  National focal points.
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The proportion of clients seeking treatment for heroin use 
varies between countries. Based on the most recent data 
available, countries can be classified into three groups 
according to the proportion of drug users seeking treatment 
who report problem use of heroin, as follows:
• below 50 % — the Czech Republic, Denmark, Hungary, 
the Netherlands, Poland, Slovakia, Finland, Sweden;
• 50–70 % — Germany, Spain, France, Ireland, Cyprus, 
Latvia, Portugal, United Kingdom, Romania;
• over 70 % — Greece, Italy, Lithuania, Luxembourg, 
Malta, Slovenia, Bulgaria (176).
Countries where a sizeable proportion of opioid clients are 
using substances other than heroin include Hungary, where 
the use of home-made opium poppy products is widespread, 
and Finland, where most opioid clients are misusing 
buprenorphine (177).
Most opioid users, like users of other drugs, seek treatment in 
an outpatient setting; however, in comparison with cocaine 
and cannabis clients, a higher proportion of opioid clients 
are treated in inpatient centres.
Most countries with significant numbers of new heroin clients 
each year (except Germany, where the reporting base has 
been extended) report that there has been a decrease in 
the last 4–5 years, although not among clients who have 
previously been in treatment. The number of repeat requests 
has generally not declined, and in most countries the total 
number of treatment demands for heroin has remained 
roughly stable. Notable exceptions are Germany and 
the United Kingdom, where total reported requests have 
increased. Overall, however, the percentage of treatment 
demands accounted for by heroin (all and new requests) 
has fallen; in the case of new demands it has declined from 
about two thirds to around 40 % between 1999 and 2004 in 
the face of increases in demands for cannabis and cocaine 
treatment (178).
It has been previously reported that the population of clients 
requesting treatment for opioid use is an ageing one, and 
this trend continued in 2004. Nearly all opioid users seeking 
treatment are over 20 years old, and almost half of them are 
over 30. Data available at European level show that only 
a small group of opioid users (less than 7 %) are younger 
than 20 when they first seek help (179). There are occasional 
reports of very young people (aged less than 15) seeking 
treatment for heroin use (180), for example children aged 
11–12 in Sofia, Bulgaria, but, in general, demand for 
treatment for heroin appears to be rare among the young.
Opioid clients are reported to be marginalised in society, 
with low levels of education, high unemployment rates and 
often unstable accommodation; Spain reports that 17–18 % 
of opioid clients are homeless.
Most opioid clients report having used these drugs for the 
first time between the age of 15 and 24 years, with around 
50 % of clients first using the drug before the age of 20 (181). 
Since the time lag between first use and first demand for 
treatment is generally between 5 and 10 years and the time 
between initiation and regular drug use is estimated to be 
1.5–2.5 years (Finnish national report), it can be concluded 
that opioid clients typically experience 3–7 years of regular 
drug use before first seeking specialised treatment.
Across Europe, among new opioid clients seeking treatment 
in outpatient centres and for whom the route of administration 
is known, just over half are injecting the drug. In general, 
levels of injecting are higher among opioid users seeking 
treatment in the new Member States (above 60 %) than in 
the EU-15 Member States (below 60 %), with the exception 
of Italy and Finland, where the proportion of opioid injectors 
among clients is 74 % and 79.3 % respectively. The 
proportion of injectors among opioid clients is lowest in the 
Netherlands (13 %) and highest in Latvia (86 %) (182).
Treatment of opioid dependence
The EU drug strategy 2005–12 places a high priority on 
improving the availability of and access to treatment and it 
calls on Member States to provide a comprehensive range 
of effective treatments. Historically, residential treatment 
represented an important setting for the treatment of problem 
opioid users. However, the increasing diversity of treatment 
options and, in particular, the considerable expansion of 
substitution treatment has meant that the relative importance 
of residential care has declined.
Data on the relative availability of different types of 
treatment for opioid problems in Europe are currently 
(176) (177) (178) (179) (180) (181) (182) 
(176) See Table TDI-5 in the 2006 statistical bulletin.
(177) See Table TDI-26 in the 2006 statistical bulletin; Reitox national reports.
(178) See Figure TDI-1 in the 2006 statistical bulletin.
(179) See Table TDI-10 in the 2006 statistical bulletin.
(180) www.communitycare.co.uk
(181) See Table TDI-11 in the 2006 statistical bulletin.
(182) See Table TDI-17 in the 2006 statistical bulletin.
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limited. In response to an EMCDDA questionnaire, experts 
in most (16) Member States indicated that substitution 
treatment is the principal form of treatment available. 
However, in four countries (the Czech Republic, Hungary, 
Poland and Slovakia), drug-free treatment is reported to be 
more common, and in two countries, Spain and Sweden, a 
balance between medically assisted treatment and drug-free 
treatment options is reported.
Substitution therapy for opioid dependence (mainly 
treatment with methadone or buprenorphine) is in place 
in all EU Member States (183) as well as Bulgaria, Romania 
and Norway, and there is now a substantial European 
consensus that it is a beneficial approach to the treatment of 
problem opioid users, although in some countries it remains 
a sensitive topic (see Chapter 2). The role of substitution 
treatment is becoming less controversial internationally; 
the UN system came to a joint position on substitution 
maintenance therapy in 2004 (WHO/UNODC/UNAIDS, 
2004), and in June 2006 WHO included both methadone 
and buprenorphine in its model list of essential medicines.
There is now a robust evidence base for the value of 
substitution programmes using drugs such as methadone or 
buprenorphine. Studies have shown that substitution therapy 
is associated with decreased use of illicit drugs, reduced 
rates of injecting, a reduction in behaviours associated with 
a high risk of spread of HIV or other infectious diseases, 
such as sharing of equipment, and improvements in both 
social functioning and general health. Research has also 
suggested that levels of criminal activity may be reduced 
and that sufficient provision of substitution treatment may 
have an impact on the number of drug-related deaths. 
Optimum outcomes depend on timely entry into the 
programme, sufficient duration and continuity of substitution 
treatment, and adequate doses of medication.
While methadone continues to be the most commonly 
prescribed substitution treatment in Europe, treatment options 
are still expanding, and buprenorphine is now available 
in 19 EU countries, Bulgaria and Norway, although it is 
not clear whether it is officially approved for maintenance 
treatment in all countries where it is reported to be used. 
Considering that high-dosage buprenorphine treatment 
was introduced in Europe only 10 years ago, the drug’s 
popularity as a therapeutic option has developed remarkably 
quickly (see Figure 1) (184).
Long-term drug substitution is not the only purpose of opioid 
pharmacotherapy. Methadone and buprenorphine are 
also used to treat opioid withdrawal, when the therapeutic 
goal is to help the individual achieve abstinence by giving 
a reducing dose over a fixed period to help minimise the 
distress of withdrawal. The opioid antagonist naltrexone, an 
aversive pharmacotherapy option for opioid dependence, is 
also sometimes used as an aid to prevent relapse, as it blocks 
the effects of heroin, although the evidence base for the use 
of this drug is still inconclusive.
Some countries (Germany, Spain, the Netherlands and the 
United Kingdom) also have heroin prescription programmes, 
although the number of patients receiving this kind of 
treatment is very small compared with other forms of drug 
substitution (probably constituting less than 1 % of the total). 
This form of treatment remains controversial and is generally 
provided on a scientific trial basis for long-term users in 
whom other therapeutic options have failed.
A recent review of the effectiveness of drug dependence 
treatment in preventing HIV transmission found that 
behavioural interventions can enhance the positive effects 
of substitution treatment on HIV prevention, whereas the 
effectiveness of psychological therapy alone is variable. 
Abstinence-based treatment showed good outcomes with 
regard to HIV prevention for those who remain in treatment 
for three months or more (Farrell et al., 2005).
Monitoring methadone provision
Methadone is a controlled drug according to Schedule I of 
the 1961 Single Convention on Narcotic Drugs, and levels of 
domestic consumption are monitored annually by the INCB.
According to the EMCDDA, as a minimum estimate from 
the EU Member States, Bulgaria, Romania and Norway 
more than 500 000 clients received substitution treatment 
during the year (see Table 4 in the 2005 annual report). 
Excluding the Czech Republic and France, where high-dose 
buprenorphine treatment (HDBT) is reported to be the most 
common option, more than 90 % of treatments in all other 
countries were with methadone.
The EU and the USA together account for 85 % of 
the world’s methadone consumption, and methadone 
consumption in these countries has shown a steady increase 
over the last decade. Amounts consumed stabilised in both 
regions between 1997 and 2000, but there has been a 
(183) (184) 
(183) In Cyprus, the use of methadone in detoxification treatment is reported since 2004 and the beginning of a methadone maintenance treatment pilot project 
has been announced, but no cases in treatment have been reported. In Turkey, methadone is officially registered for the treatment of opioid dependency, but no 
treatment cases have been reported.
(184) See the selected issue on buprenorphine in the 2005 annual report. 
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sharp increase in the United States since then. Currently, 
levels of methadone consumption in the EU are about half 
those of the USA (185).
As a rule, noticeable increases in consumption figures 
follow the introduction of this treatment option at 
national level. For example, in France, the widespread 
implementation of methadone substitution treatment in 1995 
resulted in a rapid increase in consumption, from 31 kg in 
1995 to 446 kg in 2004.
Recently, signs of a stabilisation in levels of methadone 
consumption can be observed in the statistics for Denmark, 
Spain, Malta, the Netherlands, and possibly Germany. This 
matches reported trends in the number of clients in treatment 
(see Chapter 2).
(185) 
(185) See Figure NSP-2 in the 2006 statistical bulletin.
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Drug-related infectious diseases and drug-related deaths
Drug-related infectious diseases
One of the more serious health consequences of the use 
of illicit drugs, and in particular of drug injection, is the 
transmission of HIV and other infectious diseases, notably 
hepatitis C and B. The relationship between drug injecting 
and the transmission of infection is well established. Reducing 
drug injecting and the sharing of injecting equipment 
has therefore become a primary goal of public health 
interventions in this area. Studies also point to a relationship 
between drug use and high-risk sexual activity; this suggests 
a growing importance in linking drug use interventions with 
public health strategies aimed at sexual health. In terms of 
monitoring at the European level, data on infectious disease 
are collected by regular notification sources, where drug 
injecting may be recorded as a risk factor, and during 
special studies of drug-using populations in different settings.
HIV and AIDS
Recent trends in newly reported HIV cases
At present, most countries report low rates of newly 
diagnosed HIV infection attributed to injecting drug use. 
Countries that have maintained consistently low rates of 
HIV infection among injecting drug users (IDUs) provide 
an opportunity to explore what factors can account for 
this, a question posed by the current EU drug action plan 
and currently a focus of an EMCDDA coordinated study. 
Complacency should be avoided, however; neither Spain 
nor Italy, both of which have experienced HIV epidemics 
among IDUs, provides national HIV case reporting data, 
and this has a significant negative impact on the value of 
these data for describing the overall EU picture. Furthermore, 
data emerging from some countries are raising concerns 
that HIV infection may be increasing, at least among some 
populations of IDUs.
In France, where HIV cases have been recorded only since 
2003, there has been an increase in the incidence of HIV 
among IDUs (albeit from a low level), from an estimated 
2.3 cases per million population in 2003 to 2.9 cases in 
2004. Although this generally agrees with the available 
study data (see below), it must be remembered that new 
reporting systems are often initially unstable. In Portugal, an 
apparent decline in newly diagnosed cases of HIV among 
IDUs recorded previously is called into question by the 
2004 data, which reveal an incidence of HIV infection of 
98.5 cases per million population, the highest in the EU (186). 
In the United Kingdom, the incidence of HIV among IDUs has 
slowly increased but is now stable at just under 2.5 cases 
per million population per year. In Ireland, the incidence 
increased during the late 1990s to a peak of 18.3 cases per 
million per year in 2000, fell to 9.8 per million in 2001, and 
subsequently increased to 17.8 cases per million in 2004.
HIV outbreaks related to injecting drug use occurred as 
recently as 2001 in Estonia and Latvia, and 2002 in 
Lithuania. Since then rates have strongly declined; a decline 
in the rates of newly reported cases is to be expected after 
an initial epidemic phase as an endemic level of infection 
becomes established (see below).
HIV seroprevalence among tested IDUs
Seroprevalence data from IDUs (percentage infected in 
samples of IDUs) are an important complement to HIV 
case reports. Repeated seroprevalence studies and routine 
monitoring of data from diagnostic tests can support 
conclusions drawn from case reporting data and can provide 
more detailed information on specific regions and settings. 
However, prevalence data come from a variety of sources 
and, in some cases, may be difficult to compare; thus, they 
should be interpreted with caution.
The recent increases in HIV in some countries recorded in the 
case reporting data are mostly confirmed by the available 
seroprevalence data, although the latter would suggest that 
these are not the only countries in which increased vigilance 
is necessary.
In the Baltic states, the available seroprevalence data 
indicate that transmission among IDUs may still not be under 
control (Figure 10). In Estonia, a recent study suggests that 
prevalence in IDUs is increasing in one region (Tallinn: from 
(186) 
(186) See Figures INF-2 (part i) and INF-2 (part ii) in the 2006 statistical bulletin.
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41 % of a sample of 964 in 2001 to 54 % of 350 in 2005) 
and exceptionally high in another (Kohtla-Järve: 90 % out 
of 100). In Latvia, two time series of seroprevalence data 
among IDUs show a continued increase until 2002/03 
while a third series suggests a decrease since the peak in 
2001. In Lithuania, data for 2003 suggest an increase in 
HIV among tested IDUs in drug treatment, needle exchanges 
schemes and hospitals, from between 1.0 % and 1.7 % 
during 1997–2002 to 2.4 % (27/1 112) in 2003.
In the countries that have historically had high rates of HIV 
infection among IDUs (Spain, France, Italy, Poland and 
Portugal) there are new signs of continuing transmission at 
national level or in specific regions or among specific subgroups 
of IDUs (187). In these countries, it is important to note that the 
high background prevalence, resulting from the large-scale 
epidemics that occurred in the 1980s and 1990s, increases the 
likelihood that high-risk behaviour will lead to infection.
In Spain and Italy, national data from case reporting are 
not available. Data from routine diagnostic tests are difficult 
to interpret as they may be affected by different selection 
biases; however, they are a cause for concern in these 
countries. In Spain, HIV prevalence among young IDUs 
(under 25) tested in drug treatment was stable until 2002, 
at over 12 %, and among new IDUs (defined as injecting 
for less than two years) increased from 15 % to 21 % in 
2000–01, suggesting a high incidence up to 2002. In Italy, 
trends in prevalence among IDUs differ strongly between 
regions, and some regions still show pronounced and recent 
increases (Bolzano, Liguria, Molise, Toscana and Umbria).
In Poland, local studies suggest that HIV spread has 
continued at least until recently, based on high prevalence 
rates among young IDUs (15 % in 2002 in one region, 
4–11 % in two other regions in 2004). In the 2002 study, 
four cases (9 %) of HIV were reported among the 45 new 
(187) 
(187) See Figure INF-5 (part ii) and (part vi) in the 2006 statistical bulletin.
Figure 10: HIV prevalence in tested injecting drug users, 2003–04
NB:   Figures in brackets are local data. Colour indicates midpoint of national data or, if not available, of local data.
   Data for Italy and Portugal include non-injectors and are likely to underestimate prevalence in injectors.
   * Data in part or totally before 2003 (Spain 2002–03; France 2002–03; Latvia 2002–03; Netherlands 2002) and from 2005 for Estonia.
Sources:  Reitox national focal points. For primary sources, study details and data before 2003 or after 2004, see Table INF-8 in the 2006 statistical bulletin.
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injectors in the sample; however, in the 2004 study no cases 
were found among the 20 new injectors in the sample.
Finally, in some countries that have never experienced large-
scale epidemics among IDUs, some recent prevalence data 
suggest that vigilance is warranted. This would seem to be 
the case in Luxembourg, Austria and the United Kingdom, 
although the increases remain limited and are not confirmed 
by case reporting data.
Low HIV prevalence countries
HIV prevalence among tested IDUs continues to vary widely 
between countries in the EU (Figure 10). In a number 
of countries HIV prevalence among IDUs has recently 
increased or has been high for many years. In contrast, in 
several countries, HIV prevalence among IDUs remained 
very low during 2003–04: HIV prevalence was less than 
or around 1 % in the Czech Republic, Greece, Hungary, 
Malta, Slovenia (based on national samples), and in 
Slovakia, Bulgaria, Romania, Turkey and Norway (based 
on subnational samples). In some of these countries (e.g. 
Hungary), both HIV prevalence and hepatitis C virus (HCV) 
prevalence are among the lowest in Europe, suggesting 
low levels of injecting (see ‘Hepatitis B and C’), although 
in some countries (e.g. Romania) there is evidence that the 
prevalence of hepatitis C is increasing.
Sex differences in HIV prevalence among tested IDUs
Available seroprevalence data for 2003–04 reveal 
differences between male and female tested IDUs (188). 
Combined data from Belgium, Estonia (2005), Spain 
(2002), France, Italy, Luxembourg, Austria, Poland and 
Portugal resulted in a total sample of 124 337 males and 
20 640 females, tested mostly in drug treatment centres 
or other drug service provision sites. Overall prevalence 
was 13.6 % among males and 21.5 % among females. 
Differences between countries are marked, with female 
to male ratios being highest in Estonia, Spain, Italy, 
Luxembourg and Portugal, while Belgium shows the opposite 
trend, with prevalence being higher among males.
AIDS incidence and availability of HAART
As highly active antiretroviral treatment (HAART), available 
since 1996, effectively stops progression of HIV infection to 
AIDS, AIDS incidence data have become less useful as an 
indicator for HIV transmission. However, they still show the 
overall burden of symptomatic disease and in addition form 
an important indicator of the introduction and coverage of 
HAART among IDUs.
WHO estimates that coverage of HAART among patients in 
need of treatment was high in western European countries 
(over 70 %) in 2003, but more restricted in most eastern 
European countries, including Estonia, Lithuania and 
Latvia (189). More recent data on the coverage of HAART 
suggest that the situation has markedly improved, with all 
EU and candidate countries now achieving at least 75 % 
coverage. Specific data regarding availability of HAART 
among IDUs are not available, however, and it remains to 
be seen whether improved coverage will be reflected in a 
reduction in the incidence of AIDS among IDUs in Estonia 
and Latvia.
In all four countries in western Europe most affected by 
AIDS, i.e. Spain, France, Italy and Portugal, the incidence 
has declined, since about 1996 in the case of the first three 
countries, but only since 1999 in Portugal. Portugal is still the 
country with the highest incidence of IDU-related AIDS, with 
31 cases per million population in 2004. However, in Latvia 
the incidence is similar: 30 cases per million.
EuroHIV data up to 2004 (corrected for reporting delay) 
suggest that the incidence of IDU-related AIDS is increasing 
in both Estonia and Latvia (190).
Hepatitis B and C
Hepatitis C
The prevalence of antibodies against hepatitis C virus (HCV) 
among IDUs is, in general, extremely high, although there is 
wide variation both within and between countries. Prevalence 
rates of over 60 % among various IDU samples tested in 
2003–04 are reported from Belgium, Denmark, Germany, 
Greece, Spain, Ireland, Italy, Poland, Portugal, the United 
Kingdom, Romania and Norway, while prevalence rates less 
than 40 % have been found in samples from Belgium, the 
Czech Republic, Greece, Cyprus, Hungary, Malta, Austria, 
Slovenia, Finland and the United Kingdom (191).
HCV antibody prevalence data among young IDUs (aged 
under 25) are available from 14 countries, although in 
some cases sample sizes are small. There is wide variation 
in results, with countries reporting both high and low figures 
from different samples. The highest prevalence rates among 
young IDUs in 2003–04 (over 40 %) were found in samples 
from Belgium, Greece, Austria, Poland, Portugal, Slovakia 
and the United Kingdom, and the lowest prevalence (under 
20 %) in samples from Belgium, Greece, Cyprus, Hungary, 
Malta, Austria, Slovenia, Finland, the United Kingdom 
(188) (189) (190) (191) 
(188) See Figure INF-3 (part v) in the 2006 statistical bulletin.
(189) See Figure INF-14 (part iii) and (part iv) in the 2006 statistical bulletin.
(190) See Figure INF-1 (part i) in the 2006 statistical bulletin.
(191) See Figure INF-6 (part i) in the 2006 statistical bulletin.
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and Turkey. Considering only studies of young IDUs with 
national coverage, the highest prevalence rates (over 
60 %) are found in Portugal and the lowest (under 40 %) in 
Cyprus, Hungary, Malta, Austria and Slovenia. Although the 
sampling procedures used may result in bias towards a more 
chronic group, the high prevalence of HCV antibodies found 
in a national sample in Portugal (67 % among 108 IDUs 
under 25 years) is still worrying and may be indicative of 
continuing high-risk behaviour among young IDUs (see also 
‘Recent trends in newly reported HIV cases’, p. 75).
Data on HCV antibody prevalence among new injectors 
(injecting for less than two years) are scarce and suffer from 
small sample size, but they may provide a better proxy 
indicator of very recent incidence rates than data on young 
injectors. What information is available for 2003–04 shows 
that the highest prevalence rate among new injectors (over 
40 %) was found in samples from Greece, Poland, the United 
Kingdom and Turkey and the lowest prevalence (under 
20 %) in samples from Belgium, the Czech Republic, Greece, 
Cyprus and Slovenia. Low prevalence rates have been found 
in small but national samples of new injectors in Cyprus (only 
two of 23 injectors tested positive for HCV antibodies, a rate 
of 9 %), and Slovenia (two out of 32 tested positive, or 6 %).
Hepatitis B
The prevalence of hepatitis B virus (HBV) markers also 
varies greatly both within and between countries. The most 
complete data are for anti-HBc, which indicates a history 
of infection. In 2003–04, prevalence rates of over 60 % 
among IDU samples were reported from Italy and Poland, 
while samples with prevalence rates of less than 20 % were 
recorded in Belgium, Ireland, Cyprus, Austria, Portugal, 
Slovenia, Slovakia and the United Kingdom. Hepatitis 
B notification data for the period 1992–2004, for those 
countries from which data are available, show a very diverse 
picture (192). In the Nordic region, the great majority of 
notified acute cases of hepatitis B occur among IDUs, and 
hepatitis B outbreaks have coincided with increases in drug 
injecting in several countries. For example, the data for 
Norway suggest a strongly increasing incidence of hepatitis 
B infections among IDUs between 1992 and 1998 with a 
decline thereafter. In Finland, hepatitis B notifications among 
IDUs have fallen steeply in recent years, possibly as a result 
of vaccination programmes and a comprehensive needle and 
syringe exchange system.
Preventing infectious diseases
Effective responses
A number of public health interventions have been shown 
to be useful in reducing the spread of infectious diseases 
among drug users and there is a growing consensus that a 
comprehensive approach to service provision in this area 
is most likely to be successful. Historically, the debate has 
largely focused on the prevention of HIV infection among 
drug injectors, but the need for effective measures to inhibit 
the spread of hepatitis has increasingly become recognised, 
as has the need to prevent the spread of infectious diseases 
among non-injecting drug users.
It must be noted that evidence on effectiveness is strongest 
for the prevention of HIV infection among drug injectors. A 
robust body of available evidence shows that interventions 
can be considered effective and that access to treatment of 
all types provides protection (Farrell et al., 2005; WHO, 
2005). Since the mid-1990s, the European response has 
been characterised by an increasing provision of drug 
dependence treatment (see Chapter 2), and overall this 
appears to be one of the elements that have contributed to 
the relatively encouraging picture now seen in Europe in 
terms of epidemic spread of HIV among injectors.
Treatment is only one part of a comprehensive approach 
to HIV prevention. Other elements include a range of 
information, education and communication techniques, 
voluntary infectious disease counselling and testing, 
vaccination and the distribution of sterile injecting equipment 
and other prophylactics. These measures, as well as the 
provision of medical treatment services at low-threshold 
agencies, or even sometimes at street level, can help to 
establish or improve communication with active drug users 
and their sexual partners regarding the risk and prevention of 
the health consequences of drug use.
A general commitment to a comprehensive approach 
does not mean that all these service elements are equally 
developed or supported at national level. However, some 
consensus appears to be emerging. In a survey among 
NFPs, three out of four respondents identified needle and 
syringe programmes combined with counselling and advice 
as a priority in the national policy that addresses the spread 
of infectious disease among drug injectors (Figure 11). 
(192) 
(192) See Figure INF-12 (part i) in the 2006 statistical bulletin.
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That so many countries now explicitly recognise the role 
of providing clean injecting material as part of their HIV 
prevention strategy illustrates how this form of provision 
has become mainstream in most of Europe and is no longer 
regarded as a controversial issue in most countries. That is 
not to say that there is uniform agreement on the benefits of 
this kind of provision. Greece and Sweden, for example, 
did not rate it as a policy priority, although overall a 
relatively homogeneous picture emerges across the EU in 
terms of the implementation of interventions in this area (193), 
with all countries except Cyprus reporting the existence 
of programmes for the exchange or distribution of sterile 
needles and syringes (194).
Types of needle and syringe programmes 
in European countries
Although most European countries now distribute sterile 
injecting equipment, the nature and range of provision vary 
between countries. The most common model is to provide 
the service in a fixed location, usually a specialised drugs 
service, but often this type of provision is complemented 
by mobile services that attempt to reach out to drug users 
in community settings. Syringe exchange or vending 
machines complement the available NSP services in eight 
countries (195), although provision appears to be restricted to 
a handful of sites, with only Germany and France reporting 
substantial activities (around 200 and 250 machines 
respectively). Spain is the only EU country where needle and 
syringe exchange is regularly available in a prison setting, 
with provision available in 27 prisons in 2003. The only 
other EU country reporting activity in this area is Germany, 
where provision is limited to one prison.
Pharmacy-based exchange schemes also help to extend the 
geographical coverage of the provision and, in addition, 
the sale of clean syringes in pharmacies may increase 
their availability. The sale of syringes without prescription 
is permitted in all EU countries except Sweden, although 
some pharmacists are unwilling to do so and some will even 
actively discourage drug users from patronising their premises. 
(193) (194) (195) 
(193) See Figure NSP-3 in the 2006 statistical bulletin.
(194) See the 2005 annual report for a brief summary of the evidence on effectiveness of needle and syringe programmes (p. 68).
(195) See Table NSP-2 in the 2006 statistical bulletin.
Figure 11: Priority for and extent of use of selected measures to prevent infectious diseases in drug users, according to national expert opinion: 
summary for responding countries
NB:   Priority ratings from 23 EU countries plus Bulgaria and Norway. Countries not supplying these ratings were Ireland, Cyprus, Lithuania and the Netherlands.
   Ratings on the ‘extent of use’ were provided by experts from all 25 EU countries plus Bulgaria and Norway. The French and Flemish Communities in Belgium provided 
separate ratings, bringing the total number of replies to 28.
Sources:  National focal points expert survey, SQ 23 (2004) question 5.
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Formally organised pharmacy syringe exchange or distribution 
networks exist in nine European countries (Belgium, Denmark, 
Germany, Spain, France, the Netherlands, Portugal, Slovenia 
and the United Kingdom), although participation in the 
schemes varies considerably, from nearly half of pharmacies 
(45 %) in Portugal to less than 1 % in Belgium. In Northern 
Ireland, needle and syringe exchange is currently organised 
exclusively through pharmacies.
The purchase of syringes through pharmacies may be a 
major source of contact with the health service for some 
injectors, and the potential to exploit this contact point as a 
conduit to other services clearly exists. Work to motivate and 
support pharmacists to develop the services they offer to drug 
users could form an important part of extending the role of 
pharmacies, but to date only France, Portugal and the United 
Kingdom appear to be making significant investments in this 
direction.
Mortality and drug-related deaths
Mortality among problem drug users
Most information on mortality among problem drug users 
in Europe refers to opioid users. Mortality related to other 
forms of drug use is less well known but remains an important 
public health issue.
A collaborative study that started within an EMCDDA 
project examined mortality among opioid users recruited in 
treatment in eight European locations (196). The study found a 
very high mortality among opioid users compared with their 
peers: 6–20 times higher among males and 10–50 times 
higher among females. It was estimated that in six of the 
locations (Amsterdam, Barcelona, Dublin, London, Rome 
and Vienna) 10–23 % of the overall mortality among adults 
aged 15–49 years could be attributed to opioid use, mainly 
overdoses, AIDS and external causes (accidents, suicides). 
Roughly one third of these drug-related deaths were due to 
overdoses, although this proportion was higher in cities with 
a low prevalence of HIV infection among drug injectors, and 
is likely to increase once highly active antiretroviral treatment 
(HAART) becomes more widely available.
A mortality cohort study carried out in the Czech Republic 
found that the mortality of stimulant users was 4–6 times 
higher (standardised mortality ratio — SMR) than that of 
the general population, while that of opioid users was 
9–12 times higher. A French cohort study that followed 
individuals arrested for heroin, cocaine or crack use 
found that male mortality was five times higher and female 
mortality 9.5 times higher than in the general population, 
but with a decreasing trend.
As opioid users age, mortality resulting from chronic 
conditions (cirrhosis, cancer, respiratory diseases, 
endocarditis, AIDS) adds to mortality due to external causes 
other than overdoses, such as suicide and violence (Dutch 
national reports, 2004 and 2005, from the Amsterdam 
municipal health service). The living conditions of drug 
(196) 
(196) Amsterdam, Barcelona, Dublin, Denmark, Lisbon, London, Rome and Vienna. Estimates of population mortality did not include Lisbon and Denmark. 
See EMCDDA (2002b).
Syringe coverage in Europe: is it suffi cient?
Although nearly all Member States report some availability 
of needle and syringe programmes (NSPs), the impact of this 
kind of intervention depends on the level of provision being 
adequate to meet the needs of IDUs.
Recent estimates of the number of injecting drug users and of 
the number of syringes distributed through NSPs are available 
for nine European countries. From these data, it is possible 
to make a crude estimation of the annual number of syringes 
available per injector (1). Based on the most recent data 
available, coverage rates of NSPs vary considerably, with 
the number of syringes distributed per estimated IDU per year 
varying from 2–3 in Greece, through 60–90 in the Czech 
Republic, Latvia, Austria and Portugal, to approximately 110 in 
Finland, 210 in Malta and more than 250 in Luxembourg 
and Norway. In addition, syringes are also available from 
pharmacies, and data from the Czech Republic and Finland 
allow overall syringe availability to be estimated. Combining 
distribution and sales data suggests that, in a year, drug 
injectors obtain on average 125 syringes in the Czech Republic 
and 140 syringes in Finland.
Many factors are known to infl uence injecting frequency 
among those using drugs, including patterns of use, level 
of dependency and type of drug used. A recent study 
exploring the relationship between HIV prevalence and the 
coverage of syringe distribution suggested that behavioural 
factors, e.g. injecting frequency and personal reuse of 
syringes, strongly infl uence the level of syringe distribution 
required to achieve a substantial decrease in HIV prevalence 
(Vickerman et al., 2006).
The measurement of syringe coverage is an important 
component of understanding the likely effects of syringe 
distribution in disease prevention and for assessing unmet 
needs. However, it is important to take account of the 
availability of syringes through pharmacies sales (prices, 
density of pharmacy network) as well as drug injectors’ 
behavioural patterns and environmental factors in interpreting 
these data. This issue is further discussed in the 2006 
statistical bulletin.
(1) See the 2006 statistical bulletin for technical notes.
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users (for example, homelessness, mental illness, violence, 
poor nutrition) may also contribute substantially to the high 
mortality in this group.
In addition, AIDS related to intravenous drug use accounted 
for 1 528 deaths in 2002 (197), although this is probably 
an underestimate. Other causes of drug-related deaths, 
such as illness (e.g. hepatitis), violence and accidents, are 
more difficult to assess, but it is likely that they account for 
an important number of deaths. It has been estimated that 
10–20 % of deaths among young adults in European cities 
can be attributed to opioid use (see above). To this should be 
added mortality related to other forms of drug use, although 
this is very difficult to quantify.
Drug-related deaths
Drug-related death is a complex concept. In some reports 
it refers only to deaths caused directly by the action of 
psychoactive substances, while in other cases it includes also 
deaths in which drug use played an indirect or circumstantial 
role (traffic accidents, violence, infectious diseases). A recent 
report that analysed the types of harm caused by illegal 
drug use in the United Kingdom estimated that drug-related 
death was the main harm related to drug use (MacDonald 
et al., 2005).
In this section, and in the EMCDDA protocol, the term ‘drug-
related deaths’ refers to those deaths caused directly by the 
consumption of one or more drugs and, generally, occurring 
shortly after the consumption of the substance(s). Other 
terms used to describe such deaths include ‘overdoses’, 
‘poisonings’, ‘drug-induced deaths’ or ‘acute drug 
deaths’ (198).
Between 1990 and 2003, from 6 500 to over 9 000 deaths 
were reported each year by the EU countries, adding up to 
more than 113 000 deaths during this period. These figures 
can be considered as a minimum estimate owing to probable 
under-reporting in many countries (199).
Population mortality rates due to drug-related death varied 
widely between European countries, ranging from 0.2 to 
over 50 deaths per million habitants (average 13). In most 
countries the figure lies in the range of 7–30 deaths per 
million inhabitants, with rates of over 25 being found in 
Denmark, Estonia, Luxembourg, Finland, the United Kingdom 
and Norway. Among males aged 15–39 years, mortality 
rates are typically three times higher (averaging 40 deaths 
per million), with seven countries presenting rates over 
80 deaths per million. Drug-related deaths accounted for 3 % 
of all deaths among Europeans aged 15–39 in 2003–04, 
and for more than 7 % in Denmark, Greece, Luxembourg, 
Malta, Austria, the United Kingdom and Norway. These 
figures should be considered minimum estimates, and it 
should also be taken into account that, despite improvements, 
there are still important differences in quality of reporting 
between countries, such that direct comparisons should be 
made with caution (200).
Opioid deaths
Opioids are present in most cases of ‘acute drug-related 
deaths’ due to illegal substances reported in the EU, 
although in many cases other substances are also identified 
during the toxicological examination, in particular alcohol, 
benzodiazepines and, in some countries, cocaine. In Europe 
most cases of opioid deaths are related to heroin, but other 
opioids play a role (see below) (201).
Opioid overdose is one of the leading causes of death 
among young people in Europe, particularly among males in 
urban areas. At present, overdose is also the main cause of 
death among opioid users in the EU as a whole, in particular 
in countries with a low prevalence of HIV among injectors 
(see ‘Mortality among problem drug users’, p. 80).
The majority of drug users who overdose are men (202), 
accounting for 65–100 % of cases, and in most countries the 
proportion ranges between 75 % and 90 %, with the highest 
proportion of females in the Czech Republic, Poland and 
Finland and the lowest in Greece, Italy and Cyprus. These 
findings must be interpreted in the context of differential rates 
of opioid use and injecting between men and women.
Most overdose victims are between 20 and 40 years old, 
with the mean age in most countries lying in the mid-30s (but 
ranging from 20 to 44 years). The mean age of overdose 
victims is lowest in Estonia, Slovenia, Bulgaria and Romania 
and highest in the Czech Republic, the Netherlands, Poland 
(197) (198) (199) (200) (201) (202)
(197) See EuroHIV (2005). The figure refers to the western and central areas of WHO Europe, which include some non-EU countries, and the total deaths for Estonia, 
Latvia and Lithuania (eastern area).
(198) This is the agreed common definition by the EMCDDA group of national experts. At present, most national case definitions are the same as the EMCDDA 
definition or very similar, although some countries still include cases due to psychoactive medicines or non-overdose deaths, generally as a limited proportion 
(see the 2006 statistical bulletin methodological note ’Drug-related deaths summary: definitions and methodological issues’. Section 1: EMCDDA definition 
and Section 2: National definitions and ’DRD standard protocol, version 3.0’).
(199) See Tables DRD-2 (part i), DRD-3, DRD-4 in the 2006 statistical bulletin.
(200) See Table DRD-1 (part iii) and (part iv) in the 2006 statistical bulletin.
(201) See Figure DRD-1 in the 2006 statistical bulletin.
(202) As most cases reported to the EMCDDA are opioid overdoses, general characteristics of acute drug-related deaths are used for description of opioid cases.
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and Finland. There are very few reported overdose deaths 
among people under the age of 15 years (17 cases out of a 
total number of deaths of 7 516, based on most recent data 
available for each country), although drug deaths in this age 
group could be under-reported. The EMCDDA figures include 
a few deaths among those over 65 years, with only seven 
countries reporting that more than 5 % of cases fall into this 
age group (203).
In several new Member States and candidate countries the 
mean age at death is comparatively low (Estonia, Cyprus, 
Latvia, Slovakia, Bulgaria and Romania), and there is a 
high proportion of overdose cases younger than 25 years, 
which may signal a younger heroin-using population in 
these countries. The high mean age in the Czech Republic is 
related to the inclusion of many deaths due to psychoactive 
medicaments (Figure 12).
In many Member States, the age of overdose victims is 
increasing, suggesting a decrease in initiation to heroin 
use among young people. This trend is common in EU-15 
Member States and has been observed since the early 
1990s, although in Sweden and the United Kingdom it is less 
marked. In new Member States the trend is less clear and a 
decrease in mean age is even observed in many cases (204).
Methadone deaths
Several countries reported the presence of methadone 
in a substantial proportion of drug-related deaths in their 
2005 Reitox reports. The terminology used varies between 
countries, and in some cases it is difficult to determine what 
role methadone played in the death.
Denmark reported that methadone was the cause of 
poisoning (alone or in combination) in 44 % of deaths 
(95 out of 214 in 2004), a similar proportion to 2003, 
but with a clear increase from 1997; Germany reported 
that 345 cases were attributed to ‘substitution substances’ 
(46 alone and 299 with other narcotics in 2004) with 
(203) (204)
(203) See Table DRD-1 in the 2006 statistical bulletin.
(204) See Figures DRD-3 and DRD-4 in the 2006 statistical bulletin.
Figure 12: Proportion of acute drug-related deaths occurring under the age of 25 years in 2002
NB:   ONS, Office of national statistics; DSD, drug strategy definition.
   2002 was taken as reference as it is the year for which information is available for most countries.
Sources:  Reitox national reports (2005), taken from national mortality registries or special registries (forensic or police). Based on ‘national definitions’ as presented in methodological 
notes on drug-related deaths in the 2006 statistical bulletin.
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a clear decrease since 2002; and the United Kingdom 
reported 216 cases with ‘mention’ of methadone (England 
and Wales, in 2003), also with a clear decrease from 
2002. Spain reported that there were few overdose cases 
involving methadone in isolation (2 %), but that it was 
frequently present in combination in opioid deaths (42 %) 
and cocaine deaths (20 %). Other countries did not report 
methadone deaths or the numbers reported were very 
small. It is unclear what factors lie behind these differences, 
and whether there is under-reporting of cases in some 
countries (205).
Although research shows that substitution treatment 
reduces the risk of fatal overdose, it is important to monitor 
the number of deaths related to methadone and the 
circumstances surrounding the death (the source of the 
substance, whether it was consumed in combination with 
other substances, the point in the treatment process at which 
intoxication occurred) as part of the quality assurance 
monitoring for substitution programmes.
Buprenorphine and fentanyl deaths
Deaths due to buprenorphine poisoning appear to be 
rare, a fact that is attributed to the agonist–antagonist 
pharmacological characteristics of this drug. However, some 
deaths have been reported by European countries.
In the 2005 national reports, only France and Finland 
recorded deaths related to this substance. In Finland, 
buprenorphine was found in 73 drug-related deaths in 
2004, the same number as in 2003, and was generally 
combined with benzodiazepines, sedatives or alcohol. These 
high figures parallel increases in buprenorphine treatment 
in Finland, although the numbers treated are much lower 
than the estimated 70 000 to 85 000 people receiving 
buprenorphine in France. It is therefore interesting that in 
France only four cases of buprenorphine overdose were 
reported in 2004 (compared with eight cases in 2003). Even 
taking into account a possible under-reporting of poisonings 
in France, the scale of the differences is striking. In addition 
to France and Finland, three other countries reported 
cases (only two or three in each case) of death related to 
buprenorphine, but without evidence that the substance was 
the main causal agent.
In previous years deaths due to fentanyl have been reported 
in the countries surrounding the Baltic Sea, but no such 
reports were included in the 2005 national reports.
Trends in acute drug-related deaths
National trends in drug-related deaths can provide some 
insight into developments in patterns of problematic drug 
use in each country such as heroin epidemics and high-risk 
behaviours (e.g. injection), as well as treatment provision 
and even differences in heroin availability. They can also, 
of course, reflect the success of medical emergency services 
policies in preventing fatal overdoses (206).
Data available from the EU reveal some general trends in 
drug-related deaths. Among the EU-15 Member States, a 
sharp increase was apparent during the 1980s and early 
1990s, possibly paralleling the expansion of heroin use 
and injecting. Drug deaths continued to increase between 
1990 and 2000, although less sharply (Figure 13). The total 
annual number of drug-related deaths in those Member States 
providing information (most Member States, old and new) 
increased by 14 %, from 8 054 in 1995 to 9 392 in 2000.
Since 2000, many EU countries have reported decreases 
in the numbers of drug-related deaths, possibly related 
to increases in treatment availability and harm reduction 
initiatives, although declines in the prevalence of drug use 
may also be important. At European level, drug deaths fell by 
6 % in 2001, 13 % in 2002 and by 7 % in 2003. Despite 
these improvements, there were still almost 7 000 reported 
drug-related deaths in 2003 (data from Belgium, Spain and 
Ireland are missing). However, among countries reporting 
data in 2004 (19), there was a small increase of 3 %. 
Although inferences about 2004 should be made with 
caution, 13 out of the 19 countries that reported information 
recorded an increase of some degree.
There is a marked discrepancy between trends in the old and 
new Member States in the number of deaths among people 
younger than 25 years. Among the EU-15 Member States 
there has been a steady decrease since 1996, suggesting 
a decrease in the number of young opioid injectors, while 
in new Member States a sharp increase was observed until 
2000–02, with an apparent decrease beginning only in 
2003 (207).
Gender differences are also observable. The number of 
deaths in males increased progressively from 1990 until 
2000, followed by a clear decrease (a 30 % decline by 
2003), whereas the number of reported deaths among 
females remained roughly stable between 1990 and 
2000, oscillating between 1 700 and 2 000 per year, 
and has fallen by only 15 % since then. This could be 
(205) (206) (207) 
(205) An ongoing EMCDDA field trial aims to improve the quality of information provided on substances involved in drug-related deaths, including substitution 
substances.
(206) See Figure DRD-7 in the 2006 statistical bulletin.
(207) See Figure DRD-5 in the 2006 statistical bulletin.
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due to a number of factors, including differential efficacy 
of interventions or differences in risk factors between the 
sexes (208).
In countries with a longer series of data, different patterns 
of drug-related deaths can be detected. In some countries 
drug-related deaths peaked during the early 1990s and 
subsequently decreased, for instance in Germany, where 
drug-related deaths peaked in 1991–92, Spain (1991), 
France (1994) and Italy (1991). In other countries, for 
instance Greece, Ireland, Portugal, Finland, Sweden and 
Norway, drug deaths peaked later, between 1998 and 
2001, and again subsequently declined. In other countries, 
the pattern was less clear or numbers were stable. Although 
interpretations should be made with caution, because of 
the relatively low numbers of drug-related deaths in some 
countries, these patterns could be related to the trends in 
heroin injection (209).
Deaths related to ecstasy and amphetamines
Deaths related to ecstasy started to be reported in Europe 
during the 1990s as the drug became popular. Ecstasy 
deaths cause considerable concern as they often occur 
unexpectedly among socially integrated young people.
Information on ecstasy deaths is limited, but data from 2005 
Reitox national reports suggest that deaths involving ecstasy 
remain relatively unusual compared with opioid deaths, 
although in some countries the number is not negligible. 
In Europe as a whole, there were references to 77 deaths, 
which should be considered as a minimum estimate (210). 
Cases were reported from Denmark (2), Germany (20), 
France (4), Hungary (3), and the United Kingdom (48 cases 
with ‘mentions’ — 33 in England and Wales), where 
probably reporting is better than in other countries. In Spain, 
ecstasy was present in 2.5 % of drug poisonings.
(208) (209) (210) 
(208) See Figure DRD-6 in the 2006 statistical bulletin.
(209) See Figure DRD-7 in the 2006 statistical bulletin.
(210) Depending on country, figures refer to 2003 or 2004, for ecstasy and cocaine.
Figure 13: Long-term trend in acute drug-related deaths, 1985–2004
(1)   Ten countries provided information for 2004 and six did not. Therefore, the figure for 2004 is provisional, based on a comparison of 2003 and 2004 data only for 
those countries providing data for both years.
NB:   New Member States and candidate countries are not included in this figure owing to the lack of retrospective data in most cases.
   See Table DRD-2 in the 2006 statistical bulletin for numbers of deaths in each country and notes on methodology.
Sources:  Reitox national reports (2005), taken from general mortality registries or special registries (forensic or police).
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The issue of the risk of ecstasy use has often been raised. 
Bearing in mind the margin of error in survey-based estimates 
of prevalence and the difficulties in reporting drug deaths, 
dividing the number of fatalities observed by the number 
of users per year (211) (people at potential risk) yields rates 
of 5–8 cases and 2–5 cases per 100 000 users in the two 
countries for which this calculation can be made.
Amphetamine deaths are also infrequently reported, although 
in the Czech Republic 16 deaths were attributed to pervitin 
(methamphetamine) in 2004, almost double the 2003 
figure, correlating with an increase in the estimated number 
of problem pervitin users and treatment demands. For GHB 
deaths see Chapter 4.
Deaths related to cocaine
There is increasing concern about the health risks of cocaine 
use, following increases in recreational use observed in some 
countries among young people, among people being treated 
for addiction and among marginalised populations.
Cocaine use is frequent among opioid users, and it is 
common to find cocaine in toxicological analyses of opioid 
overdoses, as well as other substances such as alcohol and 
benzodiazepines Cocaine is commonly consumed together 
with alcohol, a combination that may result in increased 
toxicity.
Current statistics available in Europe are limited, and 
variation in the criteria used to identify cocaine-related cases 
means that figures are not comparable; in addition, some 
cocaine-related deaths may go unrecognised or unreported, 
resulting in under-reporting. The data that do exist indicate 
that many deaths involving cocaine also involve opioids.
Among the countries supplying data, over 400 cocaine 
deaths were identified in the 2005 national reports; this 
is a minimum estimate. In most of these cases, cocaine 
seems to have played a causal role, although this is not 
always entirely clear from the reports. Nine countries did 
not explicitly mention the existence or absence of cocaine 
deaths. Cocaine accounted for 0–20 % of reported acute 
drug deaths, representing between 10 % and 20 % of 
such deaths in Germany, Spain, France, the Netherlands 
and the United Kingdom. Deaths in which cocaine played 
a causal role (alone or in combination) were reported by 
Germany (166), Spain (53), France (14), the Netherlands 
(20) and the United Kingdom (142 ‘mentions’ — 113 in 
England and Wales). Nine other countries reported from 
zero to two cases. In addition, cocaine is commonly found in 
toxicological analyses of opioid overdoses in some countries. 
From the limited data available, it is difficult to identify 
trends with certainty, but an increasing trend seems to exist 
in all countries with larger number of cases, i.e. Germany, 
Spain, France, the Netherlands and the United Kingdom, 
although in the Netherlands increases have halted in the 
last two years.
In addition, cocaine may be a contributor to deaths due 
to cardiovascular problems (arrhythmias, myocardial 
infarction, cerebral haemorrhages), particularly in users 
with predisposing conditions or risk factors (tobacco, 
hypertension, angiomas) or with increasing age. Many of 
these cases may go unnoticed at present because of a lack of 
awareness. Further research is needed in this area.
Reducing drug-related deaths
Effective responses
Reaching out to untreated populations of drug users and 
establishing links for communication is a precondition for risk 
education and management, and for mediating access to 
services, including treatment.
Research into the circumstances of overdoses has supported 
the development of interventions that target high-risk 
situations or high-risk individuals. Such measures may 
achieve an important reduction in the deaths attributable to 
the immediate effects of drug taking. The role of different 
interventions in reducing acute drug-related overdose deaths 
was summarised in a recent EMCDDA policy briefing 
(EMCDDA, 2004d).
As most overdose deaths in Europe involve heroin, increasing 
the proportion of heroin users in treatment can be viewed 
as an overdose prevention measure. A number of factors 
may be responsible for recent modest reversals in the trend 
in overdose deaths observed in some Member States. 
These include decreases in prevalence and injecting rates, 
increased prevention efforts, increased availability and 
uptake of, and retention in, treatment and possibly reductions 
in risk-taking behaviour.
Profile of responses
In most countries, expert opinion on the use of different 
intervention strategies to reduce drug overdose deaths 
considers opioid substitution treatment to be the most 
valuable approach (212). In Hungary and Sweden, although 
this type of treatment is available, it is not considered a 
means of reducing drug deaths. And in Estonia and Poland, 
the low level of substitution treatment provision means that 
(211) (212) 
(211) Last 12 months’ use in population surveys. 
(212) Results based on a survey conducted through 27 NFPs in 2004. The instrument can be downloaded at http://www.emcdda.europa.eu/?nnodeid=1333
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methadone substitution treatment is not currently considered a 
major response to reduce overdose deaths.
Information, education and communication (IEC)-oriented 
responses are further important measures in most European 
countries. The dissemination of risk awareness messages 
and overdose management instructions via specifically 
developed printed materials or other media (flyers, websites, 
mass media campaigns) is common or predominant in 
19 countries. However, seven countries (Estonia, France, 
Ireland, Latvia, Hungary, Malta, Finland) use such measures 
rarely, and one country (Sweden) not at all.
According to the NFPs, the approach of systematically 
integrating an individual risk assessment into counselling 
and treatment routines and organising group sessions on risk 
education and response for drug users is less common.
A broad category of activities can be defined as ‘prison pre-
release interventions’. These ranged from simple information 
dissemination, through counselling on overdose risks and 
prevention, to initiation or continuation of substitution 
treatment in prison. However, activities falling into this 
spectrum of responses were rarely used in 13 countries and 
not in use at all in another five (Latvia, Hungary, Poland, 
Romania and Sweden). In Spain, Italy and the United 
Kingdom, prison interventions are among the predominant 
approaches to a reduction in acute drug deaths.
Local conditions of risk related to public injecting have led to 
the opening of professionally supervised drug consumption 
facilities in four EU countries and Norway (213). Their target 
groups are highly marginalised and risk-prone street injectors 
(EMCDDA, 2004c).
(213)
(213) The EU countries are Germany, Spain, Luxembourg and the Netherlands.
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Drug addiction, drug dependence, drug abuse, harmful use, 
problem use: there are a variety of concepts associated with 
the EMCDDA problem drug use indicator, each carrying 
its own subtle distinctions in medical or social dimensions. 
The EMCDDA indicator of problem drug use (PDU) monitors 
‘injecting drug use or long-duration/regular use of heroin, 
cocaine and/or amphetamines’. Included in the definition, 
by convention, is the use of other opioids such as methadone.
This definition of PDU is a purely behavioural one based on 
drug consumption patterns and does not explicitly measure 
problems in any sense. Nonetheless, it is linked to the 
various concepts of addiction by the understanding that 
someone behaving in this way is very likely to fall within the 
more general concept of a ‘problem user’. It is important to 
note in this respect that the PDU indicator estimates only an 
important subgroup of those who can be thought of as having 
a drug problem of some form. Nevertheless, the approach 
does have value. As a behaviourally determined concept, its 
virtues are that:
• it has allowed monitoring to proceed without being tied to 
definitions of addiction, dependence, harm and problem 
itself;
• it is relatively easy to operationalise in research studies;
• it groups together different types of drugs and modes 
of administration as alternatives, without specifically 
differentiating between them.
Historically speaking, the EMCDDA monitoring indicator 
was a child of its time — during the 1980s, and to a large 
extent the 1990s, heroin use and injecting drug use were 
seen as key components of the drug problem that required 
estimation. Furthermore, these forms of drug use could not be 
measured convincingly by survey techniques. The addition of 
amphetamines made the definition appropriate for some of 
the Nordic countries where injecting amphetamine use was 
important; and, although cocaine was included, in practice 
it was rarely a significant component in any estimates. 
While the PDU indicator still gives us a useful window on 
an important element of the drug problem, it is increasingly 
apparent that it needs further development to meet the 
requirements of monitoring today’s more heterogeneous 
European drug situation. Increasingly, we are seeing a more 
complex picture with respect to chronic drug problems in 
Europe. To keep its relevance to a changing world of illicit 
drugs, the monitoring task has to move forward and meet 
the challenges of covering a broader spectrum of drugs, and 
covering their use in finer detail than it has to date.
The enlargement of the EU has embraced a greater variety 
of social behaviours, with illicit drug use no exception. 
Developments within the drug culture, the rise of synthetic 
drugs and illicitly used medicines, the shift towards cocaine 
and the general high prevalence of cannabis use all have to 
be acknowledged in the understanding of what constitutes 
the needs of those with problems associated with their use of 
drugs. It can be noted from earlier sections of this report that, 
although heroin users still clearly predominate in demands 
to the drug treatment services, the picture is changing with 
respect to those who are entering treatment for the first time, 
among whom reported cannabis and stimulant problems 
have been increasing (Figure 14).
This changing position must be seen against the background 
of greatly expanded treatment provision for those with 
opioid-related problems as well as increased reporting 
coverage of treatment services. Opioid substitution treatment 
in particular, locking people into long-term continuous care 
(note that this is not shown in these diagrams, which show 
only those entering treatment in the current year), emphasises 
the role of opioids in current treatment burden as compared 
with new treatment entrants. Nonetheless, in many countries 
it appears that those developing a drug problem today in 
Europe are likely to be, in terms of the substances they are 
using at least, more heterogeneous than has historically been 
the case.
The PDU indicator and counting hidden 
populations of drug users
The current PDU approach has proved extremely valuable 
in getting better estimates of the important group of drug 
users who represent the major consumers of drug treatment 
services in Europe. This approach has served to stimulate the 
development of a range of methods and statistical procedures 
to estimate the full size of this largely hidden population. In 
Chapter 8
Improving the monitoring of problem consumption 
and multiple drug consumption
kg609922insideEN.indd   88 27/10/06   10:14:10
89
Chapter 8: Improving the monitoring of problem consumption and multiple drug consumption
all these approaches measurement is grounded in the idea 
that a percentage of problem drug users are ‘administratively 
visible’ as they are in contact with a range of treatment, 
legal and emergency, and social services, and from this 
visible minority the size of the population can be estimated 
if the percentage is known. These kinds of indirect statistical 
methods complement population survey work, which, for 
a range of methodological and practical reasons, is less 
suitable for estimating the prevalence of drug use that is of 
low prevalence, stigmatised and largely hidden.
In terms of the current implementation of the PDU indicator 
across the EU, countries have adapted the definition 
to cover the practicalities of their local situation and 
the position is therefore heterogeneous. Nine countries 
essentially follow the EMCDDA definition as it stands, 
11 countries estimate only the number of opioid (or 
heroin) users and a further four countries do not exclude 
problem cannabis users although cannabis users in general 
form only a very small part of their estimates (criteria for 
including cannabis users being quite strict in terms of 
counting only dependent or very intensive use).
The more widespread use of cocaine, crack cocaine 
and stimulants in general, along with the overlap of drug 
problems with problems associated with alcohol and 
prescribed medicines, implies that even within a consistent 
implementation of the indicator the estimates would now 
cover an increased variety of drug-taking repertoires than 
before, with the possibility of more varied consequences 
and problems. In addition to monitoring the overall extent 
of problem drug use, there is therefore a need to monitor 
separately the different behaviours that make up the PDU 
indicator, i.e. injecting and each drug type within the 
PDU definition. This may be particularly important in the 
light of evidence from some countries of increasing use of 
cocaine and the patterns of amphetamine use, as well as 
allowing detailed tracking of trends in opioid use. If all 
these behaviours are reported only in total, there is clearly 
a potential for masking important developments and a lost 
opportunity for a better understanding of trends.
Earlier in this report a separate estimate of heroin use 
and injecting in Europe was provided for the first time. In 
addition, we note the increase in treatment availability for 
opioid problems, with estimates of over half a million opioid 
substitution treatments in Europe. This suggests that the 
proportion of heroin users and injectors having or having 
had contact with treatment services may be quite large in 
many countries. The EMCDDA is currently exploring with 
its national technical groups what value can be added 
by bringing together information on treatment demand, 
treatment availability, and estimates of heroin use and 
injecting drug use.
Moving beyond the PDU indicator
A further step in developing our ability to understand better 
the European drug problem is to explore the extent to which 
intensive drug use can be incorporated into the monitoring 
exercise, beyond PDU monitoring. The extent to which 
intensive drug use, however it is defined, is associated with 
dependence and levels and types of problems requires 
further elaboration, and, for example, Kandel and Davis 
(1992) estimated that in the USA around one third of daily 
Figure 14: Distribution of ‘new’ and ‘all’ clients requesting treatment 
according to their primary drug
NB:   Based on data from the Czech Republic, Denmark, Germany, Greece, Italy, 
Cyprus, Hungary, Malta, the Netherlands, Slovenia, Slovakia, Finland, 
Sweden, the United Kingdom, Bulgaria, Romania and Turkey.
Sources:  Reitox national focal points.
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cannabis users could be considered to be dependent. The 
way forward in this area requires the formalising of the 
concept of frequent, intensive use of cannabis and other 
illicit drugs as a specific target for monitoring. Frequent or 
intensive use can be measured in survey data to complement 
its estimation through indirect statistical methods. Currently, 
survey data provide a useful window on different patterns 
of cannabis use, but these are largely restricted behavioural 
and frequency of use measures. Survey data are likely to be 
important if we are to develop robust estimates of the number 
of users of drugs such as cannabis who could be described 
as dependent or harmful users, at least by self-report.
This move to defining frequent, intensive use more formally 
for a range of drugs would also assist the development of 
research tools to assess levels of problems and dependence 
related to different levels and patterns of cannabis 
consumption. A number of European countries are working 
on developing methodological tools for measuring both 
intensive use and levels of dependence and problems, and 
the EMCDDA is promoting collaboration in this area of work.
A complication of identifying intensive use as an indicator 
of those who are likely to be most at risk of becoming 
dependent or experiencing problems is that the notion of 
what constitutes intensive use is to some extent drug specific. 
Although problem opioid use is strongly characterised by 
daily patterns of use, this is often not the case for stimulant 
drugs. With these drugs, binge consumption is often 
more common, use escalating for short periods and then 
decreasing, often with the users switching to other drugs or 
alcohol to alleviate the adverse consequences of abstaining. 
Both pharmacological and contextual factors may be 
important in influencing patterns of intensive drug use, but it 
is clear that behavioural measures of intensive use will need 
to be sensitive to different patterns of drug use associated 
with different types of drug.
The challenge of reporting polydrug use problems
For good practical and methodological reasons most 
reporting on drug use describes each substance separately. 
This provides the conceptual clarity necessary to facilitate 
reporting based on the behavioural measures available, 
but it ignores the fact that individual drug users will often 
have consumed or be consuming a range of both illicit and 
licit substances and these users may also be experiencing 
problems with more than one drug. They may substitute one 
drug type for another or may change their drug of choice 
over time or may use them complementarily. This kind of 
complexity is extremely challenging to a monitoring system 
even if analysis is restricted to simple behavioural measures 
of drug consumption in different time periods. If concepts 
of problematic and dependent use are included, these 
complexities increase further and very few robust data exist 
at a European level to permit informed analysis. Nonetheless, 
it is likely that some countries have a sizeable population of 
chronic problem drug users, who are difficult to classify by 
primary substance and who may be experiencing problems 
due to their use of both licit and illicit substances. Addressing 
this problem requires developing a better understanding of 
the patterns of polydrug use and applying this to improve 
national and European-level reporting.
Poly-substitution
Within the general concept of multiple drug use, several 
specific meanings of the term must be considered. At 
one extreme, there is the use of several substances in an 
intensive and chaotic way, simultaneously or consecutively, 
in many cases each drug substituting for another according 
to availability. For instance, this is the case with problem 
users who use different opioids, as well as pharmaceuticals, 
cocaine, amphetamines and alcohol.
This pattern of use seems to exist among some chronic users, 
possibly among marginalised groups, possibly among 
people with psychiatric conditions. In many recording 
systems in Europe, these cases will be attributed to opioids.
As such, these individuals will fall within the definition and 
monitoring of problem drug users. However, there remains 
a further question of whether this intensive, chaotic polydrug 
use is enough of an entity in itself — a drug non-specific 
addiction therefore requiring targeted epidemiological 
measurements and treatment, support or harm reduction in 
a particularly difficult situation. Under these circumstances, 
any monitoring of the component parts of problem drug 
use would need to include polydrug use as one of these 
separately measured components.
Drug combinations
There is a second group of users who take several substances 
in a systematic way simultaneously, wanting the effects of the 
pharmacological combination, for instance speedballing — 
the simultaneous use of heroin and cocaine by injection.
A second drug with a functional or pharmacological 
rationale is not confined to simultaneous use but may also be 
used consecutively, as a replacement or as a complementary 
drug. For example, benzodiazepine can be used to reduce 
withdrawal symptoms when opioids are not available. In 
other cases, a second drug may be used for its compensating 
pharmacological effect: this is the case when the narcotic 
effect of opioids is modified by using cocaine, or when the 
anxiety effect of cocaine or amphetamines is placated by the 
use of opioids or other depressants.
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Increased risks through polydrug use
The potentiating effect of one drug on another is sometimes 
considerable, and here the licit drugs and medicines — such 
as alcohol, nicotine and antidepressants — have to be 
considered in conjunction with the controlled psychoactive 
substances. The risk level will depend on the dosage level 
of both substances. Concerns exist about a number of 
pharmacological pairings: alcohol and cocaine increase 
cardiovascular toxicity; alcohol or depressant drugs, when 
taken with opioids, lead to an increased risk of overdose; 
and opioids or cocaine taken with ecstasy or amphetamines 
also result in additional acute toxicity.
Limits of the data available on polydrug use
The absence of available data limits reporting on 
many aspects of polydrug use. Data are available from 
toxicological reports from drug overdoses and self-reports 
from those attending treatment services. While these sources 
allow some insights into polydrug use, the information 
available is often limited and the representativeness of the 
data needs to be considered.
Survey results do show considerable use of more than two 
drugs by individuals in the same time period. However, 
survey data often poorly report on some forms of drug use 
and, even where there are data, work needs to be done to 
develop comparable reporting standards. An example of 
the extent of polydrug use data available from population 
surveys can be seen in a recent technical report of the 
EMCDDA (2005b). Taking the example of data from Spain, 
Figure 15 shows that use of one drug results in an increased 
tendency, compared to that of the general population, to 
have used another and that this varies according to the drug 
considered. For example, among heroin users, the use of 
cocaine is relatively common, but use of other drugs is less 
apparent for cocaine users.
Developing an operational definition of polydrug use: 
a question of timing?
Consideration needs to be given to what time periods are 
selected for assessing and reporting on polydrug use. Lifetime 
prevalence rates are in general not likely to be very useful or 
relevant to public health issues compared with measures of 
more recent use.
Figure 15: Use of drugs in the last year by different user groups in the general population aged 15–34
NB:   Data for Spain 1999. See Figure GPS-34 in the 2006 statistical bulletin for more information.
Source:  EMCDDA (2005b).
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Polydrug use could be usefully defined operationally as the 
frequent use of more than one substance over a minimum 
specified time period, for example one month. This does not 
distinguish the various types of use described above, but 
gives an overall picture of what might be a high-risk group. 
The exception to discarding lifetime use in characterising 
polydrug behaviour is when dealing with the very young — 
pupils or students — in which case lifetime multiple use may 
more strongly reflect current use. The evidence, for example 
from ESPAD surveys, suggests that the more deviant/low-
prevalence patterns of drug use among students (ecstasy, 
amphetamine, hallucinogens, cocaine, heroin) cluster among 
a few individuals.
Improving monitoring of the drug 
problem in Europe and improving 
the sensitivity to polydrug consumption
Achieving a better understanding of the nature and scale 
of the European drug problem is one of the key tasks of 
the EMCDDA. Drug use is, however, a complicated issue 
encompassing a range of behaviours that are variably 
associated with several important public health and social 
problems. Drug users may be experiencing or be at risk of 
problems. Patterns of drug use vary from the experiential, 
episodic and occasional to the regular, intensive and 
uncontrolled. Drug users may be classified under clinical 
definitions of having a drug problem or being dependent, 
and in research terms both these categories can be 
elaborated into continuums. To add to this complexity, 
drug users often consume multiple substances and change 
their consumption patterns over time. No single reporting 
instrument can adequately encompass this complexity. 
In practice, the multi-indicator approach adopted by the 
EMCDDA is intended to illuminate these different aspects of 
the drug phenomenon.
The PDU indicator, by focusing on a particular set of 
behaviours, provides a valuable window on some of the 
most detrimental and costly forms of drug use. As such, it 
is an important component in understanding the European 
drug problem as a whole. However, a clear need now exists 
to complement the PDU indicator’s overall estimates with 
substance-specific component estimates in order to address 
Europe’s increasingly heterogeneous drug problem.
Given that many of the data sources available are based 
on behavioural reports of drug consumption, the concept 
of frequent or intensive use needs to be developed on this 
basis. This will widen the perspective for monitoring drug 
problems beyond that currently found in the PDU indicator. 
Locating the PDU information alongside this broader 
information set will also represent a step forward in the 
EMCDDA’s efforts to improve its overall understanding 
of both the scale and the nature of drug problems in 
Europe. In parallel, work needs to advance on developing 
reporting standards that enable patterns of polydrug use 
to be better described at the European level. The first steps 
in this direction include developing a more sophisticated 
conceptual framework for looking at different types of 
multiple drug consumption — including the adoption 
of appropriate temporal frameworks — and identifying 
appropriate data sources.
kg609922insideEN.indd   92 27/10/06   10:14:12
93
kg609922insideEN.indd   93 27/10/06   10:14:13
94
kg609922insideEN.indd   94 27/10/06   10:14:13
95
ACPO Drugs Committee (2002), A review of drugs policy and 
proposals for the future, The Association of Chief Police Officers, 
London.
Bossong, M.G., Van Dijk, J.P. and Niesink, R.J.M. (2005), 
‘Methylone and mCPP, two new drugs of abuse?’, Addiction 
biology 10(4), pp. 321–23.
Burrell, K., Jones, L., Sumnall, H. et al. (2005), Tiered approach 
to drug prevention and treatment among young people, National 
Collaborating Centre for Drug Prevention, Liverpool.
Chen, C.-Y., O’Brien, M.S. and Anthony, J.C. (2005), 
‘Who becomes cannabis dependent soon after onset of use? 
Epidemiological evidence from the United States: 2000–2001’, 
Drug and alcohol dependence 79, pp. 11–22.
Chivite-Matthews, N., Richardson, A., O’Shea, J. et al. (2005), Drug 
misuse declared: findings from the 2003/04 British Crime Survey, 
Home Office Statistical Bulletin 04/05, Home Office, London 
(http://www.homeoffice.gov.uk/rds/pdfs05/hosb0405.pdf).
CND (2005), World drug situation with regard to drug trafficking: 
report of the secretariat, Commission on Narcotic Drugs, United 
Nations Economic and Social Council, Vienna.
CND (2006), World drug situation with regard to drug trafficking: 
report of the secretariat, Commission on Narcotic Drugs, United 
Nations Economic and Social Council, Vienna.
EMCDDA (2002a), Prosecution of drug users in Europe — varying 
pathways to similar objectives, European Monitoring Centre for 
Drugs and Drug Addiction, Lisbon.
EMCDDA (2002b), ‘Mortality of drug users in the EU: coordination 
of implementation of new cohort studies, follow-up and analysis of 
existing cohorts and development of new methods and outputs’, 
Project CT.00.EP.13, European Monitoring Centre for Drugs and 
Drug Addiction, Lisbon.
EMCDDA (2004a), 2004 annual report on the drugs problem in 
the European Union and Norway, European Monitoring Centre for 
Drugs and Drug Addiction, Lisbon.
EMCDDA (2004b), An overview of cannabis potency in Europe, 
Insights no. 6, European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon.
EMCDDA (2004c), European report on drug consumption rooms, 
European Monitoring Centre for Drugs and Drug Addiction, 
Lisbon.
EMCDDA (2004d), ‘Overdose: a major cause of avoidable 
death among young people’, Drugs in focus No 13, European 
Monitoring Centre for Drugs and Drug Addiction, Lisbon.
EMCDDA (2005a), Annual report 2005: the state of the drugs 
problem in Europe, European Monitoring Centre for Drugs and 
Drug Addiction, Lisbon.
EMCDDA (2005b),’Assistance to EMCDDA for the analysis of 
drug profiles from EMCDDA databank on surveys of drug use’, 
final report, project CT.03.P1.200, European Monitoring Centre 
for Drugs and Drug Addiction, Lisbon.
EMCDDA (2005c), ‘Data collection to develop an inventory of 
social and health policies, measures and actions concerning drug 
users in prison in the recently incorporated Member States to the 
EU’, final report, project CT.04.P2.329, European Monitoring 
Centre for Drugs and Drug Addiction, Lisbon.
EuroHIV (2005), HIV/AIDS surveillance in Europe: end-year report 
2004, Institut de veille sanitaire: Saint-Maurice. No 71.
Europol (2006), ‘Drugs 2006’ (communication to the EMCDDA of 
16 January 2006, file no. 158448), Europol, The Hague.
Farrell, M., Gowing, L., Marsden, J. et al. (2005), ‘Effectiveness 
of drug dependence treatment in HIV prevention’, International 
journal of drug policy 16S, pp. S67–75.
Haasen, C., Prinzleve, M., Gossop, M. et al. (2005), ‘Relationship 
between cocaine use and mental health problems in a sample of 
European cocaine powder and crack users’, World psychiatry 
4(3), pp. 173–6.
Hibell, B., Andersson, B., Bjarnasson, T. et al. (2004), The 
ESPAD report 2003: alcohol and other drug use among students 
in 35 European countries, The Swedish Council for Information 
on Alcohol and Other Drugs (CAN) and Council of Europe 
Pompidou Group.
Higgins, S.T., Sigmon, S.C., Wong, C.J. et al. (2003), 
‘Community reinforcement therapy for cocaine-dependent 
outpatients’, Archives of general psychiatry 60, pp. 1043–52.
INCB (2006a), Report of the International Narcotics Control Board 
for 2005, United Nations International Narcotics Control Board, 
New York.
INCB (2006b), Precursors and chemicals frequently used in the 
illicit manufacture of narcotic drugs and psychotropic substances, 
United Nations International Narcotics Control Board, New York.
Kandel, D. and Davis, M. (1992), ‘Progression to regular 
marijuana involvement: phenomenology and risk factors for near 
daily use’, in: Glantz, M. and Pickens, R. (eds), Vulnerability to 
drug abuse, pp. 211–53, American Psychological Association, 
Washington.
Kumpfer, K.L., Molgaard, V. and Spoth, R. (1996), 
‘The Strengthening Families Program for prevention of delinquency 
and drug use in special populations’, in: Peters, R. and 
References
kg609922insideEN.indd   95 27/10/06   10:14:13
96
Annual report 2006: the state of the drugs problem in Europe
McMahon, R. J. (eds) Childhood disorders, substance abuse, 
and delinquency: prevention and early intervention approaches, 
Sage Publications, Newbury Park, CA.
MacDonald, Z., Tinsley, L., Collingwood, J. et al. (2005), 
Measuring the harm from illegal drugs using the drug harm index, 
Home Office Online Report 24/05, Home Office, London 
(http://www.homeoffice.gov.uk/rds/pdfs05/rdsolr2405.pdf).
Naber, D. and Haasen, C. (2006), Das bundesdeutsche 
Modellprojekt zur heroingestützten Behandlung 
Opiatabhängiger — eine multizentrische, randomisierte, 
kontrollierte Therapiestudie, Zentrum für interdisziplinäre 
Suchtforschung der Universität Hamburg,Hamburg 
(http://www.heroinstudie.de/ZIS_H-Bericht_P1_DLR.pdf).
ONS (2006), Health statistics quarterly 29, Office for National 
Statistics, London.
Poling, J., Oliveto, A., Petry, N. et al. (2006), ‘Six-month trial of 
bupropion with contingency management for cocaine dependence 
in a methadone-maintained population’, Archives of general 
psychiatry 63, pp. 219–28.
Prinzleve, M., Haasen, C., Zurhold, H. et al. (2004), ‘Cocaine 
use in Europe — a multi-centre study: patterns of use in different 
groups’, European addiction research 10, pp.147–55.
Reitox national reports (2005) 
(http://www.emcdda.europa.eu/?nnodeid=435).
Roe, E. and Becker, J (2005), ‘Drug prevention with vulnerable 
young people: a review’, Drugs: education, prevention and policy, 
12(2), pp. 85–99.
Roozen, H.G., Boulogne, J.J., van Tulder, M.W. et al. (2004), 
‘A systematic review of the effectiveness of the community 
reinforcement approach in alcohol, cocaine and opioid addiction,’ 
Drug and alcohol dependence 74, pp. 1–13.
Schäfer, C. and Paoli, L. (2006), Drogenkonsum und 
Strafverfolgungspraxis, Duncker & Humblot, Berlin.
Schottenfeld, R.S., Chawarski, M.C., Pakes, J.R. et al. (2005), 
‘Methadone versus buprenorphine with contingency management 
or performance feedback for cocaine and opioid dependence’, 
American journal of psychiatry 162, pp. 340–9.
Shearer, J. and Gowing, L.R. (2004), ‘Pharmacotherapies for 
problematic psychostimulant use: a review of current research’, 
Drug and alcohol review 23, pp. 203–11.
UNODC (2003a), Global illicit drug trends 2003, United Nations 
Office on Drugs and Crime, Vienna.
UNODC (2003b), Ecstasy and amphetamines: global survey 
2003, United Nations Office on Drugs and Crime, Vienna.
UNODC (2005), Coca cultivation in the Andean region: a survey 
of Bolivia, Colombia and Peru — June 2005, United Nations 
Office on Drugs and Crime, Vienna.
UNODC (2006), 2006 world drug report, United Nations Office 
on Drugs and Crime, Vienna.
UNODC and Government of Morocco (2005), Morocco cannabis 
survey 2004. United Nations Office on Drugs and Crime, Vienna.
Van den Brink, W. (2005), ‘Epidemiology of cocaine and crack: 
implications for drug policy and treatment’, Sucht 51(4), 
pp. 196–98.
Vickerman, P., Hickman, M., Rhodes, T. and Watts, C. (2006), 
‘Model projections on the required coverage of syringe distribution 
to prevent HIV epidemics among injecting drug users’, Journal 
of acquired immune deficiency syndromes (in press).
Von Sydow, K., Lieb, R., Pfister, H. et al. (2002), ‘What 
predicts incident use of cannabis and progression to abuse and 
dependence? A 4-year prospective examination of risk factors in 
a community sample of adolescents and young adults’, Drug and 
alcohol dependence 68(1), pp. 49–64.
WCO (2005), Customs and drugs 2004, World Customs 
Organisation, Brussels.
WHO (2005), Effectiveness of drug dependence treatment in 
preventing HIV among injecting drug users. Evidence for action 
technical papers, World Health Organisation, Geneva.
WHO/UNODC/UNAIDS (2004), ‘Substitution maintenance 
therapy in the management of opioid dependence and HIV/AIDS 
prevention’, position paper, World Health Organisation, United 
Nations Office on Drugs and Crime, UNAIDS (http://www.who.int/
substance_abuse/publications/treatment/en/index.html).
kg609922insideEN.indd   96 27/10/06   10:14:14
kg609922insideEN.indd   97 27/10/06   10:14:14
kg609922insideEN.indd   98 27/10/06   10:14:14
European Monitoring Centre for Drugs and Drug Addiction
Annual report 2006: the state of the drugs problem in Europe
Luxembourg: Office for Official Publications of the European Communities
2006 — 96 pp. — 21 x 29.7 cm
ISBN 92-9168-266-7
kg609922insideEN.indd   99 27/10/06   10:14:15
kg609922insideEN.indd   100 27/10/06   10:14:15
SALES AND SUBSCRIPTIONS
Publications for sale produced by the Offi ce for Offi cial Publications of the European 
Communities are available from our sales agents throughout the world.
You can fi nd the list of sales agents on the Publications Offi ce website 
(http://publications.europa.eu) or you can apply for it by fax (352) 29 29-42758.
Contact the sales agent of your choice and place your order.
ISBN 92-9168-266-7
,!7IJ2J1-gicggj!
TD
-A
C
-06-001-E
N
-C
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable 
and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisors; professionals 
and researchers working in the field of drugs; and, more broadly, 
the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug 
phenomenon in the EU and is an essential reference book for those seeking 
the latest findings on drugs in Europe. 
